Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review) by Nagler, Evi et al.
Cochrane Database of Systematic Reviews
Interventions for chronic non-hypovolaemic hypotonic
hyponatraemia (Review)
Nagler EV, Haller MC, Van Biesen W, Vanholder R, Craig JC, Webster AC
Nagler EV, Haller MC, Van Biesen W, Vanholder R, Craig JC, Webster AC.
Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.
Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD010965.
DOI: 10.1002/14651858.CD010965.pub2.
www.cochranelibrary.com
Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
8BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
22DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
131DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
132ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
133CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
133DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
134SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
134DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iInterventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for chronic non-hypovolaemic hypotonic
hyponatraemia
Evi V Nagler1,2, Maria C Haller2,3,4, Wim Van Biesen1,2, Raymond Vanholder1,2, Jonathan C Craig5,6,7, Angela C Webster5,6,8
1Renal Division, Sector Metabolic and Cardiovascular Conditions, Ghent University Hospital, Ghent, Belgium. 2European Renal Best
Practice (ERBP), Guidance Body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA),
London, UK. 3Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University
Vienna, Vienna, Austria. 4Department of Nephrology, Ordensklinikum Linz Elisabethinen, Linz, Austria. 5Cochrane Kidney and
Transplant, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia. 6Sydney School of Public Health,
The University of Sydney, Sydney, Australia. 7College of Medicine and Public Health, Flinders University, Adelaide, Australia. 8Centre
for Transplant and Renal Research, Westmead Millennium Institute, The University of Sydney at Westmead, Westmead, Australia
Contact address: Evi V Nagler, Renal Division, Sector Metabolic and Cardiovascular Conditions, Ghent University Hospital, De
Pintelaan 185, Ghent, 9000, Belgium. Evi.Nagler@UGent.be.
Editorial group: Cochrane Kidney and Transplant Group.
Publication status and date: New, published in Issue 6, 2018.
Citation: Nagler EV, Haller MC, Van Biesen W, Vanholder R, Craig JC, Webster AC. Interventions for chronic non-hy-
povolaemic hypotonic hyponatraemia. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD010965. DOI:
10.1002/14651858.CD010965.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Chronic (present > 48 hours) non-hypovolaemic hyponatraemia occurs frequently, can be caused by various conditions, and is associated
with shorter survival and longer hospital stays. Many treatments, such as fluid restriction or vasopressin receptor antagonists can be
used to improve the hyponatraemia, but whether that translates into improved patient-important outcomes is less certain.
Objectives
This review aimed to 1) look at the benefits and harms of interventions for chronic non-hypovolaemic hypotonic hyponatraemia
when compared with placebo, no treatment or head-to-head; and 2) determine if benefits and harms vary in absolute or relative terms
dependent on the specific compound within a drug class, on the dosage used, or the underlying disorder causing the hyponatraemia.
Search methods
We searched the Cochrane Kidney and Transplant Register of Studies up to 1 December 2017 through contact with the Information
Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE,
and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. We
also screened the reference lists of potentially relevant studies, contacted authors, and screened the websites of regulatory agencies.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of any intervention with placebo, no
treatment, standard care, or any other intervention in patients with chronic non-hypovolaemic hypotonic hyponatraemia. We also
included subgroups with hyponatraemia from studies with broader inclusion criteria (e.g. people with chronic heart failure or people
with cirrhosis with or without hyponatraemia), provided we could obtain outcomes for participants with hyponatraemia from the
report or the study authors.
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Data collection and analysis
Two authors independently extracted data and assessed risk of bias. We expressed treatment effects as mean difference (MD) for
continuous outcomes (health-related quality of life, length of hospital stay, change from baseline in serum sodium concentration,
cognitive function), and risk ratio (RR) for dichotomous outcomes (death, response and rapid increase in serum sodium concentration,
hypernatraemia, polyuria, hypotension, acute kidney injury, liver function abnormalities) together with 95% confidence intervals (CI).
Main results
We identified 35 studies, enrolling 3429 participants. Twenty-eight studies (3189 participants) compared a vasopressin receptor antag-
onist versus placebo, usual care, no treatment, or fluid restriction. In adults with chronic, non-hypovolaemic hypotonic hyponatraemia,
vasopressin receptor antagonists have uncertain effects on death at six months (15 studies, 2330 participants: RR 1.11, 95% CI 0.92 to
1.33) due to risk of selective reporting and serious imprecision; and on health-related quality of life because results are at serious risk of
performance, selective reporting and attrition bias, and suffer from indirectness related to the validity of the Short Form Health Survey
(SF-12) in the setting of hyponatraemia. Vasopressin receptor antagonists may reduce hospital stay (low certainty evidence due to risk
of performance bias and imprecision) (3 studies, 610 participants: MD -1.63 days, 95% CI -2.96 to -0.30), and may make little or no
difference to cognitive function (low certainty evidence due to indirectness and imprecision). Vasopressin receptor antagonists probably
increase the intermediate outcome of serum sodium concentration (21 studies, 2641 participants: MD 4.17 mmol/L, 95% CI 3.18
to 5.16), corresponding to two and a half as many people having a 5 to 6 mmol/L increase in sodium concentration compared with
placebo at 4 to 180 days (moderate certainty evidence due to risk of attrition bias) (18 studies, 2014 participants: RR 2.49, 95% CI
1.95 to 3.18). But they probably also increase the risk of rapid serum sodium correction - most commonly defined as > 12 mmol/L/d
(moderate certainty evidence due to indirectness) (14 studies, 2058 participants: RR 1.67, 95% CI 1.16 to 2.40) and commonly cause
side-effects such as thirst (13 studies, 1666 participants: OR 2.77, 95% CI 1.80 to 4.27) and polyuria (6 studies, 1272 participants):
RR 4.69, 95% CI 1.59 to 13.85) (high certainty evidence). The potential for liver toxicity remains uncertain due to large imprecision.
Effects were generally consistent across the different agents, suggesting class effect.
Data for other interventions such as fluid restriction, urea, mannitol, loop diuretics, corticosteroids, demeclocycline, lithium and
phenytoin were largely absent.
Authors’ conclusions
In people with chronic hyponatraemia, vasopressin receptor antagonists modestly raise serum sodium concentration at the cost of a 3%
increased risk of it being rapid. To date there is very low certainty evidence for patient-important outcomes; the effects on mortality
and health-related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be an important
effect on cognitive function, but hospital stay may be slightly shorter, although available data are limited. Treatment decisions must
weigh the value of an increase in serum sodium concentration against its short-term risks and unknown effects on patient-important
outcomes. Evidence for other treatments is largely absent.
Further studies assessing standard treatments such as fluid restriction or urea against placebo and one-another would inform practice
and are warranted. Given the limited available evidence for patient-important outcomes, any study should include these outcomes in
a standardised manner.
P L A I N L A N G U A G E S U M M A R Y
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What is the issue?
A low blood sodium concentration can be caused by many conditions and is linked to shorter survival and longer hospital stays. Many
treatments, such as fluid restriction or certain water pills called vasopressin receptor antagonists can be used to increase the blood
sodium concentration, as long as increases happen slowly enough to avoid brain damage. Whether these treatments also improve patient
outcomes (the way patients feel, function and survive) is less clear.
What did we do?
We included randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of any intervention with placebo, no
treatment, standard care, or any other intervention in patients with chronic non-hypovolaemic hypotonic hyponatraemia.
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What did we find?
Our systematic search (to December 2017) identified 35 studies, enrolling 3429 patients. Vasopressin receptor antagonists have unclear
effects on the risk of death and quality of life, with additional studies needed to answer these questions. They likely improve the
blood sodium concentration, but it sometimes happens too quickly. In addition, people who take vasopressin receptor antagonists may
experience increased thirst and urine output. There is very little information for any of the other available treatments.
Conclusions
In people with low blood sodium concentration, vasopressin receptor antagonists modestly raised the sodium concentration. The effects
on mortality and health-related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be
an important effect on cognitive function, but hospital stay may be slightly shorter, although available data are limited. Evidence for
other treatments is largely absent.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vasopressin receptor antagonists versus placebo or no treatment for chronic non-hypovolaemic hypotonic hyponatraemia
Patient or population: chronic non-hypovolaemic hypotonic hyponatraemia
Intervention: Vasopressin receptor antagonists
Comparison: placebo or no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
placebo or no treat-
ment
Vasopressin receptor
antagonists
Death
Follow-up: range 2 to
180 days
Study populat ion RR 1.11
(0.92 to 1.33)
2330 (15) ⊕©©©
VERY LOW 2,3
Interpretat ion: ef fect
uncertain; may both re-
sult in 11/ 1000 fewer to
47/ 1000 more deaths
within 6 months
143 per 1000 1 159 per 1000
(132 to 190)
Health-related quality
of lif e (assessed
with mental component
score of SF-124)
Follow-up: 30 days
The mean change f rom
baseline in health-re-
lated quality of lif e
in the control group
ranged between 0.75
and 2.39 on a 0 to 100
point scale (worst to
best) 5
The mean health-re-
lated quality of lif e in
the intervent ion group
was 4.76 higher (0.11
higher to 9.41 higher)
- 297 (2) ⊕©©©
VERY LOW 6,7
Physical component
score also measured in
both studies; RR 1.04;
CI -1.81 to 3.90
Interpretat ion:
anywhere f rom 0.1 to 9.
5/ 100 points higher in-
crease with treatment,
but quest ionable tool
for QoL measurement
in hyponatraemia and
unclear minimally im-
portant clinical dif f er-
ence
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Length of hospital stay The mean length of hos-
pital stay in the control
group was 6 to 11 days
5
The mean length of hos-
pital stay in the inter-
vent ion group was 1.63
days lower (2.96 lower
to 0.30 lower)
- 580 (2) ⊕⊕©©
LOW 8,9
Cognit ive funct ion
(assessed with various
tools)
Follow-up: 1 to 6
months
Across f ive studies,
conf idence intervals
spanned the line of no
ef fect and did not in-
clude a clinically mean-
ingful ef fect
- 1169 (5) ⊕⊕©©
LOW 10
Tools used to as-
sess cognit ive funct ion:
making test B; reac-
t ion t ime, psychomo-
tor, processing speeds;
M ini mental state exam;
overall meta-analysis
including all f ive stud-
ies not meaningfully
possible
Change f rom baseline
in serum sodium con-
centrat ion
Follow-up: range 1 to
180 days
The mean change
f rom baseline in serum
sodium concentrat ion
in the control group was
0.3 to 4.8 mmol/ L 5
The mean change
f rom baseline in serum
sodium concentrat ion
in the intervent ion
group was 4.17 mmol/
L higher (3.18 higher to
5.16 higher)
- 2641 (21) ⊕⊕⊕©
MODERATE 11
Serum sodium concen-
trat ion (response)
Follow-up: range 4 to
180 days
Study populat ion RR 2.49
(1.95 to 3.18)
2104 (18) ⊕⊕⊕©
MODERATE 11
Response most com-
monly def ined by inves-
t igators as > 5 to >
6 mmol/ L increase or
normalisat ion of serum
sodium concentrat ion
231 per 1000 1 576 per 1000
(454 to 597)
Rapid sodium increase
Follow-up: range 1 to 5
days
Study populat ion RR 1.67
(1.16 to 2.40)
2058 (14) ⊕⊕⊕©
MODERATE 12
Rapid increase most
commonly def ined as >
12 mmol/ d
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44 per 1000 1 73 per 1000
(51 to 105)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
1 Source of assumed baseline risk was calculated as the unweighted summed event rate in the control groups of the trials
included in the meta-analysis
2 Downgraded one level because studies considered at serious risk of suf fering f rom
* select ive report ing: 6/ 16 studies with treatment durat ion > 1 week did not report death and had no protocol, account ing for
16% of the total number of part icipants in those studies
* commercial sponsorship; possible f inancial conf lict of interest of the authors: all studies sponsored by pharmaceut ical
companies wanting to commercialize the treatment; all save one had author lists who featured people who had received
money for presentat ions or consultancy, or were employed by the sponsor; only used as support ing reason for downgrading.
3 Downgraded two levels for imprecision. The 95% CI of the pooled est imate includes both important reduct ion (11/ 1000
fewer) and increase (47/ 1000 more) in death with vasopressin receptor antagonists.
4 Choice of the outcome-measure based on the fact that this was the only one reported in any of the studies. There are
concerns around the validity of the SF-12 as a measure for health-related quality of lif e in the f ield of hyponatraemia as it
gauges domains and symptoms not direct ly attributable to hyponatraemia.
5 Source of the assumed baseline risk was the range of outcomes in the control groups of the trials included in the meta-
analysis
6 Downgraded one level because studies considered seriously at risk of suf fering f rom
* Performance bias: self -reported outcome, part icipants likely unblinded to treatment due to polyuria as side ef fect
* Select ive report ing bias: both mental and physical component score of SF-12 measured; at week 1 or 2 and day 30 using
two dif ferent analyt ic techniques. Only data at day 30 available for analysis.
* Attrit ion bias: overall 37% of data missing, unknown whether missing at random or not.
* Commercial sponsorship or possible f inancial conf lict of interest of authors: both studies were sponsored by the company
seeking to commercialise the treatment; both had author lists who featured people who had received money for presentat ions
or consultancy, or were employed by the sponsor; only using as support ing argument for downgrading
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7 Downgraded one level for indirectness due to concerns around validity of the SF-12 for measuring quality of lif e in the
context of hyponatraemia and one level for imprecision: only studied in two studies.
8 Downgraded one level because studies considered seriously at risk of suf fering f rom performance bias: part icipants and
personnel likely unblinded to treatment due to polyuria as side ef fect; this could have inf luenced self -reported and professional
appreciat ion of clinical condit ion and so have inf luenced decision to discharge f rom hospital.
9 Downgraded one level for imprecision. The 95% CI of the pooled est imate includes both negligible shortening (0.3 days
shorter) and clinically important shortening (3 days shorter) of hospital stay with vasopressin receptor antagonists.
10 Downgraded two levels for indirectness and imprecision. Only studied in 5/ 28 studies, with most data for lixivaptan, and
other studies not reaching the opt imal information size.
11 Downgraded one level because we considered studies seriously at risk of suf fering f rom
* Attrit ion bias: 7/ 21 studies, account ing for 53%of the total number of part icipants in those studies at high risk of bias either
due to true attrit ion or because a repeated measures analyt ic technique was used with all measurements of serum sodium
concentrat ion included unt il pat ient attrit ion, which we judged would likely have overest imated the treatment ef fect.
* Commercial sponsorship; only used as support ing argument.
12 Downgraded one level for indirectness; risks controlled in t ight ly organised randomised trial with several measurements
of serum sodium concentrat ion daily to avoid rapid correct ion. In real lif e, risk of rapid correct ion likely greater. Commercial
sponsorship bias; only used as support ing argument.
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B A C K G R O U N D
Description of the condition
Hypotonic hyponatraemia is a common condition, occurring in
up to 60% of people admitted to hospitals, depending on the def-
inition of hyponatraemia, the types of patients who are studied
and the healthcare facility to which these patients are admitted
(Upadhyay 2009). Hypotonic hyponatraemia is usually defined as
a serum sodium concentration < 135 mmol/L with an osmolality
< 285 mOsm/kg (Reynolds 2006). It develops when the body re-
tains an excess of water relative to the amount of sodium. It can be
caused by intrinsic kidney disease but usually results from incom-
plete suppression of vasopressin activity despite decreased tonicity
of the plasma. In situations of decreased circulating blood volume,
vasopressin release is increased in a physiologic response to main-
tain haemodynamic homeostasis. This occurs either with true vol-
ume depletion or with reduced effective arterial circulating vol-
ume, as seen in heart failure, liver cirrhosis or nephrotic syndrome.
In the syndrome of inappropriate antidiuretic hormone secretion,
the increased release of vasopressin is non-haemodynamic and can
have multiple causes including ectopic production of vasopressin
by a variety of tumours (Verbalis 2013).
When plasma tonicity is low, water tends to enter the cells and
causes them to swell. If blood sodium concentrations drop rapidly
(within a 48 hour period), the swelling of brain cells may lead to
brain oedema, brain stem herniation and eventually even death.
Fortunately, when blood sodium concentrations drop more grad-
ually, brain cells adapt to their hypo-osmolar surroundings and
prevent swelling by the transport of solutes from the intracellular
to the extracellular compartments. As a consequence, immediate
symptoms attributable to chronic hyponatraemia are usually less
severe than for acute hyponatraemia (Reynolds 2006). Neverthe-
less, people with chronic hyponatraemia have reduced attention
and less stable gait than those without hyponatraemia (Renneboog
2006). They fall more often and have increased risk of osteoporo-
sis and bone fractures (Arampatzis 2013; Hoorn 2011; Kinsella
2010; Renneboog 2006; Verbalis 2010). Finally, they stay in hos-
pital longer and have an increased risk of death, even when sodium
concentrations are only mildly decreased and underlying or co-
morbid conditions are adjusted for (Wald 2010).
Description of the intervention
It is accepted that acute hypotonic hyponatraemia requires an im-
mediate increase in serum sodium concentration to prevent severe
neurologic complications (Ellison 2007).What to do with chronic
hypotonic hyponatraemia is less clear. Firstly, chronic non-hypo-
volaemic hypotonic hyponatraemia has been treated under the
assumption that increasing the sodium concentration improves
important health outcomes; that patients live longer, feel better
and are hospitalised less frequently. Although several observational
studies have indicated an association between hyponatraemia and
undesirable outcomes, it is still unclear whether correcting the hy-
ponatraemia improves them (Upadhyay 2009; Wald 2010). Sec-
ondly, once brain cells have adapted to their hypo-osmolar en-
vironment, they become vulnerable to osmotic demyelination in
case the hypo-osmolar environment is restored. Although rare,
osmotic demyelination is a devastating neurologic complication
that may occur when the myelin sheath around pontine and ex-
trapontine neurons breaks down after rapid rises in serum sodium
concentration. It very rarely does if the increases stay below 8 to
12 mmol/L/24 h and 18 mmol/L/48 h - accepted limits depend-
ing on risk factors such as older age, malnutrition and alcohol
abuse (Adrogue 2012; Ellison 2007; Reynolds 2006). Treatment
for chronic hypotonic hyponatraemia must balance the uncertain
benefit of increasing the sodium concentration against the risk of
complications due to overly rapid correction.
How the intervention might work
Whatever the underlying cause, chronic non-hypovolaemic hy-
potonic hyponatraemia usually results from urine being insuffi-
ciently dilute to maintain serum osmolality within the normal
range (Adrogue 2000). Several treatment strategies can be used to
try overcoming this (Adrogue 2012; Ellison 2007; Verbalis 2013).
1. Restriction of fluid intake aims to decrease the amount of
free water needing excretion.
2. Urea and mannitol improve electrolyte-free water clearance
by increasing urine osmolality and creating osmotic diuresis
(Lindner 2012).
3. Loop diuretics, such as furosemide, bumetanide and
ethacrynic acid, impair free-water absorption in the collecting
duct by reducing the hypertonicity of the renal medulla.
4. Corticosteroids with a mineralocorticoid effect increase
renal sodium retention by active reabsorption of sodium in the
principal cells of the cortical collecting tubule.
5. Demeclocycline, lithium, phenytoin and vasopressin
receptor antagonists act by pharmacologically inhibiting the
effect of antidiuretic hormone on the principal cells of the
collecting duct, thereby limiting insertion of water channels in
the luminal membrane and thus preventing free water
reabsorption.
As hyponatraemia with true volume depletion (chronic hypo-
volaemic hypotonic hyponatraemia) is treated by restoring volume
with water and salt, we do not cover it in this review.
Why it is important to do this review
The benefits and harms of treatments for chronic non-hypo-
volaemic hypotonic hyponatraemia have not been formally evalu-
ated in a systematic review. Two systematic reviews have explored
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the efficacy and safety of vasopressin receptor antagonists (e.g.
conivaptan, lixivaptan, satavaptan, tolvaptan) versus placebo, no
treatment or fluid restriction (Jaber 2011; Rozen-Zvi 2010), but
to our knowledge there has been no attempt to compare them
with any other intervention or to compare any of the other inter-
ventions versus placebo or against one another.
Both systematic reviews have found an early increase in serum
sodium concentration, but no improvement in outcomes impor-
tant to patients. Indeed, most randomised controlled trials (RCTs)
have evaluated short-term and surrogate outcomes only, making
it difficult to adequately asses any expected benefit in the long-
term. Since the most recent systematic review was published, 12
additional RCTs comparing vasopressin receptor antagonists ver-
sus control have been completed, increasing the total sample size
by at least 50%. Although outcomes are still mostly surrogate and
short-term, the largest study was terminated early due to a nu-
meric imbalance in the number of early deaths in the experimen-
tal group (FDA 2012). Two vasopressin receptor antagonists have
received wide-spread regulatory approval, but indications and per-
mitted treatment durations vary among regions. Divergent inter-
pretations of survival and harms data are a likely cause.
O B J E C T I V E S
This review aimed to:
1. Look at the benefits and harms of interventions for chronic
non-hypovolaemic hypotonic hyponatraemia when compared
with placebo, no treatment or head-to-head;
2. Determine if benefits and harms vary in absolute or relative
terms dependent on the specific compound within a drug class,
on the dosage used, or the underlying disorder causing the
hyponatraemia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at interventions for
chronic, non-hypovolaemic hypotonic hyponatraemia.
We also included data for hyponatraemia subgroupswithin studies
with broader inclusion criteria (e.g. people with chronic heart
failure or people with cirrhosis with or without hyponatraemia)
which report outcomes for participants with hyponatraemia, or
wherewe could obtain these subgroupdata from the study authors.
Types of participants
Inclusion criteria
• Adults and children beyond the neonatal period (the
interval from birth to 28 days of age)
• Chronic, hypotonic hyponatraemia: presence of
hyponatraemia > 48 hours, serum osmolality < 285 mOsm/kg
and serum sodium concentration < 135 mmol/L, or as defined
by authors); not requiring immediate treatment and due to:
◦ decreased effective circulating volume in the setting of
heart failure, liver cirrhosis or nephrotic syndrome;
◦ inappropriate antidiuresis, associated with any
underlying condition (includes syndrome of inappropriate
antidiuretic hormone secretion and nephrogenic syndrome of
inappropriate antidiuresis); or
◦ impaired renal dilutional capacity due to kidney
disease.
Sodium concentrations can be measured in any type of blood sam-
ple (e.g. serum, plasma, whole blood, venous, arterial, capillary)
using any measurement method (e.g. flame emission spectropho-
tometry, direct or indirect reading potentiometry by an ion-selec-
tive electrode) in any setting (e.g. central laboratory, local labora-
tory, point of care device).
Exclusion criteria
• Children in the neonatal period (the interval from birth to
28 days of age)
• Isotonic or hypertonic hyponatraemia (osmolality ≥ 285
mOsm/kg)
• Hyponatraemia due to true (extracellular) volume
depletion, such as from third spacing (type of fluid leakage into
interstitial spaces seen in pancreatitis, bowel obstruction, sepsis),
and gastrointestinal, or renal sodium loss
• Hyponatraemia due to secondary adrenal insufficiency or
hypothyroidism
• Hyponatraemia due to primary psychogenic polydipsia
• Patients treated with any form of dialysis or extracorporeal
ultrafiltration.
Types of interventions
We included studies of any degree of fluid restriction or any drug
treatment that has the aim of increasing the sodium concentra-
tion. Any dose or route of administration is permitted, and inter-
ventions can be compared with placebo, no treatment, a differ-
ent dose of the same or different interventions, different adminis-
tration routes of the same or different interventions, or different
combinations of interventions.
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Treatments included (but were not limited to):
• vasopressin receptor antagonists (conivaptan, mozavaptan,
lixivaptan, satavaptan, tolvaptan)
• fluid restriction
• urea
• mannitol
• loop diuretics (furosemide, bumetanide, ethacrynic acid)
• corticosteroids (hydrocortisone or equivalent,
fludrocortisone)
• demeclocycline
• lithium
• phenytoin.
We excluded studies in which any form of dialysis treatment was
given to correct serum sodium concentration.
Types of outcome measures
We assessed outcomes up to one week, up to one, two and six
months, and up to one and five years.
Primary outcomes
• Death (all-cause mortality)
• Health-related quality of life and specifically symptoms
attributed to hyponatraemia by trialists.
Secondary outcomes
• Length of hospital stay
• Serum sodium concentration (mmol/L) at end of treatment
or change from beginning to end of treatment
• Response defined as increase of ≥ 5 mmol/L or
normalisation of serum sodium concentration (≥ 135 to 145
mmol/L, or as defined by the authors)
• Outcomes related to over-correction of serum sodium
concentration
◦ Incidence of hypernatraemia (serum sodium
concentration > 145 mmol/L, or as defined by the authors)
◦ Rapid increase in serum sodium concentration
(increase in serum sodium concentration > 8 to 12 mmol/L in
24 h or > 18 mmol/L in 48h, or as defined by the authors)
◦ Incidence of osmotic demyelination syndrome,
previously known as central pontine and extrapontine
myelinolysis (diagnosed clinically, by MRI, or post mortem)
• Any treatment-specific side effects as defined by authors
◦ AKI (demeclocycline, mannitol, loop diuretics)
◦ Chronic kidney disease (lithium)
◦ Hypotension (mannitol, loop diuretics, vasopressin
receptor antagonists)
◦ Thirst (mannitol, loop diuretics, fluid restriction,
vasopressin receptor antagonists)
◦ Central nervous system symptoms (phenytoin)
◦ Polyuria (mannitol, loop diuretics, vasopressin
receptor antagonists)
◦ Any other adverse event as reported by trialists
• Treatment discontinuation or switch
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Register of
Studies up to 1 December 2017 through contact with the Infor-
mation Specialist using search terms relevant to this review. The
Specialised Register contains studies identified from the following
sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
3. Point-of-care sources such as Dynamed and UpToDate as
well as US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) applications.
Data collection and analysis
Selection of studies
The search strategy describedwas used to obtain titles and abstracts
of studies possibly relevant to the review. The titles and abstracts
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were screened independently by two authors, who discarded stud-
ies that were not applicable; however studies and reviews that pos-
sibly included relevant data or information on studies of interest
for our analysis were retained initially. Two authors independently
assessed retrieved abstracts and, if necessary the full text, of these
studies to determine which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors us-
ing standard data extraction forms. Studies reported in non-En-
glish language journals were translated before assessment. Where
more than one publication of one study existed, reports were
grouped together and the publication with themost complete data
was used in the analyses. Where relevant outcomes were only pub-
lished in earlier versions these data were used.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (e.g. death, number of patients with
serum sodium concentration increase of ≥ 5 mmol/L, number
of patients that develop hypernatraemia, number of patients with
rapid increase in serum sodium concentration, number of patients
that develop osmotic demyelination syndrome), individual study
results were expressed as risk ratios (RR) with 95% confidence in-
tervals (CI). Where continuous scales of measurement were used
to assess the effects of treatment (e.g. length of hospital stay, serum
sodium concentration at the end of the study or its change from
beginning to the end of treatment), results were expressed as the
mean difference (MD). For outcomes reported both as dichoto-
mous and continuous data (thirst), we presented individual study
results as odds ratios (OR), by converting standardized mean dif-
ferences to the natural logarithmof the odds ratios (Higgins 2011).
Unit of analysis issues
If studies hadmultiple treatment groups, we tried to collapse these
into one where appropriate to enable single pair wise comparison
(e.g. collapsing three groups of different doses of vasopressin re-
ceptor antagonists into one group and including them in single
pair wise comparison versus placebo) (Higgins 2011).
Dealing with missing data
Any further information required from the original authors was
requested by emailing the corresponding author. If no response or
insufficient information was retrieved, we subsequently emailed
the sponsor. Any relevant information obtained in thismanner was
included in the review. Evaluation of important numerical data
such as screened, randomised patients as well as intention-to-treat,
as-treated and per-protocol population was performed. Attrition
rates, for example drop-outs, losses to follow-up and withdrawals
were investigated. Issues of missing data and imputation methods
(for example, last-observation-carried-forward) were critically ap-
praised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with I2 calculated to measure the proportion of total variation in
the estimates of treatment effect that was due to heterogeneity
beyond chance (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
Funnel plots were used to assess for the potential existence of small
study bias. If we suspected asymmetry on visual inspection and the
analysis included > 10 studies, we conducted formal hypothesis
testing, using Egger’s test for continuous outcomes and Peter’s
regression test for dichotomous outcomes (Higgins 2011).
Data synthesis
Where feasible and appropriate, data were pooled using the ran-
dom-effects model. Dichotomous outcome results were expressed
as risk ratio (RR) and continuous outcome results were expressed
as mean difference (MD), both with 95% confidence intervals.
For outcomes reported both as dichotomous and continuous data
(thirst), we converted standardized mean differences to log-trans-
formed odds ratios, combined them using the generic inverse-vari-
ance method and expressed the overall effect estimate as an odds
ratio with its 95% confidence interval (Higgins 2011). Although
the underlying conditions causing hyponatraemia are very differ-
ent, the mechanism by which hyponatraemia develops is similar
in that vasopressin activity plays a role in most forms of the dis-
order. We believe it justified pooled analysis across subgroups of
participants with different underlying conditions.
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We summarised the quality of the evidence together with abso-
lute treatment effects based on estimated baseline risks by using
the Grading of Recommendations Assessment, Development, and
Evaluation guidelines (GRADE 2008). To estimate the absolute
number of people with hyponatraemia who avoided death or in-
curred a rapid increase in serum sodium concentration with vaso-
pressin receptor antagonists, the risk estimate and 95% CI were
obtained from the control arm of the corresponding meta-analy-
ses.
Subgroup analysis and investigation of heterogeneity
We analysed data for death, length of hospital stay, change from
baseline and response in serum sodium concentration, cognitive
function and outcomes related to over correction of serum sodium
concentration within subgroups of participants dependent on the
type of vasopressin receptor antagonist they were treated with. Ad-
ditional prespecified subgroup analyses and univariate random ef-
fects meta-regression were conducted to explore potential sources
of heterogeneity in effects of vasopressin receptor antagonists on
death, change in serum sodium concentration and rapid increase
in serum sodium concentration. The potential sources of hetero-
geneity included type of vasopressin receptor antagonist under
evaluation, the underlying condition causing the hyponatraemia
(with as non-prespecified categories studies only including partic-
ipants with inappropriate antidiuresis; studies only including par-
ticipants with heart failure or liver cirrhosis or studies including
both), mean baseline serum sodium concentration, treatment du-
ration and risk of selection bias. Meta-regression was undertaken
on the log RR scale for categorical outcomes using Comprehen-
sive Meta-Analysis® software, each study weighting equal to the
inverse of the variance of the estimate for that study, with between
study variance estimated using the restricted the method of mo-
ments. Results were expressed as the ratio of the RR within each
subgroup for categorical explanatory variables and per one unit
increase for continuous variables.
Sensitivity analysis
In addition to estimating treatment effects using random effects
models, we also estimated fixed effects models to ensure robust-
ness of the model chosen and susceptibility to outliers. Finally
we also assessed whether including the number of deaths during
follow-up (in contrast to only including those occurring during
treatment) affected the estimate of the effect of treatment on all-
cause mortality.
’Summary of findings’ tables
We presented the main results of the review in ’Summary of find-
ings’ tables. These tables present key information concerning the
quality of the evidence, the magnitude of the effects of the in-
terventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of
a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the true quan-
tity of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect estimates
and risk of publication bias (Schünemann 2011b). We presented
the following outcomes in the ’Summary of findings’ tables.
• Death
• Health-related quality of life, assessed with the mental
component score and physical component score of the Short
Form Health Survey (SF-12)
• Cognitive function
• Length of hospital stay
• Change from baseline in serum sodium concentration
• Response of serum sodium concentration: defined as 4 to 6
mmol/L increase or normalisation
• Rapid sodium increase
R E S U L T S
Description of studies
Results of the search
We identified 1954 citations through electronic searches con-
ducted in 1 December 2017. We found 16 additional reports by
screening the reference lists, contacting authors, conducting on-
line searches for full reports of included abstracts, searching on-
line trial registries, and screening the website of regulatory agen-
cies. We reviewed in detail 157 reports, which led to the inclusion
of 111 reports of 35 unique studies including 3429 participants
(Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Twenty-eight studies (providing data for 3189 participants) com-
pared a vasopressin receptor antagonist versus placebo, usual
care or no treatment (ACTIV in CHF 2003; Annane 2009;
BALANCE2010;Decaux 2006;DILIPO2011; EVEREST2005;
Ghali 2006; Gheorghiade 2003; Gines 2008b; Gerbes 2003;
HARMONY 2012; HYPOCAT 2008; INSIGHT 2016; Koren
2011; LIBRA 2012; Naidech 2010; Nevens 2009; Otsuka Study
2011a; Otsuka Study 2011b; Otsuka Study 2011c; Salahudeen
2014; SALT-1 2006; SALT-2 2006; Soupart 2006; Wong 2003b;
Yang 2013; Zeltser 2007), or versus fluid restriction (Gheorghiade
2006). Studied vasopressin receptor antagonists included coni-
vaptan (Annane 2009; Ghali 2006; Koren 2011; Naidech
2010; Zeltser 2007), lixivaptan (BALANCE 2010; Gerbes 2003;
HARMONY 2012; LIBRA 2012; Wong 2003b), satavaptan
(Decaux 2006; DILIPO 2011; Gines 2008b; HYPOCAT 2008;
Soupart 2006), tolvaptan (ACTIV in CHF 2003; EVEREST
2005; Gheorghiade 2003; Gheorghiade 2006; INSIGHT 2016;
Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c;
Salahudeen 2014; SALT-1 2006; SALT-2 2006; Yang 2013) and
M0002 - also termed SPD556 or RWJ 351647 (Nevens 2009).
Two studies assessed different doses conivaptan (Kalra 2011) or
tolvaptan (Shoaf 2017)
Singhi 1995 (50 participants) compared fluid restriction with
normal maintenance fluid in children with bacterial meningi-
tis and reported data for the subgroup with hyponatraemia (26
participants). Dzau 1984 (14 participants) compared captopril
+ furosemide versus furosemide alone in adults with decompen-
sated heart failure. Jalan 2007 (24 participants) compared infu-
sion of human salt poor albumin in combination with fluid and
sodium restriction versus fluid and sodium restriction alone in
patients with liver cirrhosis and ascites. Hayes 1987 (10 partici-
pants) compared early versus delayed administration of urea, and
NATRIPHAR 2013 (19 participants) compared a change in pre-
scribed medications versus standard care in elderly patients admit-
ted to the internal medicine ward or residents of the nursing home
of the same institution.
Twenty-eight studies were conducted specifically in participants
with hyponatraemia (Annane 2009; BALANCE 2010; Decaux
2006; Dzau 1984; Ghali 2006; Gheorghiade 2006; Gines 2008b;
Gerbes 2003; HARMONY2012;Hayes 1987;HYPOCAT2008;
INSIGHT 2016; Jalan 2007; Kalra 2011; Koren 2011; LIBRA
2012; Naidech 2010; Nevens 2009; NATRIPHAR 2013; Otsuka
Study 2011b; Otsuka Study 2011c; Salahudeen 2014; SALT-1
2006; SALT-2 2006; Soupart 2006; Wong 2003b; Yang 2013;
Zeltser 2007). For five studies, participants with hyponatraemia
formed a subgroup of a larger study including both participants
with andwithout hyponatraemia (ACTIV inCHF 2003;DILIPO
2011; EVEREST 2005; Gheorghiade 2003 Singhi 1995).
Studies included on average mostly older adults (median 65
years, interquartile range 5) with moderate hyponatraemia (me-
dian 129 mmol/L; range 124 to 133). Participants had as pri-
mary cause of hyponatraemia a syndrome of inappropriate antid-
iuresis in nine studies (Decaux 2006; HARMONY 2012; LIBRA
2012; Naidech 2010; NATRIPHAR 2013; Otsuka Study 2011a;
Salahudeen 2014; Singhi 1995; Soupart 2006), heart failure in
seven studies (ACTIV in CHF 2003; BALANCE 2010; Dzau
1984; EVEREST 2005; Gheorghiade 2003; Otsuka Study 2011b;
Yang 2013) and liver cirrhosis in six studies (Gines 2008b; Hayes
1987; HYPOCAT 2008; Jalan 2007; Nevens 2009; Otsuka Study
2011c). The others included a mixed group of patients. Sample
sizes varied andwere generally small (median69participants; range
6 to 652). Treatment was mostly short-term (median 8 days; range
1 to 365). Data for at least one outcome of interest were available
from 31 studies and 3365 participants, two studies reported no
numeric data (Jalan 2007; Otsuka Study 2011c).
Excluded studies
We excluded 35 studies (46 reports). Thirty-three did not include
the appropriate population, with participants either not having
hyponatraemia at randomisation (Albert 2013; De Vita 2012;
Galton 2011; Mori 1999; Owen 2014; Ramsay 1988; Zamboli
2011; Zellweger 2001), some participants possibly having hy-
ponatraemia but without available subgroup data (Abraham 2006;
Angeli 2010; Ghali 2012; Guyader 2002; K-STAR 2017; Licata
2003; Matsuzaki 2011a; Matsuzaki 2011b; Okita 2014; Paterna
2000; Sakaida 2014; SECRET of CHF 2017; Shanmugam
2016; Suzuki 2013b; TACT-ADHF 2016; TACTICS-HF 2017;
Thuluvath 2006; Wong 2009; Wong 2010a; Wong 2012; Yang
2010b); having hyponatraemia but caused by psychogenic poly-
dipsia (Alexander 1991), prolonged exercise (Rogers 2011), or
head and neck surgery (Rajan 2015); or having severe symptoms
requiring immediate treatment SALSA 2017). One study com-
pared two different salt-restricted diets in combination with step-
wise increase of diuretic treatment for reducing weight and ascites
in patients with decompensated liver cirrhosis (Bernardi 1993);
and finally one study (Gines 2007) would have led to double
counting of participants as it represented a second randomised trial
built on top of a first included study (HYPOCAT 2008) using the
same study medication.
Risk of bias in included studies
The risk of bias is described in (Figure 2; Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The allocation sequence was adequately generated in 14 studies (
BALANCE 2010; DILIPO 2011; EVEREST 2005; Gerbes 2003;
HYPOCAT 2008; Naidech 2010; NATRIPHAR 2013; Otsuka
Study 2011a; Otsuka Study 2011b; Salahudeen 2014; SALT-1
2006; SALT-2 2006; Singhi 1995; Wong 2003b). and adequately
concealed in 12 studies (ACTIV in CHF 2003; BALANCE 2010;
EVEREST 2005; Gheorghiade 2003; Gerbes 2003; HYPOCAT
2008; Naidech 2010; NATRIPHAR 2013; Salahudeen 2014;
SALT-1 2006; SALT-2 2006; Wong 2003b). For the remaining
studies the authors provided insufficient information about the
procedures to permit a judgement of the risk of bias.
Blinding
In 26 studies, all assessing a vasopressin receptor antagonist, the
investigators attempted to blind participants and personnel by
providing a matching placebo (ACTIV in CHF 2003; Annane
2009; BALANCE2010;Decaux 2006;DILIPO2011; EVEREST
2005;Ghali 2006;Gheorghiade 2003;Gines 2008b;Gerbes2003;
HARMONY 2012; HYPOCAT 2008; INSIGHT 2016; Kalra
2011; Koren 2011; LIBRA 2012; Nevens 2009; Otsuka Study
2011a; Otsuka Study 2011b; Otsuka Study 2011c; Salahudeen
2014; SALT-1 2006; SALT-2 2006; Soupart 2006; Wong 2003b;
Zeltser 2007). Although it was probably unlikely for participants
and personnel to be fully blinded due to important increases in
urine output when treated with a vasopressin receptor antagonist,
co-interventions of fluid restriction or salt-intake were reported
and similar in 12 studies (Annane 2009; DILIPO 2011; Ghali
2006; Gerbes 2003; HARMONY 2012; HYPOCAT 2008; Kalra
2011;Koren2011; LIBRA2012; Salahudeen2014; Soupart 2006;
Zeltser 2007). For two studies, fluid restriction could be adapted
by both participant and treating physician (e.g. based on urine
output).We judged this would not have introduced important risk
of bias for death and objective outcomes related to serum sodium
concentration, but may have biased health-related quality of life
measures and resulted in biased estimates of risk of rapid increase
in serum sodium concentration (SALT-1 2006; SALT-2 2006).
Three studies explicitly reported blinding of outcomes assessors
(BALANCE 2010; SALT-1 2006; SALT-2 2006). In 28 others
we judged blinding of outcome assessors would likely have oc-
curred or measured outcomes were objective enough so that the
risk of bias was probably low (ACTIV in CHF 2003; Annane
2009;Decaux 2006;DILIPO2011;Dzau 1984; EVEREST2005;
Ghali 2006; Gheorghiade 2003;Gheorghiade 2006;Gerbes 2003;
HARMONY 2012; HYPOCAT 2008; INSIGHT 2016; Jalan
2007; Kalra 2011; Koren 2011; LIBRA 2012; Naidech 2010;
NATRIPHAR 2013; Nevens 2009; Otsuka Study 2011a; Otsuka
Study 2011b; Otsuka Study 2011c; Salahudeen 2014; Singhi
1995; Soupart 2006; Wong 2003b; Zeltser 2007).
Incomplete outcome data
In 17 studies, attrition stayed below 20% with either well doc-
umented reasons and/or limited opportunity for important bias
(ACTIV inCHF 2003; Annane 2009; BALANCE2010;DILIPO
2011; Dzau 1984; Ghali 2006; Gheorghiade 2006; HYPOCAT
2008; INSIGHT 2016; Kalra 2011; Koren 2011; Naidech 2010;
Otsuka Study 2011a; Otsuka Study 2011b; Salahudeen 2014;
Singhi 1995; Soupart 2006). Eight studies had attrition rates >
25% and either did not attempt to re-include participants in
the analysis (EVEREST 2005; Gheorghiade 2003 NATRIPHAR
2013) or used imputation methods to deal with missing serum
sodium concentration values that may have caused overestima-
tion of the effect of the study medication - e.g. last observation
carried forward, thus ignoring rebound hyponatraemia on ces-
sation of treatment (HARMONY 2012; LIBRA 2012; SALT-1
2006; SALT-2 2006; Wong 2003b; Zeltser 2007). The others
provided insufficient information to allow judgement of high or
low risk of bias (Decaux 2006; Gheorghiade 2003; Gines 2008b;
Gerbes 2003; Hayes 1987; Jalan 2007; Nevens 2009; Otsuka
Study 2011c; Yang 2013).
Selective reporting
For 15 studies, we found a registered protocol in a trial reg-
istry (ACTIV in CHF 2003; BALANCE 2010; DILIPO
2011; EVEREST 2005; HARMONY 2012; HYPOCAT 2008;
INSIGHT 2016; LIBRA 2012; Naidech 2010; NATRIPHAR
2013; Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study
2011c; SALT-1 2006; SALT-2 2006). The Otsuka Study was reg-
istered as a single study but reported was as three separate stud-
ies (Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study
2011c). Investigators fully reported all expected pre-registered out-
comes at pre-registered time-points in two studies (INSIGHT
2016; Naidech 2010). Whether a protocol was provided or not,
for 12 studies investigators reported all expected outcomes related
to benefit and harms at reasonable time-points (Annane 2009;
Decaux 2006; DILIPO 2011; Ghali 2006; HARMONY 2012;
Kalra 2011; Koren 2011; LIBRA 2012; NATRIPHAR 2013;
Singhi 1995; Soupart 2006; Zeltser 2007). In seven studies with
treatment duration > one week, authors did not report the primary
outcomes all-cause mortality or health-related quality of life or
any outcome related to rapid increases in serum sodium concen-
tration (ACTIV in CHF 2003; Gheorghiade 2003; HYPOCAT
2008; Gines 2008b; Nevens 2009; Salahudeen 2014; Yang 2013).
In eight studies with treatment duration ≤ 1 week, authors did
not report any secondary outcome related to serum sodium con-
centration or rapid increases thereof (Dzau 1984; Gheorghiade
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2006; Gerbes 2003; Jalan 2007; Otsuka Study 2011a; Otsuka
Study 2011b; Otsuka Study 2011c; Wong 2003b).
Other potential sources of bias
Bias through possible financial conflict of interest of the
authors, sponsorship bias, or both
Industry funded 28 studies (ACTIV in CHF 2003; Annane 2009;
BALANCE2010;Decaux 2006;DILIPO2011; EVEREST2005;
Ghali 2006; Gheorghiade 2003;Gheorghiade 2006;Gerbes 2003;
HARMONY 2012; HYPOCAT 2008; INSIGHT 2016; Kalra
2011; LIBRA 2012; Koren 2011; Naidech 2010; Nevens 2009;
Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c;
Salahudeen 2014; Salahudeen 2014; SALT-1 2006; SALT-2 2006;
Soupart 2006; Wong 2003b; Zeltser 2007). The funding source
was unclear for six studies (Dzau 1984; Gines 2008b; Jalan 2007;
NATRIPHAR 2013; Singhi 1995; Yang 2013). For 17 studies
we retrieved a declaration of interest for the authors featuring on
the reports (ACTIV in CHF 2003; Annane 2009; DILIPO 2011;
EVEREST 2005; Ghali 2006; Gheorghiade 2003; Gines 2008b;
Gerbes 2003; HARMONY 2012; HYPOCAT 2008; Kalra 2011;
Koren 2011; LIBRA 2012; Naidech 2010; SALT-1 2006; SALT-2
2006; Zeltser 2007). All save one (Naidech 2010) had author lists
who featured people who had received money for presentations or
consultancy, or were employed by the sponsor.
Effects of interventions
See: Summary of findings for the main comparisonVasopressin
receptor antagonists versus placebo or no treatment for chronic
non-hypovolaemic hypotonic hyponatraemia
Vasopressin receptor antagonists versus placebo or
no treatment
Primary outcomes
Vasopressin receptor antagonists had uncertain effects on mortal-
ity, results being compatible with both 11 in 1000 fewer to 47
in 1000 more deaths within six months (Analysis 1.1 (15 studies,
2330 participants): RR 1.11, 95% CI 0.92 to 1.33; I2 = 0%).
Using GRADE criteria, we downgraded the certainty of the ev-
idence three levels from high to very low, partly because of this
imprecision, partly for a risk of selective reporting (Guyatt 2010).
Six of 16 long-term studies reasonably expected to measure death
as an outcome did not, and the absence of a protocol did not al-
low to assess whether its measurement may have been planned,
but not reported (Gheorghiade 2003; Gines 2008b; HYPOCAT
2008; Nevens 2009; Wong 2003b; Yang 2013).
Vasopressin receptor antagonists increased scores for the mental
component summary of the SF-12 (Analysis 1.2.1 (2 studies, 297
participants): MD 4.76, 95% CI 0.11 to 9.41, I2 = 63%), but
had unclear effects on the physical component summary score
(Analysis 1.2.2 (2 studies, 297 participants): MD 1.04, 95% CI
-1.81 to 3.90, I2 = 0%). We downgraded the certainty of the
evidence for these outcomes one level because we judged the results
to be at serious risk of performance bias due to likely unblinding of
the participantswith a self-reported outcome; of selective reporting
bias due to outcomes being measured at two different time-points
with only one time-point reported; of attrition bias due to more
than one third of the overall data being missing. We downgraded
two additional levels for imprecision and indirectness, because of
concerns around the validity of the SF-12 for measuring quality
of life in the context of hyponatraemia.
Five studies evaluated cognitive function (BALANCE 2010;
HARMONY 2012; LIBRA 2012; INSIGHT 2016; Salahudeen
2014). In three studies, two of which provided data that could
reliably contribute to meta-analysis ((BALANCE 2010; LIBRA
2012), investigators used the trail making test part B, a neuropsy-
chological test of visual attention and task switching. They found
lixivaptan did not shorten the time to complete the test (Analysis
1.3 (858 participants): MD 6.89 sec, 95% CI -6.34 to 20.12).
A fourth study tested reaction time, psychomotor and process-
ing speeds and found no difference in change between the groups
(INSIGHT 2016, 56 participants, 0.20, 95% CI -0.10 to 0.50).
The fifth study, assessing the change in mini mental state exam
with tolvaptan, found no change from baseline (Salahudeen 2014,
30 participants, MD -0.70, 95% CI -2.23, 0.83). We considered
the evidence of moderate certainty, downgrading one level mainly
because of some indirectness and imprecision as it is unclear to
what extent the used tools reflect the impairment thought to be
caused by hyponatraemia, and the outcome was infrequently stud-
ied.
Three studies found vasopressin receptor antagonists shortened
hospital stay anywhere between 0.3 and 3 days (Analysis 1.4 (3
studies, 610 participants): MD -1.63 days, 95% CI -2.96 to -
0.30, I2 = 0%). We downgraded the certainty of the evidence one
level because we judged it at serious risk of suffering from perfor-
mance bias, as participants and personnel were likely unblinded
due to polyuria as a side-effect and this could have influenced
self-reported and professional appreciation of clinical condition
and so have influenced decision to discharge from hospital. We
downgraded an additional level for imprecision as the confidence
interval of the pooled effect included both a negligible effect and
a clinically important one.
Secondary outcomes
Vasopressin receptor antagonists caused a modest increase in
serum sodium concentration. At the end of treatment, participants
treated with placebo had an average increase in serum sodium
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concentration ranging from 0.5 to 4.7 mmol/L. In comparison,
people treated with a vasopressin receptor antagonist had an av-
erage increase that was approximately 4 mmol/L higher (Analysis
1.5 (21 studies, 2641 participants): MD 4.17 mmol/L, 95% CI
3.18 to 5.16; I2 = 91%). These results were generally consistent
for studies with shorter and longer follow-up. Although there was
substantial heterogeneity among included studies as described by
the I2, individual point estimates all favoured vasopressin recep-
tor antagonists. Investigators often also analysed serum sodium
concentration as a dichotomous outcome, defining response as an
increase of 5 to 6 mmol/L or normalisation of the absolute value.
Defined as such, the previous data translated into two and a half
as many people having a response with vasopressin receptor an-
tagonists compared with placebo (Analysis 1.6 (18 studies, 2104
participants): RR 2.49, 95% CI 1.95 to 3.18; I2 = 56%). On aver-
age 23% of participants treated with placebo had a response versus
57% treated with a vasopressin receptor antagonist. Overall, in ab-
solute terms this implies treating three adults with hyponatraemia
with a vasopressin receptor antagonist could result in one more
individual attaining an increase in serum sodium concentration
of 5 mmol/L. We downgraded the certainty of the evidence from
high to moderate because in 7/21 studies, accounting for 53% of
the total number of participants in those studies, we harboured
serious concerns around attrition bias; either because outcomes
were notmeasured in the participants that dropped out, or because
analytic techniques were used that included all measurements of
serum sodium concentration included until patient attrition, both
of which we judged would likely have overestimated the treatment
effect.
Treatment with a vasopressin receptor antagonist raised the risk of
rapid increases in serum sodium concentration by 67%, resulting
in three additional people with a rapid increase per 100 treated
with a vasopressin receptor antagonist versus placebo (Analysis
1.7 (14 studies, 2058 participants): RR 1.67, 95% CI 1.16 to
2.40; I2 = 0%). The analysis showed no significant heterogeneity.
Additional sensitivity analysis including only studies defining an
increase in serum sodium concentration of > 12 mmol/L/24 h did
not meaningfully change the results (Analysis 1.14.2 (10 studies,
1801 participants): RR 1.63, 95% CI 1.09 to 2.43; I2 = 0%).The
effects for hypernatraemia were unclear (Analysis 1.8 (10 studies,
1595 participants): RR1.37, 95%CI 0.63 to 3.01; I2 = 1%).None
of the included studies reported participants developing osmotic
demyelination syndrome. For similar concerns related to attrition
bias as, we considered the evidence to be of moderate certainty.
Overall, treatment with vasopressin receptor antagonists increased
the odds for thirst nearly three times compared versus treatment
with placebo (Analysis 1.9 (13 studies, 1666 participants): OR
2.77, 95% CI 1.80 to 4.27; I2 = 66%). Other side-effects were
generally less extensively reported. Nevertheless there was some
evidence vasopressin receptor antagonists substantially increased
the risk of polyuria (Analysis 1.10.1 (6 studies, 1272 participants):
RR 4.69, 95% CI 1.59 to 13.85, I2 = 0%). The risk remained
uncertain for hypotension (Analysis 1.10.2 (14 studies, 1748 par-
ticipants): RR 1.11, 95%CI 0.75 to 1.63; I2 = 0%), AKI (Analysis
1.10.3 (8 studies, 1920 participants): RR 0.89, 95% CI 0.67 to
1.18; I2 = 0%), and liver function abnormalities (Analysis 1.10.4
(3 studies, 811 participants): RR 2.43, 95% CI 0.88 to 6.70; I2 =
0%). Half of the studies in which the vasopressin receptor antag-
onist was administered intravenously evaluated important adverse
events related to the infusion itself. Overall there were almost three
times as many patients developing infusion-site phlebitis (Anal-
ysis 1.11.2 (2 studies, 133 participants: RR 3.52, 95% CI 1.00
to 12.41; I2 = 0%); the effects for infusion-site thrombosis were
less clear (Analysis 1.11.3 (2 studies, 133 participants): RR 1.75,
95% CI 0.21 to 14.80; I2 = 0%). There were slightly fewer people
who discontinued treatment when given placebo than when given
a vasopressin receptor antagonist (Analysis 1.12 (14 studies, 2429
participants): RR 0.93, 95% CI 0.85 to 1.00; I2 = 0%).
Analysis of heterogeneity
Using univariate meta-regression and subgroup analyses, we ex-
plored possible sources of heterogeneity in the effect of vasopressin
receptor antagonists on the change in serum sodium concentra-
tion. Our prespecified potential sources were: the specific vaso-
pressin receptor antagonist compound, the underlying condition
causing the hyponatraemia (with as non-prespecified categories
studies only including participants with inappropriate antidiure-
sis; studies only including participants with heart failure or liver
cirrhosis or studies including both), mean baseline serum sodium
concentration, treatment duration and risk of selection bias as
sources of heterogeneity. A higher serum sodium concentration at
baseline resulted in smaller increases in serum sodium with treat-
ment (Figure 4). Per 1 mmol/L increase in baseline serum sodium
concentration between 124 and 133 mmol/L, themean difference
on average decreased from 5.7 by 0.33 mmol/L (95% CI -0.89 to
-0.60) to 2.7 mmol/L (Table 1). There was no evidence that the
compound, the cause of hyponatraemia, the treatment duration
or risk of selection bias modified the effect of vasopressin receptor
antagonists on change from baseline in serum sodium concentra-
tion.
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Figure 4. Effect of baseline serum sodium concentration on change in natraemia: meta-regression
We observed asymmetry in the funnel plot for the outcomes of
response, suggesting the presence of small-study effects or pub-
lication bias, such that studies with small or null effects are not
in the public domain and were not uncovered by our sensitive
searching (Figure 5, Peters’ regression test, P = 0.002). Sensitivity
analysis for this outcome excluding four studies with the largest
effect estimates and largest estimate of variance reduced the rela-
tive risk with 30% (RR 2.07, 95% CI 1.67 to 2.56). However, the
funnel plots for other related outcomes were more symmetrical.
No asymmetry was observed in funnel plots for change and rapid
increase in serum sodium concentration, thirst, treatment discon-
tinuation, and data for death, length of hospital stay, cognitive
function, hypernatraemia or other adverse events were insufficient
to allow for detection of small-study effects.
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Figure 5. Funnel plot of comparison: 1 Vasopressin receptor antagonists versus placebo or no treatment,
outcome: 1.6 Response in serum sodium concentration.
Sensitivity analysis
Including the number of deaths occurring during follow-up rather
than during treatment had little effect on the estimate of the treat-
ment effect (Analysis 1.13 (16 studies, 2404 participants): RR
1.10, 95% CI 0.91 to 1.32).
For the serum sodium concentration analysis, when we excluded
seven studies judged at high or unclear risk of performance bias,
the summary treatment estimate remained unchanged (14 studies,
1458 participants: MD 4.89 mmol/L, 95% CI 4.02 to 5.76).
When we excluded eight studies judged at high or unclear risk
of attrition bias, we found similar treatment effect estimates (13
studies, 1342 participants: MD 4.71 mmol/L, 95% CI 3.34 to
6.08).
Conivaptan versus conivaptan
Kalra 2011 (117 participants) compared four regimens with or
without a loading dose with one another and found no significant
difference in any of the measured outcomes (death, change from
baseline serum sodium concentration, response in serum sodium
concentration, thirst, injection-site phlebitis, injection-site throm-
bosis, treatment discontinuation (data not shown).
Tolvaptan versus tolvaptan
Shoaf 2017 (30 participants) compared 3 single doses with one
another and found rapid correction in 1, 1 and 2 subjects in the
3.75, 7.5, and 15 mg dose groups respectively, but only abstract
data was available and the number of participants in each group
was not reported (data not shown).
Fluid restriction versus normal maintenance fluid
treatment
Singhi 1995 (26 participants) compared fluid restriction (calcu-
lated as 65% of normal) versus normal maintenance intravenous
fluid administration in children with bacterial meningitis. At two
days, administration of restricted volumes significantly increased
the serum sodium concentration (Figure 6 (1 study, 26 partici-
pants): MD 4.40 mmol/L, 95% CI 1.79 to 7.01), but had uncer-
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tain effects on the risk of death (Figure 6 (1 study, 26 participants):
RR 7.80, 95% CI 0.46 to 131.62).
Figure 6. Single study results
Captopril and furosemide versus captopril
Dzau 1984 (14 participants) found after five days of treatment, the
combination of captopril and furosemide resulted in a 10 mmol/
L higher serum sodium concentration compared with captopril
alone (Figure 6 (1 study, 14 participants): MD 10.00 mmol/L,
95% CI 8.60 to 11.40). The report did not include outcomes
related to death, quality of life or adverse events due to rapid
increases in serum sodium concentration caused by treatment.
Albumin versus no treatment
Jalan 2007 (24 participants) compared infusion of human salt
poor albumin in combination with fluid and sodium restriction
versus fluid and sodium restriction alone in patientswith refractory
ascites caused by liver cirrhosis. We only identified an abstract and
it did not include any comparative data.
Urea versus urea
Hayes 1987 (10 participants) compared urea given immediately
after development of hyponatraemia in people with ascites under
diuretics versus urea given after a ’no treatment interval’ of three
days. We only identified an abstract and it did not include any
comparative data.
Medication change versus standard care
NATRIPHAR 2013 (19 participants) compared a change in med-
ication regimen to standard care in older adults suspected of hav-
ing drug-induced hyponatraemia. Compared with standard care,
changing the medication regimen had uncertain effects on risk
of death (Figure 6 (1 study, 19 participants): RR 0.37, 95% CI
0.02 to 8.01), response in serum sodium concentration (Figure
6 (1 study 14 participants): RR 10.11, 95% CI 0.68 to 150.68)
and change from baseline in serum sodium concentration at one
month (Figure 6 (1 study, 14 participants): MD 1.70, 95% CI -
1.39 to 4.79). No participant in either group developed hyperna-
traemia or osmotic demyelination syndrome.
No studies evaluated the effects of urea, mannitol, loop diuretics
with or without oral sodium chloride, corticosteroids, demeclocy-
cline, lithium or phenytoin with regard to correction of hypona-
traemia.
D I S C U S S I O N
Summary of main results
This review included evidence from 35 randomised controlled tri-
als involving 3429 participants, primarily covering vasopressin re-
ceptor antagonists. Generally, the evidence for patient-important
outcomes was limited. Vasopressin receptor antagonists had very
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uncertain effects on mortality and health-related quality of life.
There was low certainty evidence for a reduction in hospital stay
(1.6 days) and for the absence of an important improvement in
cognitive function.
Most studies have focused on the intermediate biochemical out-
come and there was moderate certainty evidence that vasopressin
receptor antagonists increased the serum sodium concentration (4
mmol/L). But they were also associated with an increased risk of
rapid serum sodium correction and commonly caused adverse ef-
fects such as thirst and polyuria. On average, treating 1000 people
would cause 290 additional people to have an increase in serum
sodium concentration of at least 5 mmol/L, but it would come
at a cost of an additional 29 people having an increase exceeding
8 to 12 mmol/L/d, considered as the threshold from which on
there is an increased risk for osmotic demyelination, be it that no
such cases were documented in any of included studies. Effects
were generally consistent across the different drugs in this class.
RCT data for other interventions such as fluid restriction, urea,
mannitol, loop diuretics, corticosteroids, demeclocycline, lithium
and phenytoin were largely absent.
Overall completeness and applicability of
evidence
Although the FDA and the EMA have approved certain vaso-
pressin receptor antagonists for treating people with hypona-
traemia, regulatory approval was largely based on intermediate
outcomes in short-term studies. To date, clinically important out-
comes (e.g. reduction in all-cause mortality or improvement in
health-related quality of life, cognitive and general functional sta-
tus) remain insufficiently investigated. The data we had, indicated
with moderate confidence that vasopressin receptor antagonists
modestly increased the serum sodium concentration, but there is
insufficient evidence to conclude this truly translates in the im-
provement of patient-important outcomes.
In the context of intervention studies, a surrogate or intermediate
is a measurable outcome such as a laboratory test, which responds
to an intervention (e.g. lowering of cholesterol with statins) and is
causally associated a clinically important outcome (e.g. reduction
in mortality with statins) (Ballinger 2014). Investigators often use
surrogates instead of important health outcomes because surro-
gates can substantially reduce the cost, sample size and duration
of a randomised trial. However, not all are valid proxies of clin-
ically important outcomes. It is true that in acute and profound
hyponatraemia, the evidence from observational studies is so over-
whelming that we readily accept that increasing the serum sodium
concentration is life-saving. But as we move further from the ex-
treme of acute, profound hyponatraemia into chronic, mild hy-
ponatraemia, the evidence for such a consistent causal link weak-
ens. Although it is true that a chronically low serum sodium con-
centration is strongly and consistently associated with increased
mortality and risk of bone fractures (Wald 2010), there is currently
insufficient evidence that aside from affecting the surrogate (e.g.
increase in serum sodium concentration with a vasopressin recep-
tor antagonist) treatment in case of more chronic hyponatraemia
also changes the patient-important outcomes downstream of the
surrogate in the same causal pathway (e.g. reduction in mortal-
ity as a consequence of raising serum sodium concentration with
a vasopressin receptor antagonist). There are intuitive reasons to
assume that such causality can reasonably be extrapolated to the
entire spectrum of hypotonic hyponatraemia. But likewise, there
are reasons for caution. Lixivaptan primarily failed to obtain reg-
ulatory approval by the FDA for hyponatraemia in chronic heart
failure due to a numeric - be it statistically non-significant - imbal-
ance in early deaths. The clinical review team argued that ’while
the early death in participants with chronic heart failure and hy-
ponatraemia could reflect the underlying disease, they could not
exclude the possibility that some subjects with hyponatraemia as-
sociated with acute worsening congestive failure were exquisitely
sensitive to intravascular free water shifts and did not tolerate even
a small change in intravascular volume status or osmolality, in-
duced by lixivaptan and/or effects resulting from a compensatory
neurohumoral activation’ (BALANCE 2010).
Studies contributing to this review included mostly participants
with mild to moderate hyponatraemia (mean serum sodium con-
centration at study level≥ 123mmol/L).Meta-regression revealed
a modifying effect of the serum sodium concentration at baseline,
with lower values associated with larger increases in natraemia. Ex-
trapolation ofmeta-regression datawould suggest higher increases,
but possibly higher risks of rapid correction as the baseline serum
sodium decreases. Although no study reported osmotic demyeli-
nation, it is unclear what would happen if vasopressin receptor
antagonists were used on a larger scale and in people with sodium
concentrations below those included in the RCTs that contributed
to this review. Likewise, it is possible that while improvements in
cognitive function were not readily detected, they would emerge
for people with lower serum sodium concentrations at baseline.
Finally, studies evaluating the effectiveness of alternative interven-
tions for increasing serum sodium concentration in people with
chronic, non-hypovolaemic hyponatraemia are largely absent.
Quality of the evidence
Overall, we considered the data evaluating the effects of vasopressin
receptor antagonists for people with chronic, non-hypovolaemic,
hypotonic hyponatraemia on patient-important outcomes such as
mortality, health-related quality of life, and hospital stay limited
and of low certainty. Low certainty evidence suggests that addi-
tional studies are likely to change our confidence in the effects
(GRADE 2008). According to GRADE, RCT data is considered
high quality, but may be downgraded for several reasons (Guyatt
2010). These reasons varied for each outcome. For death it was
largely driven by the width of the confidence interval, which cap-
tured both appreciable benefit and harm, and left us with consid-
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erably uncertainty around the treatment effect. For health-related
quality of life, there was some evidence that vasopressin receptor
antagonists increased themental component summary score of the
SF-12, and unclear effects on the physical component summary
score. However, we serious questioned the validity of this tool for
measuring quality of life in the context of hyponatraemia. For one
thing, many items included in the SF-12 do not reflect readily
acknowledged signs and symptoms of hyponatraemia (e.g. bodily
pain, anxiety) and similarly, the neurocognitive signs of hypona-
traemia are not assessed by the tool. In addition to the general
content validity issues, we also judged effects for this self-reported
outcome may have been inflated because participants were likely
unblinded due to polyuria as a side-effect; results were selectively
reported for one in two measurement time-points; and more than
one-third of the data were missing.
We hadmore extensive data for outcomes related to serum sodium
concentration, resulting in moderate confidence in the effect esti-
mates all around. Downgrading occurred mainly for missing out-
come data, which we judged could have somewhat overestimated
the treatment effect; as well as indirectness, in that tight follow-
up during dose-titration, is likely to have avoided rapid correction
somewhat in the trial setting. It may result in higher risk of rapid
correction when used in clinical practice.
Of note, all studies assessing benefits and harms of vasopressin
receptor antagonists were likely instigated and sponsored by the
pharmaceutical company developing or seeking to commercialise
the compound. For the studies that provided a declaration of in-
terest for the authors of study reports, all save one had author
lists that featured people who had received money for presenta-
tions or consultancy, or were employed by the sponsor. Industry
sponsorship does not necessarily introduce bias into the design
and conduct of clinical trials, but empiric evidence does show that
pharmaceutical industry-sponsored studies are more likely to have
favourable efficacy results (RR 1.32, 95% CI 1.21 to 1.44) and
harm results (RR 1.87, 95% CI 1.54 to 2.27) than studies not
sponsored by industry (Lundh 2012).
Data for other interventions such as fluid restriction, change in
medical regimens, captopril or albumin were sparse and inconclu-
sive.
Potential biases in the review process
Although this review was conducted by two or more independent
authors, used a comprehensive search of the published and unpub-
lished research designed by a specialist librarian, and examined all
potentially relevant clinical outcomes, potential biases exist in the
review process. The major weakness of this review is the paucity
of data for treatments other than vasopressin receptor antagonists.
First, summary of existing evidence therefore focusses the discourse
on new, and expensive, treatments, rather than focusing on exist-
ing, and cheaper alternatives. RCTs are extraordinarily expensive
and consequently often conducted by the pharmaceutical indus-
try. This results in a catch-22 situation of evidence being mostly
created, and thus only available, for newer interventions in general.
Many other interventions are or have been used in clinical prac-
tice, but were driven to the background because RCT data were
largely absent. Notably, also for fluid restriction, despite it being
the currently accepted first-line treatment for both hypervolaemic
and euvolaemic hyponatraemia, there are no randomised trial data
available. Currently, there are limited opportunities for use of va-
sopressin receptor antagonists in practice. Only two vasopressin
receptor antagonists have obtained large scale regulatory approval.
Conivaptan is FDA approved for euvolaemic and hypervolaemic
hyponatraemia in hospitalised patients. It is available only as an in-
travenous preparation and treatment duration is limited to a max-
imum duration of four days because of drug-interaction effects
with other agents metabolized by the cytochrome P450 3A4 hep-
atic isoenzyme (FDA 2012). Tolvaptan, an oral agent, is also FDA-
approved for the treatment of euvolaemic and hypervolaemic hy-
ponatraemia. Although theoretically available for long-term treat-
ment, recent concerns around the potential for severe liver injury
in patients with autosomal dominant polycystic kidney disease -
be it at doses far exceeding the ones used in hyponatraemia - has
caused the FDA to restrict the use of tolvaptan to 30 days and
issue a contra-indication for patients with underlying liver disease
(Mirski 2013). Canadian regulatory authorities mandated moni-
toring liver injury tests at regular intervals, but did not limit du-
ration of use. In the European Union, tolvaptan is approved only
for the treatment of euvolaemic hyponatraemia, due to safety con-
cerns stemming from a numeric - be it statistically non-significant
- difference in treatment-emergent fatalities in patients with hy-
pervolaemia.
Agreements and disagreements with other
studies or reviews
This review largely agreed with the findings of two earlier system-
atic reviews. However, neither of these previous reviews sought to
examine any other treatments beyond vasopressin receptor antag-
onists for treating chronic non-hypovolaemic hypotonic hypona-
traemia. The first, including 15RCTs and 1619 participants found
vasopressin antagonists on average increased the serum sodium
concentration by approximately 5 mmol/L at one week (13 stud-
ies, 1119 participants: MD 5.27 mmol/L, 95% CI 4.27 to 6.26),
and approximately 3.5 mmol/L beyond the first week (8 studies,
793 participants: MD 3.49 mmol/L, 95% CI 2.56 to 4.41), but
it came at a cost of increased risk of overly rapid correction of
the serum sodium concentration (8 studies, 860 participants: RR,
2.52, 95% CI 1.26 to 5.08) (Rozen-Zvi 2010).The second review,
including 11 RCTs and 1094 participants, found vasopressin an-
tagonists on average increased the serum sodium concentration by
approximately 5 mmol/L at day 4 (11 studies, 1094 participants:
MD 4.90 mmol/L, 95% CI 4.10 to 5.80), but was associated with
a 6% increased risk of overly rapid correction of the serum sodium
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concentration (9 studies, 995 participants: RD 0.06, 95%CI 0.03
to 0.10) (Jaber 2011).
We also largely agreed with the interpretation of these data by
the respective study authors as presented in their discussion: va-
sopressin receptor antagonists effectively raise the serum sodium
concentration. But whether this translates to meaningful changes
in outcomes that matter to patients is not clear. At this stage the
available RCTs have insufficiently studied clinical outcomes to
conclude that people whose serum sodium concentration increases
under treatment will experience changes in end-points such as
general well-being, cognitive function, gait stability, bone fractures
and survival.
In 2013, a guideline group consisting of seven authors (six Ameri-
cans and one Irishman), published expert recommendations iden-
tifying several alternative treatments, including fluid restriction,
demeclocycline, urea and vasopressin receptor antagonists. Driven
by the emergence of RCT evidence for vasopressin receptor an-
tagonists as effective means for increasing the serum sodium con-
centration, and the absence of such evidence for other treatments,
they projected vasopressin receptor antagonists were likely to be-
come a mainstay of treatment for euvolaemic hyponatraemia and
probably represented the best approach to treating hyponatraemia
in most oedema-forming states (Verbalis 2013).
A European guideline published in 2014 - to which four authors of
this review contributed - suggested that in moderate or profound
hyponatraemia (serum sodium concentration < 130 mmol/L), re-
stricting fluid intake was first-line treatment (2D); increasing so-
lute intake with urea or a combination of low-dose loop diuretics
and oral sodium chloride were equal second-line treatments (2D);
and vasopressin receptor antagonists were not recommended (1C).
(Spasovski 2014). There is almost no RCT evidence for treatments
other than vasopressin receptor antagonists. The group’s rationale
to advocate some of these treatments anyway stemmed from the
premise that in the absence of unequivocal evidence that increas-
ing the serum sodium concentration leads to an improvement
in patient-important outcomes, the focus should be on avoiding
harm. They gave much weight to avoiding rapid increases in the
serum sodium concentration, for it’s - albeit very rare - association
with osmotic demyelination syndrome. And based on the absence
of observational evidence for rapid increases or other important
harms for fluid restriction, urea and low-dose loop diuretics with
oral sodium chloride, they formulated a weak recommendation
to consider these for treating people with sodium concentrations
below 130 mmol/L. Largely because of the documented risk of
rapid increase and some concern around its potential for liver dis-
ease, a negative recommendation was formulated for vasopressin
receptor antagonists.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with chronic hyponatraemia, vasopressin receptor an-
tagonists modestly raise serum sodium concentration at the cost
of an absolute 3% increased risk the increase being too rapid. To
date there is insufficient evidence for patient-important outcomes;
the effects on mortality and health-related quality of life are un-
clear and do not rule out appreciable benefit or harm; there does
not appear to be an important effect on cognitive function, but
hospital stay may be shorter, although available data are limited.
Treatment decisions must weigh the value of an increase in serum
sodium concentration against it short-term risks and unknown
effects on patient-important outcomes. Evidence for other treat-
ments is largely absent.
Implications for research
Further studies assessing commonly used treatments such as fluid
restriction would inform practice and are warranted. Also, given
the limited available evidence for patient-important outcomes,
studies with vasopressin receptor antagonists and other treatments
should include these outcomes in a standardised way. Importantly,
this requires validation of health-related quality of life measures,
tailored specifically to the context of hyponatraemia and interna-
tional consensus on how to assess hyponatraemia-specific symp-
toms.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACTIV in CHF 2003
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: yes, but randomisation not stratified according to the
subgroup
• Recruitment period: 2000 to 2001
• Treatment duration: 60 days
• Follow-up: 60 days
Participants • Countries: Argentina; USA
• Number of centres: 44
• Inclusion criteria: in-patients, hospitalised for acute exacerbation of CHF; ≥ 18
years; serum sodium concentration was not an inclusion criterion for primary study -
we included subgroup with serum sodium concentration ≤ 135 mmol/L; NYHA class
III or IV cardiac disease at screening - 2 of the following signs of heart failure: elevated
jugular vein distention; rales; chest X-ray with signs of radiographic congestion, pedal
oedema, increased abdominal girth, weight gain > 10 pounds above baseline; admission
to hospital for heart failure within 96 hours of screening
• Exclusion criteria: women of childbearing age; cardiac surgery within 60 days;
MI, sustained ventricular tachycardia, or ventricular fibrillation within 30 days; angina
at rest; primary valvular disease; hypertrophic cardiomyopathy; stroke within last 6
months; significant hepatic, renal or haematologic dysfunction; systolic arterial BP <
110 mm Hg; use of drugs known to inhibit CYP3A4 within 7 days of randomisation;
amiodarone within 10 weeks; nonsteroidal anti-inflammatory agents or aspirin > 700
mg/d; substance or alcohol abuse; uncontrolled diabetes mellitus; urinary tract
obstruction; morbid obesity; malignancy or another terminal illness.
• Characteristics randomised participants
◦ Number: treatment group 1 (15); treatment group 2 (23); treatment group 3
(15); control group (16)
◦ Number, % women: 23, 33%; numbers not reported for individual groups
◦ Age: median 65, range 52-72 years; age not reported for individual groups
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (133
± 3); treatment group 2 (131 ± 4); treatment group 3 (132 ± 3); control group (133 ± 2)
◦ Cause of hyponatraemia: heart failure (100%)
Interventions Treatment group 1
• Oral tolvaptan: 1 x 90 mg/d
Treatment group 2
• Oral tolvaptan: 1 x 60 mg/d
Treatment group 3
• Oral tolvaptan: 1 x 30 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: no
• Dietary sodium intake: no
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ACTIV in CHF 2003 (Continued)
• All received standard heart failure treatment including diuretics at the discretion
of the investigator
Outcomes • Death
• Response in serum sodium concentration: serum sodium concentration > 135
mmol/L. Insufficiently reported to allow contribution to meta-analysis
• Serum sodium concentration (continuous outcome): absolute values at discharge
Notes • Funding source: Otsuka Maryland Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’Eligible patients were randomised
... using an interactive voice recognition
system programmed with a computer-gen-
erated randomisation scheme. Randomiza-
tion was stratified by study centre in blocks
of 4.’
Comment: the randomisation procedure
produced groups in the overall study that
were not entirely balanced in age and sex,
but fairly well-balanced in terms of med-
ical history and characteristics related to
the heart failure. However, randomisation
was not stratified for serum sodiumconcen-
tration. Despite fairly similar numbers of
participants in both the experimental and
the control group, no baseline data avail-
able specifically for subgroup with hypona-
traemia, making judgement on risk of bias
difficult. The sequence generation in the
overall study was good and low risk. How-
ever this is a subgroup analysis with low
numbers relative to the number of groups
and the sequence did not stratify for them
Allocation concealment (selection bias) Low risk Quote: ’Patients were screened within 72
hours and randomised within 96 hours
of admission. Randomization occurred be-
tween 8 and 9 AM; the study drug was to
be administered at 9 AM.’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’...patients...randomised to receive .
.. tolvaptan or placebo. ’ and ’...was amulti-
center, randomised, double-blind, placebo-
controlled... trial’
Additional info provided by the spon-
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ACTIV in CHF 2003 (Continued)
sor: ’Both OPC-41061 and placebo tablets
were identical in appearance’
Comment: blinding attempted, although
participants are unlikely to be fully blinded
due to important increases in urine output.
Also, co-interventions were not reported in
detail and included standard heart failure
treatment left at discretion of investigator
and may have differed between groups ac-
cording to baseline serum sodium concen-
tration. This could have influenced out-
come measurement of serum sodium con-
centrations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional info provided by the sponsor:
’Did not have separate outcome assessors
in this trial’
Comment: blinding outcome assessors at-
tempted and measured outcome objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 10% attrition for outcome
death at 60 days; only 1 participant (1%)
excluded from analysis because of miss-
ing follow-up serum sodium concentration
measurement
Selective reporting (reporting bias) High risk Comment: protocol available with
matched primary and secondary outcomes
for the overall study. However, results in-
cluded in this review for the subgroup with
hyponatraemia are based on post-hoc anal-
yses of the data, with reported outcomes
not matching the primary and secondary
outcomes of the original study
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ ’All authors served as
consultants for Otsuka Maryland
Research Institute, received grants or
honoraria from the company, or both.’
◦ Comment: senior authors of
reports pertaining to this study are heavily
linked to the company commercialising
the study medication.
• Sponsorship bias
◦ Quote: ’The ACTIV in CHF
study and this analysis were funded by
Otsuka Maryland Research Institute’
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Annane 2009
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 5 days
• Follow-up: 12 days
Participants • Countries: Belgium; Finland; France; Germany; Italy; Netherlands; Poland;
Spain; UK
• Number of centres: 17
• Inclusion criteria: aged ≥ 18 years; serum sodium concentration < 130 mmol/L;
euvolaemia or hypervolaemia, plasma osmolality < 290 mOsmol/kg, fasting blood
glucose < 126 mg/dL
• Exclusion criteria: females if breast-feeding or pregnant; clinical volume depletion
or dehydration; symptomatic hypotension, uncontrolled hypertension, arrhythmias
requiring pacemaker or emergency treatment; untreated thyroid disorders, adrenal
insufficiency; known urinary outflow obstruction unless catheterized; SCr >2.7 mg/dL,
proteinuria > 3 g/24h, liver enzymes > 3 times upper limit of normal; bilirubin ≥ 2.5
mg/dL, < 3x 103 white blood cells/µL, humane immuno-deficiency virus infection or
active hepatitis; symptomatic hyponatraemia, expected to require emergent treatment;
any concurrent illness that could interfere with study treatment or its evaluation;
arginine vasopressin, oxytocin, or desmopressin or drugs interacting with CYP450
3A4, including certain chemotherapeutic agents, calcium channel blockers, statins,
benzodiazepines, and class III antiarrhythmic drugs; medications for SIADH
discontinued for 1 week before screening; thiazide diuretics permitted if therapy
initiated < 1 month before study enrolment
• Characteristics randomised participants
◦ Number: treatment group 1 (26); treatment group 2 (27); control group (30)
◦ Number, % women: treatment group 1 (7, 27%); treatment group 2 (9,
33%); control group (12, 40%)
◦ Mean age ± SD (years): treatment group 1 (63 ± 11); treatment group 2 (62
± 15); control group (69 ± 13)
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (126
± 4); treatment group 2 (125 ± 5); control group (126 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (12, 46%); heart failure (7, 27%); unclear
(7, 27%)
⋄ Treatment group 2: SIADH (7, 26%); heart failure (12, 44%); unclear
(8, 30%)
⋄ Control group: SIADH (12, 40%); heart failure (8, 40%); unclear (7,
23%); postsurgical (3, 10%)
Interventions treatment group 1
• Oral conivaptan: 2 x 40 mg/d
Treatment group 2
• Oral conivaptan: 2 x 20 mg/d
Control group
• Placebo: not otherwise defined
Co-interventions (all groups)
• fluid restriction: 500 mL in any 3-hour period or 2 L/d, unless changes required
for safety reasons
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Annane 2009 (Continued)
• dietary sodium intake: not reported
Outcomes • Death
• Response: serum sodium concentration ≥ 135 mmol/L or increase from baseline
≥ 6 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline until
end of treatment
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration ≥ 145 mmol/L during
treatment
◦ Rapid increase in serum sodium concentration: serum sodium concentration
≥ 145 mmol/L or an increase in serum sodium concentration from baseline ≥ 12
mmol/L/d
• Treatment-specific side-effects
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined (no extractable data reported)
◦ Liver function abnormalities: elevated liver transaminase
◦ Serious adverse event: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Astellas Pharma US, Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’Eligible patient ... were stratified
according to volume status and then ran-
domly assigned in a 1:1:1 ratio...’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’This double-blind, placebo con-
trolled ... study’, and ’...patients ... were.
..assigned to ... or placebo’, and ’All pa-
tients were prescribed fluid restriction (not
to exceed 500 mL in any 3-hour period
or 2.0 L in a 24-hour period for both oral
and parenteral fluids) prior to baseline and
throughout the study, unless changes were
necessary for safety reasons’, and ’Four pa-
tients, 2 given conivaptan 80 mg/d and 2
given placebo, violated the 2-L/d fluid re-
striction.’
Comment: blinding attempted, and al-
though participants and personnel are un-
40Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Annane 2009 (Continued)
likely to be fully blinded due to important
increases in urine output, all measured out-
comes short-term and generally objective.
Fluid restriction was prescribed in both
groups, violations reported and similar be-
tween groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors
probably attempted and main outcomes
objective. Unlikely for participants to have
been fully blinded, and plausible ’high risk’
of bias for self-reported outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 13% attrition; reasons
well documented, most occurred in the
placebo group due to adverse events. Given
<20%attrition and limited opportunity for
introducing bias in such a short-term study
- we judged it ’Low risk’
Selective reporting (reporting bias) Low risk Comment: no protocol, short term study
(≤1 week), primary outcome death and
secondary outcomes related to serum
sodium concentration and rapid increase in
serum sodium concentration reported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Guy Decaux was a paid
investigator for this trial. Neila Smith was
employed by Astellas Pharma US, Inc.
◦ Comment: Senior author was
an employee of the company
commercialising the study medication
• Sponsorship bias
◦ ’This study was supported by
Astellas Pharma US, Inc.’
BALANCE 2010
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2008 to 2010
• Treatment duration: 60 days
• Follow-up: 90 days
Participants • Country: Argentina; Canada; Chile; Czech Republic; Germany; India; Israel;
Italy; Poland; Romania; Russia; Slovakia; Spain; USA
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BALANCE 2010 (Continued)
• Number of centres: 173
• Inclusion criteria: inpatients, hospitalised for acute worsening of CHF; ≥ 18
years; serum sodium concentration 120 to < 135 mmol/L; NYHA III or IV; clinical or
laboratory evidence of volume overload, baseline fluid restriction 1.5 L/d
• Exclusion criteria: severe symptoms requiring immediate intervention; supine
systolic BP < 90 mm Hg; advanced liver disease/cirrhosis; adrenal insufficiency;
uncorrected thyroid disease; uncontrolled diabetes mellitus; inability to respond to
thirst with increased fluid intake
• Characteristics randomised participants
◦ Number: treatment group (323); control group (329)
◦ Number, % women: treatment group (90, 28%); control group (95, 29%)
◦ Mean age ± SD (years): treatment group: (65 ± 14); control group (65 ± 13)
◦ Serum sodium concentration: median 132 mmol/L; concentration not
reported for groups
◦ Cause of hyponatraemia: heart failure (100%)
Interventions Treatment group
• Oral lixivaptan: 1 x 50 mg/d up to 2 x 100 mg/d
Control group
• Oral placebo: 1 x 1 capsule/d
Co-interventions (all groups)
• Fluid restriction: discouraged during dose titration, at discretion of treating
physician
• Dietary sodium intake: not reported
Outcomes • Death
• Response: serum sodium concentration ≥ 135 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline
• Cognitive function: change from baseline time to complete the trial making test
part B, a neuropsychological test of visual attention and task switching
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase ≥ 8 mmol/L during first 8 hours, > 12 mmol/L during first 24 hours or > 18
mmol/L during first 48 hours
• Treatment-specific side-effects
◦ AKI: not otherwise defined
◦ Liver function abnormalities: elevated AST > 3 times the upper limit of
normal
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Cardiokine Inc.
• ClinicalTrials.gov: NCT00578695
• Data source: FDA Briefing Document for the Cardiovascular and Renal Drugs
Advisory (CRDAC)
Risk of bias
Bias Authors’ judgement Support for judgement
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BALANCE 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: ’...subjects were randomised by an
Interactive Voice Response System...’
Comment: central allocation occurred.
Allocation concealment (selection bias) Low risk Quote: ’...subjects were randomised by an
Interactive Voice Response System...’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’... double-blind, placebo-con-
trolled phase 3 trial...’
Comment: Blinding of participants and
personnel probably attempted, but insuf-
ficient information to assess the extent to
which it was achieved or to permit judge-
ment of ’High risk’ or ’Low risk’.. Co-in-
terventions were left at the discretion of the
treating physician
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’The Clinical Endpoints Committee was
to perform a review (blinded to treatment
group and serum sodium levels) and ad-
judicate all events assessed by the investi-
gators as clinical endpoints using predeter-
mined criteria for each end-point...’
Comment: blinding probably attempted
and although un-blinding likely to have oc-
curred for serum sodium concentration, as-
sessment of other outcomes done by inde-
pendent blinded adjudication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’The FDA statistical reviewer, Dr
Jialu Zhang, also performed a number of
sensitivity analyses to assess the impact of
missing values... All these sensitivity anal-
yses showed consistent results: a statisti-
cally significant treatment effect on serum
sodium with a modest effect size in the
range 1.2 to 1.4 mEq/L.’
Comment: overall 27% discontinuation at
30days, < 1%ofwhich never received treat-
ment; 50% of discontinuations occurred
in placebo group. Last observation carried
forward method was used as imputation
method for dealing with missing serum
sodium concentration values, which could
have caused overestimation of the effect of
the study medication. However, sensitivity
analyses conducted by the FDA statistical
reviewer indicated this effect to be negligi-
43Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BALANCE 2010 (Continued)
ble. Cognitive function tests were taken at
day 30 or the early termination visit. Given
the better scores in the placebo group, any
bias would only serve to increase the dif-
ference further in favour of the placebo
group and would not change the conclu-
sions drawn from the analysis
Selective reporting (reporting bias) Low risk Comment: the study was registered with
ClinicalTrials.gov, but no clear listing of
predefined outcome measures and time-
points. Given early stopping of trial due
to numerically more deaths in treatment
group, selective outcome reportingunlikely
to be an issue
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ No declaration of interest: data
used in this review is drawn from the
FDA briefing document
• Sponsorship bias
◦ Comment: The study sponsor
was Cardiokine Inc.
Decaux 2006
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 4 days
• Follow-up: 1 year
Participants • Countries: not reported
• Number of centres: not reported, but multi-centre
• Inclusion criteria: setting (not reported); age (not reported); serum sodium
concentration 115 to ≤ 132 mmol/L; SIADH treated with fluid restriction up to 1.5
L/d
• Exclusion criteria: not reported
• Characteristics included participants
◦ Number: treatment group 1 (22); treatment group 2 (24); control group (23)
◦ Number, % women: not reported
◦ Age: not reported
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (129
± 3); treatment group 2 (129 ± 5); control group (128 ± 4)
◦ Cause of hyponatraemia: SIADH not reported
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Decaux 2006 (Continued)
Interventions Treatment group 1
• Oral satavaptan: 1 x 50 mg/d
Treatment group 2
• Oral satavaptan: 1 x 25 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: not reported, participants were treated with fluid restriction at
enrolment
• Dietary sodium intake: not reported
Outcomes • Response: serum sodium concentration ≥135 mmol/L or increase from baseline
≥ 5 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline.
Insufficiently reported to allow contribution to meta-analysis
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase ≥ 8 mmol/L during the first day
◦ Osmotic demyelination syndrome: any neurological adverse event
• Treatment-specific side-effects: insufficiently reported to allow contribution to
meta-analysis
◦ Thirst: not otherwise defined
◦ Adverse events: defined as treatment-emergent adverse events
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Sanofi Aventis
• Publication: abstract only; contact author confirmed the study was never
published in any form other than abstract form
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’randomised... study’, and ’Patients
... were randomly assigned’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’...double-blind,
placebo-controlled...study’, and ’Patients..
.were... assigned to ... or placebo’
Comment: blinding probably attempted,
but insufficient information to assess to
what extent it was achieved or to permit
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Decaux 2006 (Continued)
judgement of ’High risk’ or ’Low risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective. Unlikely for
participants to have been fully blinded, and
plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: overall 16% attrition, reasons
not documented. Given < 20% attrition
in short-term study, we judged this not at
high risk of bias per se, rather insufficient
information to permit judgement of ’High
risk’ or ’Low risk’
Selective reporting (reporting bias) Low risk Comment: no protocol, short-term study
(≤ 1 week), secondary outcomes related to
serum sodium concentration and over-cor-
rection of serum sodium concentration re-
ported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ No declaration of interest
• Sponsorship bias
◦ Quote: ’Grant/Research
Support: Sanofi-Aventis; Consultant:
Sanofi-Aventis
DILIPO 2011
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 4 days
• Follow-up: not reported
Participants • Countries: Argentina; Australia; Belgium; Canada; Chile; Denmark; Greece;
Hungary; Israel; Poland; Portugal; Romania; South Africa; Sweden; USA
• Number of centres: 48
• Inclusion criteria: setting not reported; ≥ 18 years; serum sodium concentration
115 to < 132 mmol/L; dilutional hyponatraemia not caused by SIADH or liver
cirrhosis
• Exclusion criteria: adrenal insufficiency; untreated hypothyroidism; clinical or
laboratory evidence of hypovolaemia; fasting glycaemia ≥ 200 mg/dL; Hb < 9 g/dL,
neutrophil cell count < 1500/µL, platelet count < 100,000/µL; SCr > 2 mg/dL or CrCl
< 30 mL/min; serum ALT or AST > 2 times upper limit of normal; QTcB interval ≥
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DILIPO 2011 (Continued)
500 ms; serum potassium concentration > 5 mmol/L; having received inducers of
CYP3A4 or potent and moderate inhibitors of CYP3A4 < 2 weeks before study; other
AVP V2-receptor antagonists, lithium or demeclocycline < 1 month before study, urea
< 2 days before study; positive pregnancy test and absence of medically approved
contraceptive methods; pregnancy or breast-feeding
• Characteristics randomised participants
◦ Number: treatment group 1 (41); treatment group 2 (35); control group (42)
◦ Number, % women: treatment group 1 (16, 39%); treatment group 2 (19,
54%); control group (15, 36%)
◦ Mean age ± SD (years): treatment group 1 (71 ± 12); treatment group 2 (69
± 16); control group (69 ± 11)
◦ Serum sodium concentration (mmol/L): treatment group 1 (128 ± 4);
treatment group 2 (128 ± 4); control group (129 ± 3)
◦ Cause of hyponatraemia
⋄ Treatment group 1: heart failure 28 (68%); other 13 (32%)
⋄ Treatment group 2: heart failure 28 (80%); other 7 (20%)
⋄ Control group: heart failure 34 (81%); other 8 (19%)
Interventions Treatment group 1
• Oral satavaptan: 1 x 50 mg/d
Treatment group 2
• Oral satavaptan: 1 x 25 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: 1 to 1.5 L/d
• Dietary sodium intake: not reported
Outcomes • Response: serum sodium concentration ≥ 135 mmol/L or increase from baseline
≥ 5 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration ≥ 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase ≥ 12 mmol/L/d
◦ Osmotic demyelination syndrome: neurologic symptoms
• Treatment-specific side-effects
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined
◦ Adverse event: not otherwise defined
◦ Serious adverse events: defined as serious treatment-emergent adverse events
• Treatment discontinuation
Notes • Funding source: Sanofi-Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote:’...eligible patients were randomly
allocated to...’, and ’4 patients were not
randomised through the interactive voice
recognition system’
Comment: Central allocation probably
occurred. The randomisation produced
groups well-balanced in age and serum
sodium concentration, less so in sex
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...patients were randomly allocated
to ... or placebo’, and ’The randomised,
double-blind, placebo-controlled ...’, and
’...recommended fluid intake 1000-1500
mL’
Comment: blinding attempted, and al-
though participants and personnel are un-
likely to be fully blinded due to impor-
tant increases in urine output, all mea-
sured outcomes short-term and fairly ob-
jective. Fluid restriction was prescribed in
all groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors
probably attempted and all measured out-
comes objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 11% attrition, due to
treatment discontinuation, reasons fairly
well documented, asymmetrically in ex-
perimental group receiving highest dose
due to adverse events. Missing data dealt
with using last observation carried forward
method.Given < 20%attrition and limited
opportunity for introducing bias in such a
short-term study - we judged it ’Low risk’
Selective reporting (reporting bias) Low risk Comment: study registered with Clini-
calTrials.gov in 2005. Primary outcome
matches, more outcomes reported than
originally registered - predominantly out-
comes related to harms. Short-term study
(≤ 1 week), secondary outcomes related to
serum sodium concentration and rapid in-
crease in serum sodium concentration re-
ported
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Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ M.M. was an employee of
Sanofi-Aventis at the time of the study. All
other listed authors have received research
funds to conduct the DILIPO study.’
◦ Comment: One of the authors
was an employee of the company
developing the study medication
• Sponsorship bias
◦ Quote: ’This study was
supported by a research grant from
Sanofi-Aventis
Dzau 1984
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 5 days
• Follow-up: 8 days
Participants • Country: USA
• Number of centres: 1
• Inclusion criteria: serum sodium concentration ≤135 mmol/L; heart failure -
NYHA class III-IV
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: treatment group (8); control group (6)
◦ Number, % women: treatment group (2, 25%); control group (0, 0%)
◦ Mean age, range: 58, 3 to 72 years
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group (129 ±
1); control group (130 ± 1)
◦ Cause of hyponatraemia: heart failure (100%)
Interventions Treatment group
• Oral captopril 3 x 12.5 mg/d up to 3 x 150 mg/d
• Furosemide: at doses adjusted to give a sustained diuretic effect without increasing
azotaemia
Control group
• Oral captopril: 3 x 12.5 mg/d up to 3 x 150 mg/d
Co-interventions (all groups)
• Fluid restriction: free access to water
• Dietary sodium intake: 0.9 g/d
Outcomes • Serum sodium concentration (continuous outcome): absolute value at end of
treatment
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Notes • Funding source: National Institutes of Health and National Aeronautics and
Space Administration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’The patients were randomly di-
vided in two groups...’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding not attempted
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding not attempted, but
main outcomes objective such that un-
blinding of outcome detection unlikely to
be an important source of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition or treatment discon-
tinuation not specifically reported, but it
appears as if all participants completed the
treatment protocol
Selective reporting (reporting bias) High risk Comment: no protocol, short-term study
(≤ 1 week), secondary outcomes related to
rapid increase in serum sodium concentra-
tion not reported
Other bias Low risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: no declaration of
interest
• Sponsorship bias
◦ Quote: ’Grant support:
supported in part by grants ... from the
National Institutes of Health and ....from
the National Aeronautics and Space
Administration.’
◦ Comment: no commercial
sponsorship
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Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: yes, randomisation not stratified based on serum
sodium concentration
• Recruitment period: 2003 to 2006
• Treatment duration: minimum 2 months
• Follow-up: 2 years
Participants • Countries: Argentina; Belgium; Brazil; Bulgaria; Canada; Czech Republic; France;
Germany; Italy; Lithuania; Netherlands; Norway; Poland; Romania; Russian
Federation; Spain; Sweden; Switzerland; UK; USA
• Number of centres: 359
• Inclusion criteria: hospital in-patients recruited within 48 hours of
hospitalisation; ≥ 18 years; serum sodium concentration not an inclusion criterion for
primary study (we included subgroup with serum sodium concentration < 135 mmol/
L); history of CHF - defined as requiring treatment for a minimum of 30 d before
hospitalisation; left ventricular ejection fraction ≤ 40%; signs of volume expansion;
NYHA III/IV; hospitalisation for exacerbation of chronic HF ≤ 48 h earlier
• Exclusion criteria: cardiac surgery < 60 days of enrolment; cardiac mechanical
support; biventricular pacemaker < 60 days; comorbid conditions with expected
survival < 6 months; acute MI at the time of hospitalisation; haemodynamically
significant uncorrected primary cardiac valvular disease; refractory end-stage heart
failure; haemofiltration or dialysis; supine systolic arterial BP < 90 mm Hg; SCr > 3.5
mg/dL; serum potassium concentration > 5.5 mmol/L; Hb < 9 g/dL; history of
hypersensitivity or idiosyncratic reaction to benzazepine derivatives; positive urine
pregnancy test; inability to provide written informed consent; history of drug or
medication abuse within the past year, or current alcohol abuse; previous participation
in this or any other tolvaptan clinical trial; inability to take oral medications;
participation in another clinical drug or device trial in which the last dose of drug was
within the past 30 d or an investigation medical device is implanted
• Characteristics included participants
◦ Number: treatment group (243); control group (232)
◦ Number, % women: treatment group (35, 14%); control group (52, 22%)
◦ Mean age ± SD (years): treatment group (64 ± 14); control group (65 ± 14)
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group (131 ±
3); control group (130 ± 4)
◦ Cause of hyponatraemia: heart failure (100%)
Interventions treatment group
• Oral tolvaptan: 1 x 30 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: not reported
• Dietary sodium intake: not reported
Outcomes • Death during follow-up
• Length of hospital stay
• Serum sodium concentration (continuous outcome): change from baseline until
day 7
• Outcomes related to over-correction of serum sodium concentration
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◦ Hypernatraemia: not otherwise defined
◦ Osmotic demyelination syndrome: not otherwise defined
• Treatment-specific side effects
◦ AKI: not otherwise defined
◦ Hypotension: not otherwise defined
◦ Thirst (categorical outcome): not otherwise defined
◦ Polyuria: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Otsuka
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’...within each centre, patients were
randomised to... according to a centralized,
blocked randomization performed using a
central Interactive Voice Response System’
Additional info provided by the sponsor:
’Subjects were not stratified by baseline
serum sodium’
Comment: the randomisation procedure
was adequate and produced well balanced
groups in the overall study. Although ran-
domisation was not stratified for serum
sodium concentration, fairly similar num-
bers of participants in both the experimen-
tal and the control group, with similar ages
and baseline serum sodium concentration
Allocation concealment (selection bias) Low risk Quote: ’...within each centre, patients were
randomised to... according to a centralized,
blocked randomisation performed using a
central Interactive Voice Response System’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’Patients...assigned to receive oral
tolvaptan 30mgormatching placebo. ’ and
’...is and international, ..., double-blind,
placebo-controlled study...’
Additional info provided by the sponsor:
’The trial drug was packaged so that each
subject received an identical number of
tablets regardless of the treatment group as-
signed’
Comment: blinding attempted, although
participants are unlikely to be fully blinded
due to important increases in urine output.
Also, co-interventions were not reported
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and may have differed between groups ac-
cording to baseline serum sodium concen-
tration. This could have influenced out-
come measurement of serum sodium con-
centrations and length of hospital stay
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional info provided by the sponsor:
’Did not have separate outcome assessors
in this trial’
Comment: blinding outcome assessors at-
tempted and all measured outcomes objec-
tive
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 30% (33% in experimental
group, 29% in control group) attrition
from analysis of serum sodium concentra-
tion at day 7
Selective reporting (reporting bias) High risk Comment: protocol available with
matched primary and secondary outcomes
for the overall study. However, results in-
cluded in this review for the subgroup with
hyponatraemia are based on post-hoc anal-
yses of the data, with reported outcomes
not matching the primary and secondary
outcomes of the original study
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Ms Krasa received
compensation through her Otsuka salary
and Ms Bechhofer received compensation
through a contract between the University
of Wisconsin and Otsuka Marylad
Research Institute.’, and ’Mr. Cyr, Ms.
Olchanski, Ms. Slawsky, and Dr. Gross
received research funding from Otsuka
America Pharmaceutical, which markets
tolvaptan. Ms. Krasa and Dr. Zimmer are
employees of Otsuka Pharmaceutical
Development and Commercialization. Dr.
Hauptman is a clinical investigator for and
a consultant to Otsuka Pharmaceutical
Development and Commercialization’
◦ Comment: senior authors of
reports pertaining to this study are heavily
linked to the company commercialising
the study medication
• Sponsorship bias
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◦ Quote: ’Otsuka funded the
EVEREST trial under the guidance of the
EVEREST steering committee’, and ’the
data collection and management for this
study was by Otsuka; analysis was by the
University of Wisconsin Statistical Data
Analysis centre and Otsuka’.
◦ Comment: Data collection,
management and analysis was also done
by the pharmaceutical company
Gerbes 2003
Methods • Design: parallel RCT (phase II)
• Hyponatraemia subgroup: no
• Recruitment period: 1997 to 1998
• Treatment duration: 7 days
• Follow-up: not reported
Participants • Country: not reported
• Number of centres: 17
• Inclusion criteria: 18 to ≤ 80 years; serum sodium concentration 115 to ≤ 132
mmol/L; urine/plasma osmolality > 1; written informed consent
• Exclusion criteria: major haemodynamic or pulmonary insufficiency; creatinine
concentration >200 µmol/L; systolic arterial pressure < 80 mm Hg; Hb < 9 g/dL;
encephalopathy; any evidence of active myocardial ischaemia within past two months;
heart failure NYHA IV; recent antibiotic treatment
• Characteristics included participants
• Number: treatment group 1 (36); treatment group 2 (37); control group (39)
• Number, % women: not reported
• Mean age: 58 years (not reported for individual groups)
• Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (128 ± 4);
treatment group 2 (128 ± 4); control group (129 ± 4)
• Cause of hyponatraemia: SIADH (31, 28%); heart failure (14, 13%); liver
cirrhosis (61, 54%) (not reported for individual groups)
Interventions Treatment group 1
• Oral lixivaptan: 2 x 100 mg/d
Treatment group 2
• Oral lixivaptan: 2 x 50 mg/d
Control group
• Oral placebo: 2 x 1/d
Co-interventions (all groups)
• Fluid restriction: < 1 L/d
• Dietary sodium intake: not reported
Outcomes • Response: serum sodium concentration ≥ 136 mmol/L
• Serum sodium concentration (continuous outcome): absolute value at end of
treatment
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• Outcomes related to over-correction of serum sodium concentration
◦ Osmotic demyelination syndrome: any neurologic abnormality
• Treatment-specific side-effects
◦ AKI: SCr > 200 µmol/L
◦ Thirst (continuous outcome): measured on a 0 to 100 VAS
◦ Serious adverse events: requiring treatment discontinuation
Notes • Funding source: Wyeth Ayerst Research
• Publication: abstract-only publication (full publication reports the subgroup of
participants with cirrhosis only)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’A computer-generated randomi-
sation table was available at each partici-
pating hospital. A patient number was as-
signed when a patient had qualified during
the pre-study screening. Before administra-
tion of the first study medication, the pa-
tient was assigned a randomisation num-
ber by an unblinded site pharmacist. This
unblinded dispenser did not administer the
drug to patients, and the contact between
him and the investigators and study nurses
was kept to a minimum.’
Comment: the randomisation procedure
produced well balanced groups in terms of
baseline serum sodium concentration, no
information on other baseline characteris-
tics
Allocation concealment (selection bias) Low risk Comment: the randomisation procedure
produced well balanced groups in terms of
baseline serum sodium concentration, no
information on other baseline characteris-
tics
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...randomised, double
blind, placebo-controlled study...’, and ’...
patients were randomised to placebo or 50
mg twice a day...’
Comment: blinding attempted, and al-
though participants and personnel are un-
likely to be fully blinded due to important
increases in urine output, all measured out-
comes short-term and fairly objective. Co-
intervention of fluid restriction similar in
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all groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective. Unlikely for
participants to have been fully blinded, and
plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: published in abstract form only,
insufficient information to permit judge-
ment of ’High risk’ or ’Low risk’
Selective reporting (reporting bias) High risk Comment: no protocol, short-term study
(≤ 1 week) but no reporting of primary
outcomes death or health-related quality of
life or secondary outcomes related to rapid
increase in serum sodium concentration in
a way that permitted data extraction
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’P Ginès has been a
consultant for Wyeth Ayerst Research, H.
Gandjini and J. Djian are employees at
Wyeth Ayerst Research.’
◦ Comment: senior author of all
publications related to this study is an
employee at the company developing the
study medication
• Sponsorship bias
◦ Comment: this study was
funded Wyeth Ayerst Research
Ghali 2006
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 5 days
• Follow-up: 14 days
Participants • Countries: Canada; Israel; USA
• Number of centres: 21
• Inclusion criteria: ≥18 years; serum sodium concentration 115 to < 132 mmol/L;
euvolaemia or hypervolaemia; plasma osmolality < 290 mOsm/kg
• Exclusion criteria: women if lactating, pregnant or not using barrier method of
birth control; fasting serum glucose concentration ≥ 275 mg/dL; uncontrolled
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hypertension; orthostatic hypotension or supine systolic BP < 85 mm Hg;
uncontrolled arrhythmia; untreated severe hypothyroidism, hyperthyroidism, adrenal
insufficiency; estimated CrCl < 20 mL/min; ALT or AST > 5 times upper limit of
normal; serum albumin concentration ≤ 1.5 g/dL; prothrombin time > 22 s or
international normalised ratio > 2.0 without anticoagulants or ≥ 3.0 with therapy;
WCC < 3000/µL; HIV infection or active hepatitis; patients expected to have
hyponatraemia necessitating emergent treatment during study; concurrent illness that
could interfere with study treatment or evaluation; participation in clinical trial with
30 days of screening
◦ Characteristics included participants
◦ Number: treatment group 1 (27); treatment group 2 (24); control group (23)
◦ Number, % women: treatment group 1 (13, 48); %); treatment group 21 (2,
50%); control group (13, 56%)
◦ Mean age, range (years): treatment group 1 (69, 35 to 90); treatment group
2 (66, 38 to 93); control group (73, 41 to 94)
◦ Serum sodium concentration (mmol/L): treatment group 1 (125 ± 4);
treatment group 2 (125 ± 4); control group (123 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: heart failure (11, 41%); COPD (2, 7%);
malignancy (3, 11%); idiopathic (7, 26%); other (4, 15%)
⋄ Treatment group 2: heart failure (10, 42%); malignancy (2, 8%);
idiopathic (5, 21%); other (7, 29%)
⋄ Control group: heart failure (11, 48%); COPD (1, 4%); malignancy
(3, 13%); idiopathic (3, 13%); other (5, 22%)
Interventions Treatment group 1
• Oral conivaptan: 2 x 40 mg/d
Treatment group 2
• Oral conivaptan: 2 x 20 mg/d
Control group
• Oral placebo: 2 x/d
Co-interventions (all groups)
• Fluid restriction: ≤ 500 mL in any 3-hour period or < 2L/d; treatment group 1
(67%), treatment group 2 (75%), control group (61%) drank 2 to 3 L/d
• Dietary sodium intake: remained stable throughout the study
Outcomes • Death
• Response: serum sodium concentration ≥ 135 mmol/L or increase from baseline
≥ 6 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L/d or total increase > 24 mmol/L or serum sodium concentration
> 145 mmol/L or reduced or temporarily withheld treatment after increase in serum
sodium concentration judged by investigator as too rapid
• Treatment-specific side-effects
◦ AKI: SCr > 1.6 mg/dL
◦ Hypotension: not otherwise defined
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◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Astellas Pharma US, Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’Eligible patients were stratified by
volume status and assigned randomly in a
1:1:1 ratio...’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’This double-blind, placebo-con-
trolled ... study’, and ’Fluid intake was lim-
ited to ..up to a maximum of 2.0 litres in
24h. ....and 24-h sodium intake remained
stable throughout the study’
Comment: blinding attempted, and al-
though participants and personnel are un-
likely to be fully blinded due to impor-
tant increases in urine output, all measured
outcomes short-term and fairly objective.
Fluid restriction and stable sodium intake
were prescribed in all groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors
probably attempted and all measured out-
comes objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 9% attrition, 5% ex-
clusions for never having received the
drug, 4% due to treatment discontinu-
ation, reasons well-documented. Missing
data dealt with through analytic techniques
for repeated measures using the last avail-
able measurement before discontinuation.
Given <20% attrition and limited oppor-
tunity for introducing bias in such a short-
term study - we judged it ’Low risk’
Selective reporting (reporting bias) Low risk Comment: no protocol, short term study
(≤1 week), secondary outcomes related to
serum sodium concentration and rapid in-
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crease in serum sodium concentration re-
ported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ ’J.K.G. was a principal
investigator from 1999-2004 for trials
sponsored by Astellas Pharma US, Inc. N.
S. is employed by Astellas Pharma US,
Inc.’
◦ Comment: senior author is an
employee of the company
commercialising the study medication.
• Sponsorship bias
◦ Quote: ’This study was
supported by Astellas Pharma US, Inc
(formerly Yamanoushi Pharma America,
Inc)
Gheorghiade 2003
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: yes, but randomisation not stratified according to the
subgroup
• Recruitment period: 1998 to 1999
• Treatment duration: 25 days
• Follow-up: 58 days
Participants • Countries: Argentina; USA
• Number of centres: 30
• Inclusion criteria: outpatients recruitment from university, community and
veterans affairs hospitals; ≥ 18 years; serum sodium concentration: not an inclusion
criterion for primary study (we included subgroup with serum sodium concentration
≤ 135 mmol/L); CHF with clinical signs of volume overload; stable oral furosemide
dose (40 to 240 mg) ≥ 7 days before enrolment
• Exclusion criteria: cardiac surgery < 90 days prior, MI < 60 days prior; sustained
ventricular tachycardia, ventricular fibrillation or automatic implantable cardiac
defibrillator discharge < 30 days prior; atrial fibrillation with ventricular rate 115 BPM;
diastolic BP > 95 mm Hg; diuretics other than furosemide < 14 days prior; NSAIDS or
aspirin 700 mg/d; SCr > 3.0 mg/dL or BUN > 60 mg/dL; serum potassium
concentration < 3.4 mmol/L; serum digoxin concentration > 2.2 ng/mL; uncontrolled
diabetes mellitus; urinary tract obstruction; morbid obesity; history of intrinsic hepatic
disease or liver enzymes ≥ 3 times upper limit of normal; any disorder precluding
participation or limiting survival; women if breast-feeding, of childbearing potential,
and not using contraception
• Characteristics randomised participants
◦ Number: treatment group 1 (20); treatment group 2 (14); treatment group 3
(15); control group (21)
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◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (133
± 2); treatment group 2 (133 ± 2); treatment group 3 (134 ± 1); control group (133 ± 1)
◦ Cause of hyponatraemia: heart failure (100%)
Interventions Treatment group 1
• Oral tolvaptan: 1 x 60 mg/d
Treatment group 2
• Oral tolvaptan: 1 x 45 mg/d
Treatment group 3
• Oral tolvaptan: 1 x 30 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: no
• Dietary sodium intake: ’during the study patients were asked to follow a no-salt-
added diet
• All received standard heart failure treatment including diuretics at the discretion
of the investigator
Outcomes • Response in serum sodium concentration: serum sodium concentration > 135
mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): defined as change from
baseline
• Treatment-specific side-effects
◦ AKI: insufficiently reported to allow contribution to meta-analysis
◦ Thirst: insufficiently reported to allow contribution to meta-analysis
◦ Polyuria: insufficiently reported to allow contribution to meta-analysis
• Treatment discontinuation: insufficiently reported to allow contribution to meta-
analysis
Notes • Outcomes insufficiently reported to allow contribution to meta-analysis
• Funding source: Otsuka Maryland Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’...central random assignment pro-
cedure ... by means of an Interactive Voice-
Response System’
Comment: the randomisation procedure
produced groups in the overall study that
were not entirely balanced in age and sex,
not in terms of medical history or char-
acteristics related to the heart failure. The
randomisation was not stratified for serum
sodium concentration. The large number
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of groups relative the total number of par-
ticipants would have made it likely for
the groups to be unbalanced in prognos-
tic characteristics. However, the absence of
baseline data specifically for the subgroup
with hyponatraemia, make it difficult to
judge bothmagnitude and direction of pos-
sible bias
Allocation concealment (selection bias) Low risk Quote: ’...central random assignment pro-
cedure ... by means of an Interactive Voice-
Response System’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’...were assigned to receive...or
placebo...’, and ’...a double-blind, ran-
domised trial’
Additional info provided by sponsor: ’Both
OPC-41061 and placebo tablets were iden-
tical in appearance’
Comment: blinding attempted, although
participants are unlikely to be fully blinded
due to important increases in urine output.
Also, co-interventions were not reported in
detail for the subgroupwith hyponatraemia
and included standard heart failure treat-
ment left at discretion of investigator and
may have differed between groups accord-
ing to baseline serum sodium concentra-
tion. This could have influenced outcome
measurement of serum sodium concentra-
tions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional info provided by sponsor: ’Did
not have separate outcome assessors in this
trial’
Comment: blinding outcome assessors at-
tempted, main outcome objective. Un-
likely for participants to have been fully
blinded, and plausible ’high risk’ of bias for
self-reported outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 34% attrition for outcomes re-
lated to serum sodium concentration mea-
surements in comparison with numbers
provided in the study report
Selective reporting (reporting bias) High risk Comment: no protocol available, long-
term study (> 1 week), primary outcomes
and secondary outcomes not reported in a
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way that allowed extraction of raw data
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: ’Dr Gheorghiade is
a consultant for and has received a grant
support from Otsuka Maryland Research
Institute (OMRI), Rockville, Md. Dr.
Niazi has received grant support from
OMRI, and Drs. Ouyang, Czerwiec,
Kambayashi, and Orlandi are OMRI
employees.’
◦ Comment: multiple authors,
including the senior author, are employees
of the company commercialising
• Sponsorship bias
◦ Comment: this study was
industry instigated and supported by
Otsuka Maryland Research Institute
Gheorghiade 2006
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: no
• Recruitment period: 1998 to 1999
• Treatment duration: 12 days
• Follow-up: 65 days
Participants • Country: USA
• Number of centres: 9
• Inclusion criteria: university and community hospital in-patients; ≥ 18 years;
serum sodium concentration < 135 mmol/L; euvolaemia or hypervolaemia
• Exclusion criteria: acute coronary ischaemic events < 60 days after randomisation;
history of sustained ventricular tachycardia or ventricular fibrillation; SCr > 2.8 mg/dL
• Characteristics randomised participants
◦ Number: treatment group (17); control group (11)
◦ Number, % women: treatment group: (7, 41%); control group (5, 45%)
◦ Mean age ± SD (years): treatment group (66 ± 13); control group (67 ± 9)
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group (129 ±
3); control group (129 ± 4)
◦ Cause of hyponatraemia: SIADH 10 (36%); heart failure 14 (50%); liver
cirrhosis 4 (14%) (not reported for individual groups)
Interventions treatment group
• Oral tolvaptan: 1 x 10 mg/d up to 1 x 60 mg/d
Control group
• Fluid restriction: ≤ 1.2 L/d with changes left to discretion of investigator + 1 x 1/d
Co-interventions (all groups)
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• Fluid restriction: see above
• Dietary sodium intake: a no salt added diet was recommended throughout the
study
Outcomes • Death
• Response in serum sodium concentration (categorical outcome):serum sodium
concentration ≥ 135 mmol/L or 10% increase from baseline
• Serum sodium concentration (continuous outcome):change from baseline until
day 5
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: not otherwise defined
• Treatment-specific side-effects
◦ Thirst (continuous outcome): measured on a 0 to 100-point VAS
◦ Hypotension: not otherwise defined
Notes • Funding source: Otsuka Maryland Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’...subjectswere randomised...’, and
’This study was a multicenter, prospective,
randomised.... trial.’
Additional info provided by the sponsor:
’The study was conducted using local (per
site) randomisation.’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’This study was a multicen-
ter, prospective, randomised, open-label....
trial’, and ...subjects were randomised ... to
tolvaptan or fluid restriction plus placebo’
Additional info provided by the sponsor:
’The study drug was supplied as either
5 mg, 15 mg OPC-4 1061 tablets or
matching placebo. All tablets were iden-
tical in appearance.’ and ’(investigators
were) not concealed as separate instructions
were given to investigators for subjects on
fluid-restriction/placebo and those on ac-
tive therapy.’
Comment: blinding of participants at-
tempted, and although participants are un-
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likely to have been fully blinded due to im-
portant increases in urine output, serum
sodium concentration short-term and gen-
erally objective. Personnel were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding of outcome assessors
not attempted, but main measured out-
comes objective. Participants not blinded,
and plausible ’high risk’ of bias for self-re-
ported outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’Two of the 17 subjects assigned to
the tolvaptan group and 3 of the 11 sub-
jects assigned to the fluid restriction group
were withdrawn during the run-in phase
because of protocol violations or because
withdrawal criteria were met.’
Comment: overall 17% attrition -12% in
experimental group, 27% in placebo group
- due to protocol violation or because par-
ticipants never received the study medica-
tion. Reasons not documented in detail.
Given <20%attrition, short-term study, we
judged risk of bias to be ’Low’
Selective reporting (reporting bias) High risk Comment: no protocol, short-term study
(<1 week), secondary outcomes related to
rapid increase in serum sodium concentra-
tion not reported. Treatment duration 12
days, yet primary outcome measured at 5
days; Thirst measured at last inpatient visit,
which could have been anywhere between
5 and 12 days after study initiation and dif-
ferent for both groups
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: Three authors,
including the senior author are affiliated
to Otsuka Maryland Research Institute,
Rockville, Maryland
• Sponsorship bias
◦ Quote: ’This trial was funded
by Otsuka Maryland Research Institute’.
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Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 1 year
• Follow-up: not reported
Participants • Country: not reported
• Number of centres: not reported
• Inclusion criteria: serum sodium concentration < 130 mmol/L; liver cirrhosis and
ascites
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: treatment group (92); control group (47)
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Control group: liver cirrhosis 47 (100%)
Interventions Treatment group
• Oral satavaptan: 1 x 5 mg/d up to 1 x 50 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: not reported
• Dietary sodium intake: not reported
Outcomes • Length of hospital stay: average number of days/year/patient
• Treatment-specific side-effects
◦ AKI: SCr increase > 50% from baseline or SCr > 1.5 mg/dL
Notes • Funding source: not reported
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’Patients...were randomised...’.
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’.
No baseline characteristics presented
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’Patients...were randomised into a
multi-centre, single-blind study to receive
in a 2:1 ratio either a flexible dose-regi-
men of satavaptan (5-50 mg once daily) or
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placebo’
Comment: blinding of participants prob-
ably attempted. However, insufficient in-
formation for assessing to what extent it
was achieved, or to permit judgement of
’High risk’ or ’Low risk’. Blinding of per-
sonnel not attempted. No information on
how differential treatment and follow-up
was avoided
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: ’Patients...were randomised into a
multi-centre, single-blind study...’
Comment: outcome assessors not blinded
andmain outcomemeasure - objective out-
come measures
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Selective reporting (reporting bias) High risk Comment: no protocol and long term (>
1 week) study, primary outcomes and sec-
ondary outcomes related to rapid increase
in serum sodium concentration not re-
ported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: no declaration of
interest. From declarations of interest
from Gines 2008a it is clear that ’Dr.
Ginès is a consultant for Sanofi-Aventis.
Dr. Wong is a consultant for Sanofi-
Aventis. Dr. Watson owns stock in Sanofi-
Aventis’
• Sponsorship bias
◦ Comment: all of the studies in
which a vasopressin receptor antagonist
was evaluated were industry sponsored. It
seems very likely this one was industry
sponsored too, but at this stage
insufficient information
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Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2009 to 2010
• Treatment duration: 6 months
• Follow-up: 7 months
Participants • Countries: Belgium; Czech Republic; Israel; India; Italy; Mexico; Peru; USA
• Number of centres: 61
• Inclusion criteria: long-term care facilities and nursing homes; ≥ 18 years; serum
sodium concentration < 135 mmol/L; euvolaemia; willing to be observed in a
monitored setting for the first 8 hours following treatment initiation; in the
Investigator’s judgement the patient has adequate visual and auditory acuity to allow
participation in the trial
• Exclusion criteria: overt symptoms requiring immediate intervention; acute or
transient hyponatraemia, pseudohyponatraemia, hypovolaemic hyponatraemia; drug-
induced hyponatraemia; hyponatraemia due to hypothyroidism or adrenal
insufficiency; hypertonic hyponatraemia, hypokalaemia; demeclocycline, lithium
carbonate, urea, or any other vasopressin antagonist within 7 days of participation;
supine systolic BP ≤ 90 mm Hg; SCr > 3 mg/dL; uncontrolled diabetes; severe
malnutrition; documented cirrhosis or alcoholic liver disease; terminal illness;
psychogenic polydipsia; urinary tract obstruction; myocardial ischaemia; MI or
cerebrovascular accident within 30 days; neurologic impairment such as dementia;
conditions causing inability to respond to thirst; NYHA class III or IV; women
pregnant or breastfeeding or planning to
• Characteristics randomised participants
◦ Number: treatment group (154); control group (52)
◦ Number, % women: treatment group (81, 53%); control group (25, 48%)
◦ Mean age ± SD (years): treatment group (67 ± 14); control group (63 ± 14)
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group (130 ±
4); control group (130 ± 4)
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group
• Oral lixivaptan: 1 x 25 mg/d, titrated to 1 x 100 mg/d
Control group
• Oral matching placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: investigators were instructed, when possible, to not institute
fluid restriction for at least the first 72 hours of dosing. However, fluid restriction could
be initiated at the investigator’s discretion throughout the duration of the study
• Dietary sodium intake: not reported
Outcomes • Death
• Response: serum sodium concentration 135 to ≤ 145 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Cognitive function (continuous outcome): measured by the time to complete the
Trail Making Test - Part B; continuous outcome - as measured by change from baseline
in the Medical Outcomes Study 6-Item Cognitive Function Scale (MOS-6) score -
insufficiently reported to allow contribution to meta-analysis
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• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration ≥ 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase ≥ 8 mmol/L during first 8 hours, > 12 mmol/L during first 24 hours or > 18
mmol/L during first 48 hours
◦ Osmotic demyelination syndrome: not otherwise defined
• Treatment-specific side-effects
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined
◦ Polyuria: not otherwise defined
◦ Adverse event: treatment-emergent adverse events, not otherwise defined
◦ Serious adverse events: serious treatment-emergent adverse events, not
otherwise defined
• Treatment discontinuation
Notes • Funding source: No clear statement about funding but from author affiliations
and declarations of interest clear this is an industry instigated study
• Additional data source: FDA Briefing Document for the Cardiovascular and
Renal Drugs Advisory (CRDAC)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’The HARMONY study was a ...
randomised .... study’, and ’Subjects were
initially randomised to ... ’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’The HARMONY study was a ...
double-blind, placebo-controlled ... study’
Comment: blinding probably attempted,
although due to increase in urine output,
un-blinding likely to have occurred. Fluid
restriction was largely left to the discretion
of the investigator, but fewer participants
receiving the study medication had fluid
restriction initiated or tightened by day 30
(11% versus 21%)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective. Unlikely for
participants to have been fully blinded, and
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plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: overall 17% discontinuation at
8 weeks, numbers and reasons similarly dis-
tributed between experimental and placebo
group. However, 67% discontinuation at
24 weeks, according to the FDA brief-
ing document because, quote ’According
to the applicant, because the primary and
secondary efficacy endpoints targeted time
points between the initial eight weeks from
randomisation, therefore, when the last
subject enrolled in the study had completed
eight weeks of treatment, the applicant in-
structed the investigators to stop blinded
therapy in all subjects in the study’
Selective reporting (reporting bias) Low risk Comment: the study was registered with
ClinicalTrials.gov, but no clear listing
of predefined outcome time-points. That
said, all preregistered outcomes and out-
comes related to over correction reported.
Some additional outcomes were insuffi-
ciently reported for contribution to meta-
analysis
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’WTA has received
consulting fees from Cardiokine. GD has
received consulting fees from Wyeth
(Pfizer), Sonofi, Cardiokine, Otsuka
Pharmaceuticals, and Yamanouchi. RCJ
has served as a Principal Investigator on
vaptan-related phase III clinical trials
sponsored by Astellas, Otsuka, and
Cardiokine. He has also served as a
consultant for Otsuka and Cardiokine.
NK has served on the speakers’ bureau for
Otsuka. DGB has received consulting fees
from Cardiokine, received consulting fees
from Cardiokine, receives grants from
Otsuka, and is a paid consultant for
Otsuka Canada. CO is an employee of
Cardiokine. MM received consulting fees
from Otsuka. HPT and YY have no
relevant relationships to disclose.’
• Sponsorship bias
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◦ Quote: ’Medical writing and
editorial assistance, supported by
Cardiokine, ...’
◦ No clear statement about
funding but from author affiliations and
declarations of interest clear this is an
industry instigated study
Hayes 1987
Methods • Design: parallel RCT
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: not reported
• Follow-up: not reported
Participants • Country: UK
• Number of centres: not reported, presumably 1
• Inclusion criteria: serum sodium concentration < 130 mmol/L; liver cirrhosis and
ascites
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: 10 (not reported for individual groups)
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: liver cirrhosis (100%)
Interventions Treatment group
• Oral urea: 3 x 20 mg/d within 24 hours of development of hyponatraemia
Control group
• Oral urea: 3 x 20 mg/d after 3 days of no treatment after development of
hyponatraemia
Co-interventions (all groups)
• Fluid restriction: not reported
• Dietary sodium intake: not reported
Outcomes • Serum sodium concentration (mmol/L) from beginning to end of treatment (no
comparative data)
• Treatment-specific side-effects
◦ Diarrhoea and vomiting: no data provided
Notes • Funding source: not reported
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: ’Patients...randomised...’.
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’.
No baseline characteristics presented
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Selective reporting (reporting bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Other bias Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
HYPOCAT 2008
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: no
• Recruitment period: 2004 to 2005
• Treatment duration: 14 days
• Follow-up: 21 days
Participants • Countries: Argentina; Australia; Belgium; Canada; Croatia; Czech Republic;
France; Germany; Hungary; Italy; Romania; Spain; USA
• Number of centres: 30
• Inclusion criteria: ≥ 18 years; serum sodium concentration ≤ 130 mmol/L;
cirrhosis diagnosed by liver biopsy or combination of clinical, biochemical,
ultrasonographic and endoscopic findings; moderate/tense ascites defined as grade 2-3
ascites according to previously established criteria
• Exclusion criteria: serum bilirubin concentration > 8 mg/dL; INR > 3; platelet
count < 30,000/mm3 ; SCr > 2mg/dL; serum potassium concentration > 5.5 mmol/L;
hepatocellular carcinoma > Milan criteria; hepatic encephalopathy > grade 1; bacterial
infection/gastrointestinal bleeding < 10 days; large-volume paracentesis < 7 days prior;
cardiac disease, systolic BP < 80 mm Hg; inducer or inhibitors of CYP450 CYP3A <
14 days prior
• Characteristics randomised participants
◦ Number: treatment group 1 (28); treatment group 2 (26); treatment group 3
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(28); control group (28)
◦ Number % women: treatment group 1 (8, 29%); treatment group 2 (7,
27%); treatment group 3 (12, 43%); control group (6, 21%)
◦ Mean age ± SD (years): treatment group 1 (59 ± 10); treatment group 2 (56
± 9); treatment group 3 (57 ± 8); control group (55 ± 10)
◦ Mean serum sodium concentration ± SD (mmol/L): treatment group 1 (126
± 6); treatment group 2 (128 ± 4); treatment group 3 (127 ± 5); control group (126 ± 4)
◦ Cause of hyponatraemia: liver cirrhosis (100%)
Interventions Treatment group 1
• Oral satavaptan: 1 x 25 mg/d
Treatment group 2
• Oral satavaptan: 1 x 12.5 mg/d
Treatment group 3
• Oral satavaptan: 1 x 5 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: < 1.5 L/d, unless patients were thirsty or there was a medical
need to increase fluid intake
• Dietary sodium intake: ≤ 2.7 g/d
Outcomes • Response in serum sodium concentration (categorical outcome): increase from
baseline in serum sodium concentration ≥ 5 mmol/L or serum sodium concentration
≥ 135 mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase ≥ 8 mmol/L/24 h
◦ Hypernatraemia: serum sodium concentration ≥ 145 mmol/L at any point
during treatment
◦ Osmotic demyelination syndrome: neurological symptoms
• Treatment-specific side-effects
◦ Thirst (categorical outcome): measured on a VAS (cut-offs for categorisation
not reported)
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Sanofi-Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Each participating centre received
blocks of study treatment which contained
equal numbers of each of the four therapies
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on a random sequence generated by a com-
puter program’, and ’The median number
of patients included in the 30 participating
centres was 3 (range 1 to 14)’
Comment: The randomisation procedure
generated groups well-balanced for age, sex
and baseline serum sodium concentration.
The severity of liver disease as assessed by
the serum bilirubin concentration, Child-
Pugh and MELD score was greater for
the placebo group in comparison with the
other groups. We assumed the influence
of the imbalance thus generated would be
negligible in practice
Allocation concealment (selection bias) Low risk Comment: considering randomi-
sation procedure and extent of attempting
to blind, likely adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’This was a ...double-blind,
placebo-controlled efficacy study’, and ’all.
..were maintained on a low-sodium diet ..
. and daily fluid intake was limited to 1.5L
unless patients were thirsty or there was a
medical need to increase fluid intake’
Comment: blinding attempted, and al-
though participants and personnel are un-
likely to be fully blinded due to impor-
tant increases in urine output, all measured
outcomes short-term and fairly objective.
Fluid restriction occurred in all groups, any
increase in fluid intake likely to have oc-
curred in the intervention groups, with pos-
sible bias favouring the placebo group for
outcomes related to serum sodium concen-
tration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors
probably attempted, main measured out-
comes objective. Unlikely for participants
to have been fully blinded, and plausible
’high risk’ of bias for self-reported outcome
of thirst
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 5% attrition, presum-
ably due to treatment discontinuation, de-
spite efforts to measure outcomes regard-
less. Reasons for treatment discontinuation
well documented. Missing data dealt with
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through analytic techniques for repeated
measures using the last available measure-
ment before discontinuation. Given <20%
attrition and limited opportunity for intro-
ducing bias in such a short-term study - we
judged it ’Low risk’
Selective reporting (reporting bias) High risk Comment: protocol registered after com-
pletion of the study. Outcomes related to
serum sodium concentration said to be
measured at 14 days, yet only reported at
day 5. Protocol also lists ’trail making test’
and ’quality of life’ as outcomes, which are
not reported in the study publication
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Dr. Ginès is a
consultant for Sanofi-Aventis. Dr. Wong
is a consultant for Sanofi-Aventis. Dr.
Watson owns stock in Sanofi-Aventis.’
• Sponsorship bias
◦ Quote: ’The sponsor, Sanofi-
Aventis, and the academic principal
investigator designed the study, developed
the protocol, and prepared the first and
subsequent drafts of the manuscript’, and
’The sponsor and the academic principal
investigator held and analysed the data’
◦ Comment: the principal
investigator is a consultant for the
company developing the study drug
INSIGHT 2016
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2007 to 2009
• Treatment duration: 21 days
• Follow-up: 28 days
Participants • Country: USA
• Number of centres: 12
• Inclusion criteria: ≥ 50 years; serum sodium concentration 123 to ≤ 134 mmol/
L and for 118 to ≤ 122 mmol/L inclusion based on consultation and approval from
the study medical monitor
• Exclusion criteria: conditions or history which may present a safety concern to the
subject or their offspring or extreme susceptibility to hypotension with sudden fluid
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loss; hyponatraemia that is acute, easily reversible, artifactual, or due to a condition not
associated with vasopressin excess; conditions associated with an independent
imminent risk of morbidity and mortality; conditions which may confound the
assessment of endpoints, history of poor compliance, participation in a clinical trial
believed by the principal investigator or sponsor likely to confound endpoint
assessments; conditions which may confound primary endpoints of cognitive function
• Characteristics randomised participants
◦ Number: treatment group (29); control group (28)
◦ Number, % women: treatment group (15, 52%); control group (19, 68%)
◦ Mean age ± SD (years): treatment group (71 ± 10); control group (71 ± 10)
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: not reported
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 1 x 60 mg/d
Control group
• Oral matching placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: fluid restrictions to be loosened during dose titration phase,
reinstated at any time if serum sodium concentration fails to improve, left at discretion
of investigator
• Dietary sodium intake: not reported
Outcomes • Serum sodium concentration (continuous outcome): change from baseline until
end of treatment
• Cognitive function (Neurocognitive Composite Score of Speed Domains) change
from baseline in sum of all speed domain Z-scores: reaction time (Simple = recognize
“yes” 50 times; choice = recognize “yes” or “no” 50 times; digit vigilance = match 45
digits); psychomotor speed (morse tapping = tap button for 30 s with right & left
hands); processing speed (rapid visual information processing = detect consecutive
sequences of 3 odd or 3 even digits; numeric working memory = recognize numbers
from series of 5 digits among 30; word recognition = remember 15 prior learned words
from 30 total; results age-matched to healthy controls from Cognitive Drug Research
normative data
• Gait test: change from baseline timed get-up-and-go test = time it takes for a
seated subject to rise from a chair, walk 3 m, walk around an object and return to sit in
chair. Values: under 10 s (no difficulties), 10 to 20 s (starting to have balance difficulty)
, over 30 s (at high risk for falls and dependent in most activities of daily living and
mobility); test assesses risk to elderly subjects of falling and higher scores in seconds
indicate higher risk of falling
• Treatment-specific side-effects
◦ Thirst: not otherwise defined
◦ Adverse event: not otherwise defined
◦ Serious adverse events: serious treatment-emergent adverse events
• Treatment discontinuation
Notes • Funding source: Otsuka Pharmaceutical Development & Commercialization
• Publication: protocol registry only
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’Subjects will be randomised...’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’A pilot...double-blind, placebo-
controlled ... study’, and ’Subjects will be
randomised to ... or matching placebo
tablet’, and ’during this period, fluid restric-
tions should be loosened or suspended, un-
til the subject’s response to therapy can be
evaluated, typically over the first few days of
therapy. Fluid restriction may be reinstated
at any time in subjects whose sodium fails
to improve or worsens with study therapy.
Subjects entering ...with a serum sodium
concentration less than 130 mEq/Lmay be
fluid restricted if necessary at the discretion
of the investigator’
Comment: blinding of both participants
and personnel attempted. However, un-
likely for participants to have been fully
blinded due to likely important increases in
urine output. Also, fluid restriction was not
mandatory and could be adapted at the dis-
cretion of the investigator. This may have
biased outcome measures at one month in
favour of the study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective. Unlikely for
participants to have been fully blinded, and
plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 9% attrition, 8% due
to treatment discontinuation, asymmetri-
cal due to adverse events in the experimen-
tal group. Given < 10% attrition in long-
term study, we judged opportunity for in-
76Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
INSIGHT 2016 (Continued)
troducing attrition bias ’Low’
Selective reporting (reporting bias) Low risk Comment: study registered with Clinical-
Trials.gov in 2007 before study initiation.
Primary and secondary outcomes includ-
ing time-points match
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ No declaration of interest
• Sponsorship bias
◦ Quote: ’Sponsor: Otsuka
Pharmaceutical Development &
Commercialization’
◦ Comment: no further
information as study not published at this
time
Jalan 2007
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 7 days
• Follow-up: not reported
Participants • Country: UK
• Number of centres: not reported (presumably 1)
• Inclusion criteria: serum sodium concentration < 130 mmol/L despite 3 days of
fluid restriction; liver cirrhosis with refractory ascites
• Exclusion criteria: active infection; hepatic encephalopathy > grade 2; creatinine
concentration >150 µmol/L; systolic BP < 80 mm Hg; alcoholic hepatitis; adrenal
insufficiency; hypothyroidism; hyperthyroidism; diabetes; severe cardiovascular disease;
head injury; diuretics within 7 days; paracentesis < 1 week
• Characteristics randomised participants
◦ Number: 24
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: not reported; liver cirrhosis (100%)
Interventions Treatment group
• IV human salt-poor albumin: 1 x 40 g/d
Control group
• No treatment
Co-interventions (all groups)
• Fluid restriction: < 1.5 L/d
• Dietary sodium intake: 1.8 g/d
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Outcomes • Serum sodium concentration (continuous outcome): absolute values;
insufficiently reported to allow contribution to meta-analysis
Notes • Funding source: not reported
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’...a randomised clinical trial’.
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’treatment group 1: Fluid restric-
tion (1.5 L)+Na restriction (80 mmol/d),
Group 2: Human Salt Poor Albumin (40
gm/d) + Fluid (1.5 L) + Na restriction (80
mmol/d)
Comment: attempts at blinding not men-
tioned, blinding unlikely to have happened
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Selective reporting (reporting bias) High risk Comment: no protocol, short-term study
(≤ 1 week) but no reporting of primary
outcomes death or health-related quality
of life, and no reporting of secondary out-
comes related to rapid increase in serum
sodium concentration in a way that per-
mitted data extraction
Other bias Unclear risk • Bias through possible financial
conflict of interest of the authors
◦ No declaration of interest
• Sponsorship bias
◦ Comment: insufficient
information to permit judgement of
’High risk’ or ’Low risk’
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Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 2 days
• Follow-up: 7 days
Participants • Countries: India; Israel; USA
• Number of centres: 25
• Inclusion criteria: ≥ 18 years; serum sodium concentration 115 to ≤ 134 mmol/
L; euvolaemia or hypervolaemia
• Exclusion criteria: women of childbearing potential with positive pregnancy test;
clinical evidence of volume depletion; mechanical circulatory or respiratory support;
supine systolic BP < 85 mm Hg; history of significant orthostatic hypotension;
requiring emergent treatment for hyponatraemia
• Characteristics included participants
◦ Number: treatment group 1 (29); treatment group 2 (30); treatment group 3
(30); control group (28)
◦ Number, % women: treatment group 1 (18, 62%); treatment group 2 (13,
43%); treatment group 3 (16, 53%); control group (14, 40%)
◦ Mean age ± SD (years): treatment group 1 (63 ± 22); treatment group 2 (61
± 20); treatment group 3 (65 ± 14); control group (59 ± 20)
◦ Serum sodium concentration (mmol/L): treatment group 1 (124 ± 5);
treatment group 2 (124 ± 4); treatment group 3 (125 ± 4); control group (125 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: not specified; euvolaemia (27, 93%);
hypervolaemia (2, 7%)
⋄ Treatment group 2: not specified; euvolaemia (28, 93%);
hypervolaemia (2, 7%)
⋄ Treatment group 3: not specified; euvolaemia (27, 90%);
hypervolaemia (3, 10%)
⋄ Control group: not specified; euvolaemia (25, 89%); hypervolaemia (3,
11%)
Interventions Treatment group 1
• IV conivaptan: 20 mg loading dose in 30-min infusion + conivaptan 1 x 20 mg/d
in premixed bag without propylene glycol solvent, in continuous infusion
Treatment group 2
• IV conivaptan: 20 mg loading dose in 30-min infusion + conivaptan 1 x 20 mg/d
in ampoule with propylene glycol solvent, in continuous infusion
Treatment group 3
• IV placebo: loading dose in 30-min infusion + conivaptan 1 x 20 mg/d in
premixed bag without propylene glycol solvent, in continuous infusion
Control group
• IV placebo: loading dose in 30-min infusion + conivaptan 1 x 20 mg/d in
ampoule with propylene glycol solvent, in continuous infusion
Co-interventions (all groups)
• Fluid restriction: < 2 L/d
• Dietary sodium intake: not reported
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Outcomes • Death: time-point measurement unclear
• Response in serum sodium concentration (categorical outcome): increase from
baseline in serum sodium concentration > 4 mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L during the first day or serum sodium concentration > 145
mmol/L at any time during treatment
• Treatment-specific side-effects
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
◦ Injection-site reactions (continuous outcome): severity of injection-site
reactions as measured by the ISR modified 5-point scale; and as categorical outcome
not otherwise defined
◦ Injection-site phlebitis: not otherwise defined
◦ Injection-site thrombosis: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Astellas Pharma US, Inc.
• Request for additional information sent 27/10/2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’This was a randomised, parallel-
group study..’, and ’Eligible patients were..
. randomised to...’
Comment: large number of groups relative
to the number of included participantsmay
have caused simple randomisation to fail:
groups are not entirely balanced in terms
of age and sex. Insufficient information to
permit judgement of ’High risk’ or ’Low
risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’The placebo ampoules and pre-
mixed bags contained all the components
of the active formulation except conivap-
tan. For the ampoule formulation, the con-
tents of the 4 mL ampoule was added to a
bag containing 96 mL of 5% dextrose in-
jection, so that the final volume was 100
mL for the loading dose or a bag contain-
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ing 246 mL of 5% dextrose injection for
the continuous infusion.’
Comment: blinding of participants and
personnel attempted and given all groups
included active ingredient, un-blinding
due to differences in urine output not very
likely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors ad-
equate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 17% attrition due to
exclusion after randomisation (3%) and
treatment discontinuation (14%); reasons
well-documented. Missing data dealt with
through analytic techniques for repeated
measures using the last available measure-
ment before discontinuation. Given < 20%
attrition and limited opportunity for intro-
ducing bias in such a short-term study - we
judged it ’Low risk’
Selective reporting (reporting bias) Low risk Comment: no protocol and short term
study (< 1 week), secondary outcomes re-
lated to both serum sodium concentration
and rapid increase in serum sodium cor-
rection reported. Because a repeated mea-
sures analytic technique was used, unclear
at what time point serum sodium concen-
tration was measured for all participants,
yet given short term study, bias thus intro-
duced probably negligible in practice
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Dr. Velez has received a
grant and honorarium from and served on
the speakers bureau for Astellas Pharma.
Drs McNutt and Abeyratne and Ms.
Klasen are employed by Astellas Pharma
US, Inc.’
◦ Comment: Senior authors are
employed by company commercialising
the study medications
• Sponsorship bias
◦ Comment: this study was
sponsored by Astellas Pharma, Inc
81Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Koren 2011
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 2 days
• Follow-up: 30 days
Participants • Countries: India; USA
• Number of centres: 16
• Inclusion criteria: hospital in-patients; ≥ 18 years; serum sodium concentration
115 to ≤1 30 mmol/L; euvolaemia or hypervolaemia
• Exclusion criteria: women of childbearing potential with positive pregnancy test;
volume depletion or dehydration; haemodynamic instability; unable to provide consent
due to significantly altered mental status; hypertonic saline administered in previous 24
h; expected to require emergent treatment of hyponatraemia supine systolic BP < 85
mm Hg; significant orthostatic hypotension; uncontrolled hypertension; uncontrolled
arrhythmias requiring emergent pacemaker placement or treatment; severe
hypothyroidism; hyperthyroidism; adrenal insufficiency; creatine clearance < 20 mL/
min, urinary outflow obstruction unless catheterized; alanine transaminase or aspartate
transaminase > 5 times upper limit of normal, serum albumin concentration ≤ 15 g/L;
white blood cell count < 3 x 109/L, concomitant illness that could interfere with
treatment or evaluation of safety; history of hepatic encephalopathy, hematemesis or
melena, moderate-to-severe hepatic impairment, moderate ascites secondary to hepatic
dysfunction, non-fasting blood glucose concentration ≥ 200 mg/dL
• Characteristics included participants
◦ Number: treatment group 1 (20); treatment group 2 (20); control group (9)
◦ Number, % women: treatment group 1 (11, 55%); treatment group 2 (7,
35%); control group (8, 89%)
◦ Mean age ± SD (years): treatment group 1 (68 ± 15); treatment group 2 (59
± 17); control group (62 ± 20)
◦ Serum sodium concentration (mmol/L): treatment group 1 (126 ± 4);
treatment group 2 (126 ± 4); control group (126 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (9, 45%); heart failure (6, 30%); unclear
(5, 25%)
⋄ Treatment group 2: SIADH (6, 30%); heart failure (5, 25%); nephrotic
syndrome (1, 5%); alcoholism (1, 5%); unclear (6, 30%)
⋄ Control group: SIADH (2, 22%); heart failure (3, 33%); impaired salt
intake due to hypertension (1, 11%); unclear (3, 33%)
Interventions Treatment group 1
• IV conivaptan: 2 x 20 mg/d in 30-min infusion
Treatment group 2
• IV conivaptan: 1 x 20 mg/d in 30-min infusion
Control group
• IV placebo: 2 x 100 mL 5% dextrose in water in 30-min infusion
Co-interventions (all groups)
• Fluid restriction: < 2 L/d
• Dietary sodium intake: not reported
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Outcomes • Death
• Response in serum sodium concentration (categorical outcome): increase from
baseline in serum sodium concentration > 4 mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration > 145 mmol/L; insufficiently
reported to allow contribution to meta-analysis
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L during the first day
◦ Osmotic demyelination syndrome: not otherwise specified
• Treatment-specific side-effects
◦ Hypotension: supine systolic BP < 85 mm Hg
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
◦ Injection-site reactions
◦ Injection-site phlebitis
◦ Injection-site thrombosis
• Treatment discontinuation
Notes • Funding source: Astellas Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’This randomised, double-blind...
’ and ’Eligible patients were stratified by
baseline SSC (serum sodium concentra-
tion) ... and then randomly assigned..
Comment: methods for sequence genera-
tion not reported. Due to the large num-
ber of groups relative to the number of in-
cluded participants, adequate simple ran-
domisation may have failed to produce
groups with similar baseline prognosis. E.
g. there is an imbalance in age, sex and vol-
ume status across the groups. We assumed
the influence of the imbalance thus gener-
ated would be negligible in practice
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’In each dosing regimen, conivap-
tan or placebo was administered via a 30-
minute i.v. infusion using a 100 mL plas-
tic bag containing either 20 mg conivap-
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tan hydrochloride in 5% dextrose injec-
tion or placebo (5% dextrose injection). In
the once-daily regimen, conivaptan was ad-
ministered at 0 and 24 hours, and placebo
was administered at 12 and 36 hours to
maintain blinding’
Comment: blinding attempted, and al-
though participants and personnel are un-
likely to be fully blinded due to important
increases in urine output, all measured out-
comes very short-term and fairly objective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors
probably attempted and all measured out-
comes objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 18% attrition due to ex-
clusion after randomisation (2%) and treat-
ment discontinuation (16%); reasons fairly
well-documented. All save 1 were re-in-
cluded in the analysis for sodium concen-
tration measurements using the analytic
techniques for repeated measures using the
last available measurement before discon-
tinuation. Given < 20% attrition and lim-
ited opportunity for introducing bias in
such a short term study, we judged it ’Low
risk of bias’
Selective reporting (reporting bias) Low risk Comment: no protocol and short term
study (≤ 1 week), secondary outcomes re-
lated to both serum sodium concentration
and rapid increase in serum sodium correc-
tion reported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Ms. Klasen, Dr
Abeyratne, and Dr. McNutt are employees
of Astellas Pharma US Inc.’
◦ Comment: Several authors are
employees of the company who
commercialised the study drug
• Sponsorship bias
◦ Quote: ’Supported by a grant
from Astellas Pharma Global
Development, Inc.’
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LIBRA 2012
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2008 to 2010
• Treatment duration: 30 days
• Follow-up: 60 days
Participants • Country: Belgium; Canada; Germany; India; Poland; USA
• Number of centres: 37
• Inclusion criteria: ≥ 18 years; serum sodium concentration 120 to < 130 mmol/
L; euvolaemia; hospitalised or willing to stay for 48 to 72 hours
• Exclusion criteria: overt symptoms requiring immediate intervention; acute or
transient hyponatraemia, pseudohyponatraemia or hypertonic hyponatraemia;
hyponatraemia due to hypothyroidism, adrenal insufficiency; psychogenic polydipsia;
creatinine > 3 mg/dL, HbA1c > 9%, urinary tract obstruction; severe pulmonary artery
hypertension expected to deteriorate, NYHA III or IV; ST-segment elevation, MI
previous 30 days, active myocardial ischaemia; cerebrovascular accident previous 30
days, significant neurological impairment; nephrotic syndrome, advanced liver disease,
documented cirrhosis or alcoholic liver disease; terminal illness; radiotherapy or
chemotherapy within 2 weeks; demeclocycline, lithium carbonate, urea, vasopressin
antagonist within 7 days; women pregnant or breastfeeding or planning to
• Characteristics randomised participants
◦ Number: treatment group (54); control group (52)
◦ Number, % women: treatment group 1 (28, 52%); control group (22, 42%)
◦ Mean age ± SD (years): treatment group (66 ± 14); control group (65 ± 13)
◦ Serum sodium concentration (mmol/L): treatment group (125 ± 5); control
group (124 ± 5)
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group 1
• Oral lixivaptan: 1 x 50 mg/d, titrated to 1 x 25 mg/d or 1 x 100 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: investigators were instructed, when possible, to not institute
fluid restriction for at least the first 72 hours of dosing. However, fluid restriction could
be initiated at the investigator’s discretion throughout the duration of the study
• Dietary sodium intake: not reported
Outcomes • Death
• Response: serum sodium concentration ≥ 135 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline until
treatment discontinuation
• Cognitive function (continuous outcome): time to complete the Trail Making
Test - Part B; (continuous outcome) change from baseline in the Medical Outcomes
Study 6-Item Cognitive Function Scale (MOS-6) score; insufficiently reported to allow
contribution to meta-analysis
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration ≥ 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
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increase ≥ 8 mmol/L during first 8 h, > 12 mmol/L during first 24 hours or > 18
mmol/L during first 48 h
◦ ODS: clinical signs and symptoms consistent with the diagnosis
• Treatment-specific side-effects
◦ Hypotension: not otherwise defined
◦ Adverse event: treatment-emergent adverse events, not otherwise defined
◦ Serious adverse events: serious treatment-emergent adverse events, not
otherwise defined
• Treatment discontinuation
Notes • Funding source: Cardiokine Biopharma.
• Additional data source: FDA Briefing Document for the Cardiovascular and
Renal Drugs Advisory (CRDAC)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’The LIBRA study was a ... ran-
domised .... study’, and ’Subjects were ini-
tially randomised to ... ’
Comment: Overall insufficient informa-
tion to permit judgement of ’High risk’ or
’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’The Libra study was a ... double-
blind, placebo-controlled ... study’
Comment: blinding probably attempted,
although due to increase in urine output,
un-blinding likely to have occurred. Fluid
restriction was largely left to the discretion
of the investigator, and more participants
receiving the studymedication had fluid re-
striction initiated or tightened by day 30
(32% versus 23%), but more participants
in the placebo group were on fluid restric-
tion at baseline (37% versus 65%) and at
any time-point throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding insufficiently reported
but main outcomes objective such that un-
blinding of outcome detection unlikely to
be an important source of bias
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: overall 13% discontinuation at
7 days, 5% of which never received treat-
ment; 67% of discontinuations occurred in
placebo group. 31% discontinuation at 30
days, with last observation carried forward
method as imputation method for dealing
with missing serum sodium concentration
values, which may have caused overestima-
tion of the effect of the study medication.
Cognitive function tests were taken at day
30 or the early termination visit.We judged
outcomes measured at 7 days to at ’Low
risk’, but those at 30 days to be at ’High
risk’ of attrition bias
Selective reporting (reporting bias) Low risk Comment: protocol first registered with
ClinicalTrials.gov in 2008. Primary regis-
tered outcome was average daily area under
the curve (AUC) of change from baseline
in serum sodium concentrations up to 72
hrs, whereas the reported primary outcome
is change in serum sodium concentration at
7 days. That said, all reregistered outcomes
were reported and secondary outcomes re-
lated to over-correction also reported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’WTA has received
consulting fees from Cardiokine. PA....
has received honoraria for this work and
from Otsuka for presentations and
participation in advisory committees.
DGB has received consulting fees from
Cardiokine and received grants from and
is paid consultant for Otsuka
Pharmaceuticals. RCJ has served as a
principal investigator on vaptan-related
phase-III clinical trials sponsored by
Astellas, Otsuka, and Cardiokine. He has
also served as a consultant for Otsuka and
Cardiokine. At the time of the study and
manuscript preparation, CO was an
employee of Cardiokine Biopharma’
• Sponsorship bias
◦ Quote: ’Medical writing and
editorial assistance, supported by
Cardiokine Biopharma, ...’
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◦ No clear statement about
funding but from author affiliations and
declarations of interest clear this is an
industry instigated study
Naidech 2010
Methods • Design: parallel RCT (phase 4)
• Hyponatraemia subgroup: no
• Recruitment period: 2008 to 2009
• Treatment duration: 1 day
• Follow-up: until discharge from hospital
Participants • Country: USA
• Number of centres: 1
• Inclusion criteria: patients admitted to a dedicated neuro/spine intensive care unit
of a teaching hospital; ≥ 18 years: serum sodium concentration < 135 mmol/L and
Glasgow Coma Scale < 15; or < 130 mmol/L
• Exclusion criteria: enrolment in the NMH high-risk spine protocol; expected
death from any cause; known sensitivity or allergy to conivaptan; baseline creatinine >
1.5 mg/dL; clinical diagnosis of hypovolaemia, or by central venous pressure < 5 mm
Hg if a central venous catheter is in place; concomitant use of potent inhibitors of
cytochrome P-450 isoenzyme 3A4; clinical diagnosis of liver failure or insufficiency;
pregnancy; intra-arterial vasodilators within 24 h; concern by the Neuro-intensive care
unit pharmacist of a drug-drug interaction that would meaningfully impact care;
diabetes insipidus or treated with vasopressin; congestive heart failure, inclusion
declined by the attending physician or consulting study nephrologist
• Characteristics randomised participants
◦ Number: treatment group (3); control group (3)
◦ Number, % women: not reported
◦ Median age, range (years): treatment group (20, 45 to 64); control group
(65, 67 to 69)
◦ Mean serum sodium concentration (mmol/L): treatment group (131);
control group (132)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (100%) (central nervous system-infection
(1); brain metastasis (1); tuberous sclerosis (1))
⋄ Control group: SIADH (100%) (central nervous system-infection (1);
seizures (1); cerebrotrauma (1))
Interventions Treatment group
• IV conivaptan: 1 x 20 mg loading dose + 20 mg/d continuous infusion
Control group
• Usual care
Co-interventions (all groups)
• Fluid restriction: at discretion of treating physician
• sodium intake: at discretion of treating physician
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Outcomes • Death
• Serum sodium concentration (continuous outcome): change from baseline
• Treatment-specific side-effects
◦ Hypotension: systolic BP < 100 mm Hg or new vasopressor medication
Notes • Funding: Astellas Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’...the patient was randomised by
opening the lowest numbered, sealed enve-
lope.’
Comment: although methods for gener-
ating the sequence were not reported, we
judged it likely for methods to have been
adequate given researchers went to trouble
of using sealed, numbered envelopes
Allocation concealment (selection bias) Low risk Quote: ’...the patient was randomised by
opening the lowest numbered, sealed enve-
lope.’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants nor personnel
blinded to treatment allocation. Treatment
consisted of the study drug added to stan-
dard care versus usual care alone. Usual
care was left at the discretion of the treat-
ing physician with two participants treated
with the study medication versus one par-
ticipant treated with usual care receiving
hypertonic saline. This differential treat-
ment in the two groups could have influ-
enced the outcome in favour of the study
drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: from ClinicalTrials.gov ’Masking:
single blind - outcomes assessor’
Comment: still unclear whether outcome
assessors of non patient-reported outcomes
other than Glasgow Coma Scale and NHS
Stroke Scale were blinded, but outcomes
objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ’all randomised patients completed
the protocol’
Comment: no attrition or exclusion
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Selective reporting (reporting bias) Low risk Comment: protocol registered with Clin-
icalTrials.gov, reported outcomes match
those originally registered
Other bias Unclear risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’AMN is responsible for
data integrity and the statistical analysis.
AMN acknowledges past research support
from NovoNordisk, the Neurocritical
Care Society, and the Northwestern
Memorial Foundation for an unrelated
project. AMN acknowledges research
support from Gaymar Inc unrelated to
this study.’
◦ Comment: study commercially
sponsored, but declaration of interest
available and indicating limited further
influence
• Sponsorship bias
◦ Quote: ’This study was funded
by Astellas Pharma, US. The study
sponsor had no role in the design of the
protocol, recruitment of patients, analysis
or decision to submit for publication.
AMN is responsible for data integrity and
the statistical analysis. AMN
acknowledges past research support from
NovoNordisk, the Neurocritical Care
Society, and the Northwestern Memorial
Foundation for an unrelated project.
AMN acknowledges research support
from Gaymar Inc unrelated to this study
◦ Comment: study commercially
sponsored, but declaration of interest
available and indicating limited further
influence. We felt unclear on what this
means for risk of bias
NATRIPHAR 2013
Methods • Design: parallel RCT (phase not applicable)
• Hyponatraemia subgroup: no
• Recruitment period: 2010 to 2011
• Treatment duration: not reported
• Follow-up: three months
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Participants • Country: France
• Number of centres: 1
• Inclusion criteria: people admitted to the internal medicine ward or resident of
the nursing home of the same institution; ≥ 65 years; serum sodium concentration
123 to ≤ 134 mmol/L; detected on routine biochemistry
• Exclusion criteria: not receiving medications with the ability to cause
hyponatraemia; hypervolaemia caused by heart failure or liver cirrhosis; treatment
modification not possible according to treating physician; dementia
• Characteristics randomised participants
◦ Number: treatment group (9); control group (10)
◦ Number, % women: treatment group (5, 56%); control group (6, 60%)
◦ Mean age ± SD (years): treatment group (91 ± 4); control group (89 ± 7)
◦ Serum sodium concentration (mmol/L): treatment group (132 ± 2); control
group (130 ± 2)
◦ Cause of hyponatraemia: drug-induced hyponatraemia (100%)
Interventions Treatment group
• Change in prescribed medications
Control group
• Standard care
Co-interventions (all groups)
• Fluid restriction: no restriction
• sodium intake: no restriction save for one patient in treatment group who stopped
dietary salt restriction after pharmacologist advice.
Outcomes • Death
• Response in serum sodium concentration (categorical outcome): serum sodium
concentration > 135 mmol/L
• Serum sodium concentration (continuous outcome):change from baseline as well
as absolute values
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: not otherwise defined
◦ Osmotic demyelination syndrome: not otherwise defined
Notes • Funding source: ’a pharmacological association’
• Registration number: ID RCB 2010-A00778-31
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Les patients ont été randomisés en
deux bras...’
Additional informationprovided by the au-
thors: ’Random sequence was managed as
a single randomisation list managed by the
sponsor’
Comment: the small number of partici-
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pants may have caused simple randomisa-
tion to fail in producing balanced groups,
participants in experimental group had
slightly higher baseline serum sodium con-
centration and took more medications.
Consequences for risk of bias judged to be
low
Allocation concealment (selection bias) Low risk Additional information provided by the
authors: ’Allocation was concealed using
masking envelope’
Comment: Allocation concealment
method considered adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Additional informationprovided by the au-
thors: ’No measures were taken to prevent
participants or personnel from knowing to
which treatment participants had been al-
located’
Comment: blindingnot attempted anddif-
ficult because of intervention type. There
were no specific instructions concerning
co-interventions. Differences in co-inter-
ventions may have influenced difference in
outcome in favour of experimental treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional informationprovided by the au-
thors: ’No measures were taken to prevent
outcome assessors from knowing to which
treatment participants had been allocated’
Comment: blinding of outcome assessors
not attempted, but main measured out-
comes objective
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: overall 26% incomplete out-
come data at four weeks; 1 attrition in con-
trol group, due to being released from hos-
pital before four weeks; 1 exclusion in ex-
perimental group for gastrointestinal bleed
after withdrawing proton pump inhibitor;
3 in control group: 2 for stopping a drug
possibly causing hyponatraemia - hence
possibly biasing results in favour of experi-
mental treatment - 1 due to death
Selective reporting (reporting bias) Low risk Comment: protocol available, long-term
study (> 1 week), and both primary out-
come death and secondary outcomes re-
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lated to serum sodium concentration re-
ported. Given lowest serum sodium con-
centration equalled 129 mmol/L and the
intervention consisted of medication with-
drawal, potential for rapid increases in
serum sodium concentration very limited
Other bias Low risk • Bias through possible financial
conflict of interest of the authors
• Sponsorship bias
◦ Additional information
provided by the authors: ’The study was
sponsored by a pharmacological
association’
◦ Comment: Unlikely for
commercial sponsorship to be an issue
Nevens 2009
Methods • Design: parallel RCT (phase 2a)
• Hyponatraemia subgroup: yes
• Recruitment period: 2007
• Treatment duration: 15 days
• Follow-up: 45 days
Participants • Country: Belgium
• Number of centres: 5
• Inclusion criteria: hospitalised participants from university teaching hospitals; 18
to ≥75 years; liver cirrhosis and ascites
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: treatment group (10); control group (5)
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: liver cirrhosis (100%)
Interventions Treatment group
• Oral M0002 (RWJ-351647): 0.3 mg/d up to 6 mg/d titrated every 3 days
Control group
• Oral placebo
Co-interventions (all groups)
• Fluid restriction: not reported
• sodium intake: not reported
Outcomes • Response in serum sodium concentration (categorical outcome): normalisation of
serum sodium concentrations = insufficiently reported to allow contribution to meta-
analysis
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• Treatment-specific side-effects
◦ Adverse events: not otherwise defined
◦ Serious adverse events: bacterial peritonitis, duodenal perforation and
daydreaming
Notes • Funding source: Early Development, Movetis, Turnhout, Belgium
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’In a randomised, double-blind,
placebo-controlled trial, 15...were treated..
.’
Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’In a randomised, double-blind,
placebo-controlled trial, 15...were treated..
.’
Comment: blinding of participants and
personnel attempted. However, lack of de-
tail in reporting of outcomes makes it diffi-
cult to assess to what extent it was actually
achieved. insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Selective reporting (reporting bias) High risk Comment: no protocol, long-term study
(> 1 week) but no reporting of primary
outcomes death or health-related quality of
life, no reporting of secondary outcomes
related to rapid increase in serum sodium
concentration
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: No declaration of
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interest. Last two authors’ affiliations are
linked to the commercial company
developing the medication
• Sponsorship bias
◦ Quote: ’Early Development,
Movetis, Turnhout, Belgium’
Otsuka Study 2011a
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: no
• Recruitment period: 2008 to 2009
• Treatment duration: 7 days
• Follow-up: 14 days
Participants • Country: China
• Number of centres: 9
• Inclusion criteria: 18 to 75 years; serum sodium concentration < 135 mmol/L;
SIADH
• Exclusion criteria: serum sodium concentration < 120 mmol/L with apathy,
clouded consciousness and convulsion; hypovolaemia; acute of transient
hyponatraemia cause by brain trauma or surgery; uncontrolled hypothyroidism or
adrenal insufficiency; cardiac surgery, sustained ventricular tachycardia or ventricular
fibrillation and not using cardioverter defibrillator; severe stable or unstable angina,
cerebrovascular accident within 30 days of recruitment; psychogenic polydipsia;
systolic BP < 90 mm Hg; history of hypersensitivity of benzodiazepines; drug abuse;
fasting glucose concentration > 220 mg/dL; advanced terminal illness or severe
pulmonary hypertension; drug-induced hyponatraemia excluding diuretics; creatinine
> 1.5 x upper limit; central nervous system diseases; transaminase > 2.5 x upper limit;
requiring intravenous fluid for any reason; use of vasopressin analogues; treatment of
hyponatraemia within 13 days of recruitment; nursing or pregnancy
• Characteristics randomised participants
◦ Number: treatment group (21); control group (24)
◦ Number, % women: treatment group (11, 52%); control group (9, 38%)
◦ Mean age ± SD (years): treatment group (63 ± 14); control group (61 ± 13)
◦ Serum sodium concentration (mmol/L): treatment group (127 ± 5); control
group (125 ± 6)
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 1 x 60 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: ’fluid restriction (1500 mL/d) was added at the discretion of the
investigator when the patient’s serum sodium levels were below 130 mmol/L
persistently’
• sodium intake: not reported
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Outcomes • Death
• Response: serum sodium concentration ≥ 135 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline
• Treatment-specific side-effects
◦ Thirst: not otherwise defined; insufficiently reported to allow contribution
to meta-analysis
Notes • Funding source: Otsuka Pharmaceutical
• Trial acronym: We allocated the trial acronym ’Otsuka study’ from the quote ’the
present study analysed SIADH patients recruited in the ....Otsuka study’, to indicate
the three separately reported subgroups belonged to the same trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’This randomised double-blind
placebo-controlled trial...’ and ’Randomi-
sation was stratified by underlying disease
and whether the hyponatraemia was mild.
..or marked...’
Comment: since the investigators went to
the trouble to stratify allocation, it seems
probable enough that sequence generation
was adequate
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’This randomised double-blind
placebo-controlled trial...’ and ’Patients re-
ceived tolvaptan or matching placebo..’
Comment: blinding probably attempted,
although due to increase in urine output,
un-blinding likely to have occurred. Fluid
restriction was largely left to the discretion
of the investigator, but fewer participants
receiving the study medication had fluid
restriction initiated or tightened by day 30
(11% versus 21%)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: No attrition formain outcomes
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Selective reporting (reporting bias) High risk Comment: the study was registered with
ClinicalTrials.gov, but only primary ef-
ficacy outcome clearly listed, short-term
study (≤1 week) death reported, but no re-
porting of secondary outcomes related to
rapid increase in serum sodium concentra-
tion. Also study results - incompletely/dif-
ferentially - reported for the subgroups of
SIADH, heart failure and cirrhosis sepa-
rately
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: Insufficient
information to permit judgement of
’High risk’ or ’Low risk’
• Sponsorship bias
◦ Quote: ’This study was funded
by Otsuka Pharmaceutical, which
provided consultancy fees or honorarium,
support for travel to meetings and for
language polishing.’
Otsuka Study 2011b
Methods • Design: parallel RCT (phase 2)
• Hyponatraemia subgroup: no
• Recruitment period: 2008 to 2009
• Treatment duration: 7 days
• Follow-up: not reported
Participants • Country: China
• Number of centres: 11
• Inclusion criteria: inpatients, hospitalised for congestive heart failure; 18 to 80
years; serum sodium concentration < 135 mmol/L
• Exclusion criteria: hypovolaemia; haemodynamic instability; insertion of heart
valves; open heart surgery or artificial pacemaker insertion within 60 days of
recruitment; heart valve insertion or heart transplant within 30 days of recruitment;
acute MI; cardiac hypertrophy; active myocarditis or amyloid cardiomyopathy; severe
aortic stenosis; severe pulmonary hypertension; uncontrolled low function of thyroid
or adrenal glands; epilepsy; Guillain-Barre Syndrome; anuria; ventricular tachycardia;
ventricular fibrillation; implantable cardioverter defibrillators; cerebral vascular
accidents within 30 days of recruitment; allergy to benzodiazepines; medication or
alcohol abuse; BMI > 35 kg/m; supine systolic pressure < 90 mm Hg; abnormal
laboratory results at the time of recruitment: fasting blood sugar > 12.2 mmol/L,
haemoglobin <80 g/L, total bilirubin > 85.5 µmol/L, SCr > 2 x the upper limit,
potassium > 5.5 mmol/L, transaminases > 5 x the upper limit, sodium < 120 mmol/L
• Characteristics randomised participants
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◦ Number: treatment group (35); control group (30)
◦ Number, % women: treatment group (15, 43%); control group (12, 40%)
◦ Mean age ± SD (years): treatment group (63 ± 15); control group (65 ± 15)
◦ Serum sodium concentration (mmol/L): treatment group (130 ± 4); control
group (131 ± 3)
◦ Cause of hyponatraemia: heart failure (100%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 1 x 60 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: not reported
• sodium intake: not reported
Outcomes • Death
• Serum sodium concentration (continuous outcome): change from baseline
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: not otherwise defined
• Treatment-specific side-effects
◦ Hypotension: systolic BP < 100 mm Hg or new vasopressor medication
Notes • Funding source: Otsuka Pharmaceutical
• Primary paper in Mandarin - Translated by Sunny Wu
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’This randomised double-blind
placebo-controlled trial...’ and ’Randomi-
sation was stratified by underlying disease
and whether the hyponatraemia was mild.
..or marked...’
Comment: since the investigators went to
the trouble to stratify allocation, it seems
probable enough that sequence generation
was adequate
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’This randomised double-blind
placebo-controlled trial...’
Comment: blinding of participants and
personnel attempted. However, lack of de-
tail in reporting of outcomes makes it diffi-
cult to assess to what extent it was actually
achieved. insufficient information to per-
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mit judgement of ’High risk’ or ’Low risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: No attrition formain outcomes
Selective reporting (reporting bias) High risk Comment: the study was registered with
ClinicalTrials.gov, but only primary ef-
ficacy outcome clearly listed, short-term
study (≤ 1 week) but no reporting of
primary outcomes death or health-related
quality of life, no reporting of secondary
outcomes related to rapid increase in serum
sodium concentration in a way that per-
mitted data extraction. Also study results
- incompletely/differentially - reported for
the subgroups of SIADH, heart failure and
cirrhosis separately
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: Insufficient
information to permit judgement of
’High risk’ or ’Low risk’
• Sponsorship bias
◦ Quote: ’The study was
conducted by Otsuka Beijing Research
Institute. The institute is funded by
Otsuka Pharmaceutical CO., Ltd. Japan.’
Otsuka Study 2011c
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 7 days
• Follow-up: not reported
Participants • Country: China
• Number of centres: not reported
• Inclusion criteria: liver cirrhosis
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: not reported
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◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: liver cirrhosis (100%)
Interventions Treatment group
• Oral tolvaptan: 1 x 30 mg/d up to 1 x 60 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: not reported
• Dietary sodium intake: not reported
Outcomes • Response: normalisation of serum sodium concentration; insufficiently reported
to allow contribution to meta-analysis
• Serum sodium concentration (continuous outcome) change from baseline until
day 4 and 7; insufficiently reported to allow contribution to meta-analysis
Notes • Funding source: Otsuka Pharmaceutical
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’A multicenter, randomised, dou-
ble-blind,..’, and ’Patientswere randomised
to receive...’
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ’A multicenter,..., double-blind,
placebo-controlled clinical trial...’, and ’Pa-
tients were randomised to receive placebo
or tolvaptan...’
Comment: ’insufficient information to
permit judgement of ’High risk’ or ’Low
risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: ’insufficient information to
permit judgement of ’High risk’ or ’Low
risk’
Selective reporting (reporting bias) High risk Comment: the study was registered with
ClinicalTrials.gov, but only primary effi-
cacy outcome clearly listed,, short-term
study (≤ 1 week) but no reporting of
primary outcomes death or health-related
quality of life, and no reporting of sec-
ondary outcomes related to rapid increase
in serum sodium concentration in a way
that permitted data extraction. Also study
results - incompletely/differentially - re-
ported for the subgroups of SIADH, heart
failure and cirrhosis separately
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ No declaration of interest
• Sponsorship bias
◦ Quote: ’This study was funded
by Otsuka Pharmaceutical, which
provided consultancy fees or honorarium,
support for travel to meetings and for
language polishing.’
Salahudeen 2014
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2011 to 2012
• Treatment duration: 14 days
• Follow-up: 30 days
Participants • Country: USA
• Number of centres: 1
• Inclusion criteria: patients admitted to University of Texas MD Anderson cancer
centre; ≥ 18 years; serum sodium concentration 125 to ≤ 130 mmol/L; non-
hypovolaemia; Eastern Cooperative Oncology Group performance status from 0 (fully
active) to 3 (capable of only limited self-care and confined to bed or chair ≥50% of
waking hours)
• Exclusion criteria: critical illness; GFR < 25 mL/min; correctable hyponatraemia;
use of demeclocycline, lithium or CYP 3A4 modulators; life-expectancy < 3 months
• Characteristics randomised participants
◦ Number: treatment group (24); control group (24)
◦ % women: treatment group (47%); control group (46%)
◦ Median age, range (years): treatment group (69, 52 to 81); control group
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(60, 20 to 85)
◦ Serum sodium concentration (mmol/L): treatment group (128 ± 2); control
group (129 ± 1)
◦ Cause of hyponatraemia: cancer (100%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 60 mg/d
Control group
• Oral matching placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: fluid restriction < 1.5 L/d, but participants were allowed to
drink to thirst
• Dietary sodium intake: not reported
Outcomes • Death
• Length of hospital stay (continuous outcome): insufficiently reported to allow
contribution to meta-analysis
• Cognitive function (Mini Mental State Exam score (range 1 to 16)): change from
baseline
• Response: serum sodium concentration ≥ 136 mmol/L
• Serum sodium concentration (continuous outcome): change from baseline
• Treatment-specific side-effects
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined
◦ Polyuria: increase urination frequency and volume
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation: insufficiently reported to allow contribution to meta-
analysis
Notes • Funding source: Otsuka America Pharmaceuticals Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’...we chose Baysian adaptive ran-
domisation for its several reported useful
features.’ and ’After obtaining the patient’s
consent, the research coordinator logged
into the Clinical Trial Conduct website to
register and randomise the patients.’
Comment: valid randomisation methods
produced imbalanced groups in terms of
age due to small sample size, sex and base-
line serum sodium concentration were well
balanced and the imbalance in age was
likely favouring the control group as they
contained the younger participants
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Allocation concealment (selection bias) Low risk Comment: ’After obtaining the patient’s
consent, the research coordinator logged
into the Clinical Trial Conduct website to
register and randomise the patients.’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’All research personnel except ther-
apy distributing pharmacy and biostatisti-
cian were blinded to the treatment alloca-
tion.’
Comment: blinding probably attempted,
and although participants are unlikely to
be fully blinded due to important increases
in urine output, measured outcomes were
short-term and mostly objective for the
data used in meta-analysis. Co-interven-
tions were similar between groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ’All research personnel except ther-
apy distributing pharmacy and biostatisti-
cian were blinded to the treatment alloca-
tion.’
Comment: Blinding of outcome assessors
probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: overall 42% attrition for serum
sodium concentration, 46% in placebo
group, 29% in tolvaptan group, extensive
sensitivity analysis including worst case im-
putation methods still resulted in statis-
tically significant results. No attrition for
death
Selective reporting (reporting bias) High risk Comment: study protocol registered with
ClinicalTrials.gov in 2010. Only study’s
primary outcome serum sodium concen-
tration registered. Long-term study (>1
week) with primary outcome death re-
ported. However secondary outcomes re-
lated to rapid increase in serum sodium
concentration not reported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Dr Salahudeen has
received financial compensation in the
form of honorarium for a lecture and a fee
for attending 1 medical board meeting.’
• Sponsorship bias
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◦ Quote: ’This investigator-
initiated study was funded by Otsuka
America Pharmaceuticals Inc.’ and ’Dr
Salahudeen has received financial
compensation in the form of honorarium
for a lecture and a fee for attending 1
medical board meeting.’
SALT-1 2006
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2003 to 2005
• Treatment duration: 30 days
• Follow-up: 37 days
Participants • Country: USA
• Number of centres: 42
• Inclusion criteria: recruitment from university hospitals, community hospitals
and veteran’s medical centres, both in- and outpatients; ≥ 18 years; serum sodium
concentration < 135 mmol/L, with at least 50% of included participants < 130 mmol/
L; hypervolaemia or euvolaemia
• Exclusion criteria: psychogenic polydipsia, head trauma, postoperative conditions,
uncontrolled hypothyroidism or adrenal insufficiency; any hyponatraemic condition
associated with the use of medications that could have been safely withdrawn;
hypovolaemic hyponatraemia; cerebrovascular accident, multiple strokes; sustained
ventricular tachycardia or fibrillation, severe angina; systolic BP < 90 mm Hg; central
venous pressure < 5 cm H2O; PCW < 5 mm Hg; SCr > 3.5 mg/dL; Child-Pugh > 10;
severe pulmonary hypertension, urinary tract obstruction; uncontrolled diabetes
mellitus; progressive or episodic neurologic disease; little chance of short-term survival
or those not tolerating sudden shifts in fluid volumes or pressures; serum sodium
concentration < 120 mmol/L in association with neurologic impairment
• Characteristics randomised participants
◦ Number: treatment group (102); control group (103)
◦ Number, % women: treatment group (50, 49%); control group (41, 40%)
◦ Mean age ± SD (years): treatment group (60 ± 14); control group (60 ± 13)
◦ Serum sodium concentration (mmol/L): treatment group (129 ± 5); control
group (129 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (25, 25%); heart failure (36, 35%); liver
cirrhosis (23, 22%); other (18, 18%)
⋄ Control group: SIADH (23, 22%); heart failure (34, 33%); liver
cirrhosis (19, 18%); other (27, 26%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 1 x 60 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
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• Fluid restriction: no restriction
• sodium intake: no specific dietary requirements
Outcomes • Death: death due to treatment-emergent adverse events started before 7 days
follow-up
• Health-related quality of life (continuous outcome): change from baseline
measured by physical and mental component of the Medical Outcomes Study 12-item
Short Form General Health Survey. Only the mental component score available for
analysis
• Response in serum sodium concentration (categorical outcome): serum sodium
concentration > 135 mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline as well
as absolute values
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration > 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L during the first day
◦ Osmotic demyelination syndrome
• Treatment-specific side-effects (insufficiently reported for contribution to meta-
analysis)
◦ AKI: not otherwise defined
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Otsuka Maryland Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Patients...underwent central ran-
domisation with the use of random per-
muted blocks and stratification according
to whether the hyponatraemia was mild or
marked...’
Comment: the randomisation procedure
produced well balanced groups
Allocation concealment (selection bias) Low risk Quote: ’Patients...underwent central ran-
domisation with the use of random per-
muted blocks and stratification according
to whether the hyponatraemia was mild or
marked...’
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...trials were...randomised, dou-
ble-blind, placebo-controlled efficacy stud-
ies...’ and ’Patients were assigned...to re-
ceive oral tolvaptan...or matching placebo.
..’, and ’Fluid restriction was not manda-
tory’. Additional info supplied by spon-
sor: ’Study medication was supplied for
each subject in monthly kits per randomi-
sation number, each labelled with a two-
panel double-blind disclosure label specify-
ing the treatment assignment (i.e., the com-
pound name, strength, and lot number)
in the concealed portion of the label. The
study drug was packaged so that each sub-
ject received an identical number of tablets
regardless of the treatment group assign-
ment. All tablets were identical in appear-
ance. The investigatorwas instructed tonot
open the treatment assignment code unless
knowledge of the subject’s treatment was
required for the subject’s clinical care and
safety. In this event, the investigator was to
contact OMRI by telephone with an expla-
nation of the need for opening the treat-
ment assignment code before or within 24
hours of opening the code.’
Comment: blinding of both participants
and personnel attempted. However, un-
likely for participants to have been fully
blinded due to important increases in urine
output. We judged this would not have in-
troduced important risk of bias for death
and the outcomes related to serum sodium
concentration, but may have biased health-
related quality of life measures in favour of
the studymedication. Also, fluid restriction
was not mandatory and could be adapted
by both participant and treating physician
- e.g. based on urine output. This may have
resulted in underestimation of the risk of
rapid increase in serum sodium concentra-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional info provided by the sponsor:
’Serum sodium samples were collected and
analysed at the site’s local hospital labora-
tory. All serum sodium samples were col-
lected and analysed at the same local hos-
pital for purposes of consistency of efficacy
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analysis. Local laboratory results for serum
sodiumwere captured in the electronic case
report form (CRF). Study personnel mea-
suring secondary endpoints were blinded as
above and recorded results in the electronic
CRF.’
Comment: outcome assessors of non pa-
tient-reported outcomes were blinded.
However, unlikely for participants to have
been fully blinded given important in-
creases in urine output, which may have
biased the self-reported outcome health-re-
lated quality of life
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ’Patients who received at least one
dose of the study medication were included
in the safety analyses. Patients whose serum
sodium concentrations were evaluated at
baseline and one or more times after base-
line were included in the efficacy analysis’.
And ’serum sodium concentrations were
measured at days 2, 3, 4,11, 18, 25, 30, and
37’
Comment: overall 26%attrition at 30days,
25% in treatment group 1, 26% in the
placebo group; reasons not reported in de-
tail. Repeated measures analytic technique
was used with all measurements of serum
sodium concentration included until pa-
tient attrition. We judged this may likely
have overestimated the change in serum
sodium concentration in favour of the
study medication. For the mental compo-
nent score of the SF-12 health survey, mea-
sured at 30 days, attrition reached 30% in
treatment group 1 and 44% in the placebo
group
Selective reporting (reporting bias) High risk Comment: study protocol registered with
ClinicalTrials.gov.Outcomemeasures were
only registered in September 2005.Health-
related quality of life not registered as one
of the outcomes; both themental and phys-
ical component of the SF-12 health survey
were reported separately and measured at
day 4 and day 30 using two analytic tech-
niques, but only data for the statistically
significant mental component score at day
30 were available for analysis from the pub-
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lished paper. Also because a repeated mea-
sures analytic technique was used, unclear
at what time point serum sodium concen-
tration was measured for all participants
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Dr. Schrier reports
having served as a consultant to Otsuka,
Astellas, Bayer, and Amgen. Dr. Gross
reports having served as a consultant to
Sanofi-Synthelabo, having received lecture
fees from Astellas, and having received
grant support from GlaxoSmithKline,
Takeda, Amgen, Roche, and Fresenius.
Dr. Gheorghiade reports having served as
a consultant to Otsuka, PDL, Sigma Tau,
Medtronic, and GlaxoSmithKline and
having received honoraria from
Medtronic, Astra Zeneca, Scios,
GlaxoSmithKline, Otsuka, PDL, Abbott,
and Sigma Tau. Dr. Berl reports having
served as a consultant to Bayer and
Astellas and having received grant support
from Otsuka. Dr. Verbalis reports having
served as a consultant to Otsuka,
Yamanouchi Pharma American, Astellas,
Ferring Research, Bristol-Myers Squibb,
and Sanofi Aventis and having received
grant support from Yamanouchi Pharma
American and Astellas. Drs. Czerwiec and
Orlandi are employees of Otsuka
Maryland Research Institute. No other
potential conflict of interest relevant to
this article was reported.’
◦ Comment: senior author is an
employee of the company
commercialising the compound
• Sponsorship bias
◦ Quote: ’ Supported by the
Otsuka Maryland Research Institute.’
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Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2003 to 2005
• Treatment duration: 30 days
• Follow-up: 37 days
Participants • Countries: Belgium; Canada; Czech Republic; Germany; Hungary; Italy; Poland;
Spain; USA
• Number of centres: 50
• Inclusion criteria: recruitment from university hospitals, community hospitals
and veteran’s medical centres; both in- and outpatients; ≥ 18 years; serum sodium
concentration < 135 mmol/L, with at least 50% of included participants < 130 mmol/
L; hypervolaemia or euvolaemia
• Exclusion criteria: psychogenic polydipsia, head trauma, postoperative conditions,
uncontrolled hypothyroidism or adrenal insufficiency; any hyponatraemic condition
associated with the use of medications that could have been safely withdrawn;
hypovolaemic hyponatraemia; cerebrovascular accident, multiple strokes; sustained
ventricular tachycardia or fibrillation, severe angina; systolic BP < 90 mm Hg; central
venous pressure < 5 cm H2O; PCW < 5 mm Hg; SCr > 3.5 mg/dL; Child-Pugh > 10;
severe pulmonary hypertension, urinary tract obstruction; uncontrolled diabetes
mellitus; progressive or episodic neurologic disease; little chance of short-term survival
or those not tolerating sudden shifts in fluid volumes or pressures; serum sodium
concentration < 120 mmol/L in association with neurologic impairment
• Characteristics randomised participants
◦ Number: treatment group (123); control group (120)
◦ Number, % women: treatment group (48, 39%); control group (47, 39%)
◦ Mean age ± SD (years): treatment group (62 ± 15); control group (63 ± 14)
◦ Serum sodium concentration (mmol/L): treatment group (130 ± 4); control
group (129 ± 5)
◦ Cause of hyponatraemia
⋄ Treatment group: SIADH (24, 20%); heart failure (36, 29%); liver
cirrhosis (37, 30%); other (26, 21%)
⋄ Control group: SIADH (30, 25%); heart failure (34, 28%); liver
cirrhosis (33, 28%); other (49, 20%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg/d up to 1 x 60 mg/d
Control group
• Oral placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: no restriction
• sodium intake: no restriction
Outcomes • Death
• Health-related quality of life (continuous outcome): change from baseline
measured by physical and mental component of the Medical Outcomes Study 12-item
Short Form General Health Survey
• Response in serum sodium concentration (categorical outcome): serum sodium
concentration > 135 mmol/L at any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline as well
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as absolute values
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration > 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L during the first day
◦ Osmotic demyelination syndrome
• Treatment-specific side-effects
◦ AKI: not otherwise defined
◦ Hypotension: not otherwise defined
◦ Thirst: not otherwise defined
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Otsuka Maryland Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Patients...underwent central ran-
domisation with the use of random per-
muted blocks and stratification according
to whether the hyponitraemia was mild or
marked...’
Comment: the randomisation procedure
produced well balanced groups
Allocation concealment (selection bias) Low risk Quote: ’Patients...underwent central ran-
domisation with the use of random per-
muted blocks and stratification according
to whether the hyponatraemia was mild or
marked...’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...trials were...randomised, dou-
ble-blind, placebo-controlled efficacy stud-
ies...’ and ’Patients were assigned...to re-
ceive oral tolvaptan...or matching placebo.
..’, and ’Fluid restriction was not manda-
tory’
Comment: blinding of both participants
and personnel attempted. However, un-
likely for participants to have been fully
blinded due to important increases in urine
output. We judged this would not have in-
troduced important risk of bias for death
and the outcomes related to serum sodium
concentration, but may have biased health-
related quality of life measures in favour of
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the studymedication. Also, fluid restriction
was not mandatory and could be adapted
by both participant and treating physician
- e.g. based on urine output. This may have
resulted in underestimation of the risk of
rapid increase in serum sodium concentra-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: unclear whether outcome as-
sessors of non patient-reported outcomes
were blinded, but outcomes fairly objec-
tive. However, unlikely for participants to
have been fully blinded given important in-
creases in urine output, which may have
biased the self-reported outcome health-re-
lated quality of life
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ’Patients who received at least one
dose of the study medication were included
in the safety analyses. Patients whose serum
sodium concentrations were evaluated at
baseline and one or more times after base-
line were included in the efficacy analysis’.
And ’serum sodium concentrations were
measured at days 2,3,4,11,18,25,30, and
37’
Comment: overall 26% attrition at 30
days, 25% in treatment group 1, 26% in
placebo group; reasons not reported in de-
tail. Repeated measures analytic technique
was used with all measurements of serum
sodium concentration included until pa-
tient attrition. We judged this may likely
have overestimated the change in serum
sodium concentration. For the mental
component score of the SF-12 health sur-
vey, measured at 30 days, attrition reached
31% in treatment group 1 and 29% in the
placebo group
Selective reporting (reporting bias) High risk Comment: study protocol registered with
ClinicalTrials.gov.Outcomemeasures were
only registered in September 2005.Health-
related quality of life not registered as one
of the outcomes. Note that the study was
registered as separate trial, but the health-
related quality of life outcomes and ad-
verse events were reported in a joint anal-
ysis for the two studies together without
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data allowing separation for the purpose of
this review. Also because a repeated mea-
sures analytic technique was used, unclear
at what time point serum sodium concen-
tration was measured for all participants
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Dr. Schrier reports
having served as a consultant to Otsuka,
Astellas, Bayer, and Amgen. Dr. Gross
reports having served as a consultant to
Sanofi-Synthelabo, having received lecture
fees from Astellas, and having received
grant support from GlaxoSmithKline,
Takeda, Amgen, Roche, and Fresenius.
Dr. Gheorghiade reports having served as
a consultant to Otsuka, PDL, Sigma Tau,
Medtronic, and GlaxoSmithKline and
having received honoraria from
Medtronic, Astra Zeneca, Scios,
GlaxoSmithKline, Otsuka, PDL, Abbott,
and Sigma Tau. Dr. Berl reports having
served as a consultant to Bayer and
Astellas and having received grant support
from Otsuka. Dr. Verbalis reports having
served as a consultant to Otsuka,
Yamanouchi Pharma American, Astellas,
Ferring Research, Bristol-Myers Squibb,
and Sanofi Aventis and having received
grant support from Yamanouchi Pharma
American and Astellas. Drs. Czerwiec and
Orlandi are employees of Otsuka
Maryland Research Institute. No other
potential conflict of interest relevant to
this article was reported.’
◦ Comment: senior author is an
employee of the company
commercialising the compound
• Sponsorship bias
◦ Quote: ’Supported by the
Otsuka Maryland Research Institute.’
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Methods • Design: parallel RCT (initiated after licensing)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 1 dose
• Follow-up: 1 day
Participants • Country: not reported
• Number of centres: > 1
• Inclusion criteria: ≥ 18 years; serum sodium concentration > 120 mmol/L and <
133 mmol/L; SIADH
• Exclusion criteria: not reported
• Characteristics randomised participants (data not provided for individual groups)
◦ Number: 30
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group
• Oral tolvaptan: 1 x 15 mg
Treatment group 2
• Oral tolvaptan: 1 x 7.5 mg
Control group
• Oral tolvaptan: 1 x 3.75 mg
Co-interventions (all groups)
• Fluid restriction: no restriction
• sodium intake: not reported
Outcomes • Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 8 mmol/L in the first 8 hours or ≥ 12 mmol/L during the first day
Notes • Funding source: not reported
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’subjects...were randomised’.
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’In a multi-center...double blind
trial’.
Comment: insufficient information to per-
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mit judgement of ’High risk’ or ’Low risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ’In a multi-center...double blind
trial’.
Comment: insufficient information to per-
mit judgement of ’High risk’ or ’Low risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition or treatment discon-
tinuation not specifically reported, but
given single dose study, risk of bias seems
low nonetheless
Selective reporting (reporting bias) Low risk Comment: no protocol, short-term study
(single dose), secondary outcomes related
to over-correction of serum sodium con-
centration reported
Other bias Unclear risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: Insufficient
information to permit judgement of
’High risk’ or ’Low risk’
• Sponsorship bias
◦ Comment: sponsorship not
reported
Singhi 1995
Methods • Design: parallel RCT (phase not applicable)
• Hyponatraemia subgroup: yes, with randomisation stratified according to the
subgroup
• Recruitment period: not reported
• Treatment duration: 2 days
• Follow-up: 2 days
Participants • Country: India
• Number of centres: 1
• Inclusion criteria: consecutive admissions to a paediatric emergency service of a
teaching hospital; 2 months to 7 years; serum sodium concentration < 130 mmol/L;
previously healthy children with acute bacterial meningitis
• Exclusion criteria: heart disease; respiratory illness including pneumonia;
gastrointestinal illness; renal disease; central nervous system disease other than
meningitis; weight for age < 60% of expected; endocrinopathy; malignancy;
immunodeficiency; previous anticonvulsant therapy
• Characteristics randomised participants
◦ Number: treatment group (15); control group (11)
◦ Number, % girls: treatment group (6, 40%); control group (4, 36%)
◦ Mean age ± SD: treatment group (11 years ± 13 months); control group (9
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years ± 12 months)
◦ Serum sodium concentration (mmol/L): treatment group (126 ± 4); control
group (126 ± 4)
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group 1
• IV one-fifth NaCl 0.9% in dextrose 5%, 65% of calculated normal daily
maintenance requirement calculated according to 110 mL/kg for first 10 kg, 50 mL/kg
for next 10 kg, 25 mL/kg for subsequent weight - increased to 10 mL/kg/8 hours after
24 hours; 100% of calculated requirement after 48 hours
Control group
• IV one-fifth NaCl 0.9% in dextrose 5%, 100% of calculated normal daily
maintenance requirement calculated according to 110 mL/kg for first 10 kg, 50 mL/kg
for next 10 kg, 25 mL/kg for subsequent weight
Co-interventions (all groups)
• Not reported
Outcomes • Death
• Serum sodium concentration (continuous outcome): change from baseline to the
end of treatment
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Patients in both groups were as-
signed randomly to receive...’ and ’a ran-
domisation list was prepared with help of
random tables before initiation of the study.
’
Comment: valid randomisation methods
may have produced imbalanced groups due
to small sample size, but any imbalance was
likely favouring the experimental group as
control group contained the sicker children
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: blinding of participants prob-
ably not relevant given setting, short-term
study and objective outcomes. Attempts to
blind personnel not reported, probably not
done, may have influenced administration
of co-interventions not reported in the pa-
per
115Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Singhi 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding of outcome assessors
probably not done, but unlikely this will
have caused substantial bias given short-
term study and objectivity of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no attrition
Selective reporting (reporting bias) Low risk Comment: no protocol, but primary out-
come and secondary outcome related to
serum sodium concentration reported
Other bias Low risk • Bias through possible financial
conflict of interest of the authors
• Sponsorship bias
◦ Not reported, but given nature
of the intervention, unlikely that
sponsorship bias would have occurred
Soupart 2006
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: 2001 to 2003
• Treatment duration: 5 days
• Follow-up: 5 days
Participants • Countries: Belgium; France; Germany; Hungary
• Number of centres: not reported
• Inclusion criteria: ≥ 18 years; serum sodium concentration 115 to ≤ 130 mmol/
L; Other: SIADH secretion based on true serum hypo-osmolality; inappropriate
urinary osmolality; clinical euvolaemia; elevated urinary sodium excretion while on a
normal salt and water intake; normal renal, adrenal and thyroid functions - including
participants with sodium excretion ≤ 20 mmol/L as a result of low solute intake
• Exclusion criteria: cardiac failure; symptomatic liver disease; ALT or AST > 2 x
upper limit of normal; blood glucose ≥ 200 mg/dL; creatinine > 1.7 mg/dL; Hb < 9 g/
dL, neutrophils < 1500/mm3 , platelets < 100,000/mm3 , hypothyroidism or adrenal
deficiency; radiotherapy or chemotherapy <2 weeks before drug administration;
demeclocycline < 1month or lithium < 2 days; women of childbearing potential with
positive pregnancy test or medically approved contraception method
• Characteristics randomised participants
◦ Number: treatment group 1 (12); treatment group 2 (14); control group (9)
◦ Number, % women: treatment group 1 (8, 67%); treatment group 2 (7,
50%); control group (7, 78%)
◦ Mean age ± SD (years): treatment group 1 (69 ± 14); treatment group 2 (71
± 11); control group (62 ± 19)
◦ Serum sodium concentration (mmol/L): treatment group 1 (127 ± 5);
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treatment group 2 (125 ± 6); control group (126 ± 3)
◦ Cause of hyponatraemia: SIADH (100%)
Interventions Treatment group 1
• Oral satavaptan: 1 x 50 mg/d
Treatment group 2
• Oral satavaptan: 1 x 25 mg/d
Control group
• Placebo: 1 x 1/d
Co-interventions (all groups)
• Fluid restriction: < 1.5 L/d
• Dietary sodium intake: no restriction, kept at levels consistent with baseline
Outcomes • Response in serum sodium concentration (categorical outcome):serum sodium
concentration increase ≥ 5 mmol/L or serum sodium concentration ≥ 135 mmol/L at
any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline to the
end of treatment
• Outcomes related to over-correction of serum sodium concentration
◦ Hypernatraemia: serum sodium concentration > 145 mmol/L
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 8 mmol/L during the first day
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L/d at any time point during study
• Treatment-specific side-effects
◦ Hypotension (orthostatic hypotension): systolic BP standing - supine ≤ -20
mm Hg
◦ Thirst (continuous outcome): expressed on a VAS
◦ Adverse events: not otherwise defined
◦ Serious adverse events: not otherwise defined
• Treatment discontinuation
Notes • Funding source: Sanofi-Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’...patients were randomly assigned
to take placebo or a once-daily dose...’
Comment: due to the large number of
groups relative to the number of included
participants, the randomisation procedure
may have failed to produce groups with
similar baseline prognosis. E.g. there is
an imbalance in age, SCr, urinary sodium
across the groups. We assumed the influ-
ence of the imbalance thus generatedwould
be negligible in practice
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Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...patients were randomly assigned
to take placebo or a once-daily dose of 25
or 50 mg of satavaptan during a double-
blind period of up to 5 days...’, and ’The
double-blind period was followed by 23 d
of open-label treatment...’
Comment: blinding probably attempted,
and although participants are unlikely to
be fully blinded due to important increases
in urine output, all measured outcomes are
short-term and fairly objective. Co-inter-
ventions similar for all groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
measured outcomes objective. Unlikely for
participants to have been fully blinded, and
plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: only 1 participant (3%), in the
placebo group, dropped out due to wors-
ening of pre-existing vasculitis
Selective reporting (reporting bias) Low risk Comment: no protocol, but short-term
study (≤ 1 week) and both secondary out-
comes related to serum sodium concentra-
tion and rapid increase in serum sodium
concentration reported
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’This study was
designed by H.M.H., G.D. and Dr. J.G.
Verbalis.’
◦ Comment: No declaration of
interest. H.M.H - Hassan M. Heshmati’s
affiliations: Clinical Development, Sanofi-
Aventis, Malvern, Pennsylvania
• Sponsorship bias
◦ Quote: ’This study was
sponsored by Sanofi-Aventis.
◦ Comment: H.M.H - Hassan
M. Heshmati’s affiliations: Clinical
118Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Soupart 2006 (Continued)
Development, Sanofi-Aventis, Malvern,
Pennsylvania
Wong 2003b
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: 1998 to 1999
• Treatment duration: 8 days
• Follow-up: 8 days
Participants • Countries: Canada, USA
• Number of centres: 13
• Inclusion criteria: serum sodium concentration < 130 mmol/L
• Exclusion criteria: Child-Pugh > 12; creatinine ≥ 3 mg/dL without cirrhosis;
creatinine ≥ 2 mg/dL with cirrhosis; adrenal insufficiency, thyroid dysfunction; fasting
blood glucose > 13.8 mmol/L; infection ≤ 2 weeks; MI ≤ 2 months; surgery or head
trauma; surgery or head trauma; systolic BP < 80 mm Hg; symptomatic orthostatic
hypotension; lithium, vasopressin analogues, demeclocycline, desmopressin, oncologic
agents salt tablets or hypertonic saline
• Characteristics randomised participants
◦ Number: treatment group 1 (10); treatment group 2 (11); treatment group 3
(12); control group (11)
◦ Number, % women: treatment group 1 (2, 20%); treatment group 2 (3,
40%); treatment group 3 (7, 60%); control group (1, 9%)
◦ Mean age ± SD (years): treatment group 1 (51 ± 3); treatment group 2 (55 ±
4); treatment group 3 (48 ± 3); control group (52 ± 3)
◦ Serum sodium concentration (mmol/L): treatment group 1 (126 ± 1);
treatment group 2 (121 ± 1); treatment group 3 (126 ± 0.4); control group (127 ± 1)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (1, 10%); heart failure (2, 20%); liver
cirrhosis (7, 70%)
⋄ Treatment group 2: heart failure (1, 9%); liver cirrhosis (10, 91%)
⋄ Treatment group 3: SIADH (3, 25%); heart failure (1, 8%); liver
cirrhosis (8, 67%)
⋄ Control group: SIADH (1, 9%); heart failure (1, 9%); liver cirrhosis (8,
73%); heart failure and cirrhosis (1, 9%)
Interventions Treatment group 1
• Oral lixivaptan: 2 x 250 mg/d
Treatment group 2
• Oral lixivaptan: 2 x 125 mg/d
Treatment group 3
• Oral lixivaptan: 2 x 25 mg/d
Control group
• Placebo: 2 x 1/d
Co-interventions (all groups)
• Fluid restriction: < 1.5 L/d, adapted according to urine output
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• Dietary sodium intake: no restriction, sodium intake determined by each
investigator and kept at levels constant throughout study
Outcomes • Serum sodium concentration (continuous outcome): change from baseline to the
end of treatment
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 8 mmol/L/d throughout the study; or serum sodium concentration > 142
mmol/L
• Treatment-specific side-effects
◦ Thirst (continuous outcome): expressed on a 0 to 100 mm VAS
• Treatment discontinuation
Notes • Funding source: Wyeth-Ayerst
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’patients were randomised at a cen-
tral site by the Computerized Randomiza-
tion/Enrollment (CORE) system’
Comment: due to the large number of
groups relative to the number of included
participants, randomisationproceduremay
have failed to produce groups with similar
baseline prognosis. E.g. there is an imbal-
ance in age across the groups. We assumed
the influence of the imbalance thus gener-
ated would be negligible in practice
Allocation concealment (selection bias) Low risk Quote: ’patients were randomised at a cen-
tral site by the Computerized Randomiza-
tion/Enrollment (CORE) system’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ’...randomised...to receive twice
daily per os either placebo, ...’
Comment: blinding probably attempted,
but due to increase in urine output, un-
blinding likely to have occurred and as fluid
intake was adjusted to urine output, this
may likely have resulted inunderestimation
of the incidence of rapid increase in sodium
concentration as well as influenced thirst
measurements
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment:
unclear whether assessors of non patient-
reported outcomes were blinded, but main
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measured outcomes objective. Unlikely for
participants to have been fully blinded, and
plausible ’high risk’ of bias for self-reported
outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 27%attrition, due to treatment
discontinuation (21%); reasons well-docu-
mented. ’High risk’ for sodium concentra-
tion measurements given re-inclusion oc-
curred using last availablemeasurement be-
fore discontinuation
Selective reporting (reporting bias) High risk Comment: no protocol - study duration
8 days without adequate reporting of sec-
ondary outcomes related serum sodium
concentration permitting data
• Timing outcome assessment
◦ Comment: Last-observation
carried forward method may have caused
measurements at different time-points
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Comment: No declaration of
interest
• Sponsorship bias
◦ Quote: ’Data were collected
centrally at Wyeth-Ayerst Laboratories
and initially analysed at Wyeth-Ayerst’
◦ Comment: the sponsor
initiated and funded the study, and had
direct control over data and their analysis
Yang 2013
Methods • Design: parallel RCT (phase not reported)
• Hyponatraemia subgroup: no
• Recruitment period: not reported
• Treatment duration: 8 days
• Follow-up: 8 days
Participants • Country: China
• Number of centres: not reported
• Inclusion criteria: > 18 years; CHF
• Exclusion criteria: not reported
• Characteristics randomised participants
◦ Number: treatment group (8); control group (8)
◦ Number, % women: not reported
◦ Mean age ± SD (years): not reported
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◦ Serum sodium concentration (mmol/L): not reported
◦ Cause of hyponatraemia: CHF (100%)
Interventions Treatment group
• Oral tolvaptan: dose and duration not reported
Control group
• Not reported
Co-interventions (all groups)
• Not reported
Outcomes • Health-related quality of life: (measured by the Minnesota quality of life score):
insufficiently reported to allow contribution to meta-analysis
• Serum sodium concentration (continuous outcome)
• Treatment-specific side-effects (insufficiently reported to allow contribution to
meta-analysis)
◦ Thirst: dry mouth
◦ Serious adverse events: not otherwise specified
Notes • Funding source: not reported
• Publication: abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’...they were randomly divided...’
Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Selective reporting (reporting bias) High risk Comment: no protocol, study duration >
1 week, primary and secondary outcomes
insufficiently reported
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Other bias Unclear risk Comment: insufficient evidence to permit
judgement of ’Low risk’ or ’High risk’
Zeltser 2007
Methods • Design: parallel RCT (phase 3)
• Hyponatraemia subgroup: no
• Recruitment period: 2000 to 2003
• Treatment duration: 2 days
• Follow-up: not reported
Participants • Countries: Canada, Israel, South Africa, USA
• Number of centres: not reported
• Inclusion criteria: ≥ 18 years; serum sodium concentration: 115 to ≤ 130 mmol/
L; plasma osmolality < 290 mOsm/kg H2O; fasting blood glycaemia < 275; euvolaemia
(defined as absence of pitting oedema or ascites determined by clinical assessment);
hypervolaemia (defined as presence of oedema determined by clinical assessment)
• Exclusion criteria: hypovolaemia; supine systolic BP < 85 mm Hg; orthostatic
hypotension - systolic BP < 80 mm Hg on standing or decrease of > 20 mm Hg from
supine to standing; uncontrolled hypertension; bradyarrhythmia or tachyarrhythmia
necessitating emergent pacemaker implantation or treatment; untreated severe thyroid
disease or adrenal insufficiency; severe renal dysfunction (CrCl < 20 mL/min);
medications known to interact with cytochrome P450 3A4, AVP, oxytocin,
desmopressin and other medications used to treat hyponatraemia, specifically, lithium
salts, urea, and demeclocycline; hyponatraemia necessitating emergent treatment
during the study
• Characteristics included participants
◦ Number: treatment group 1 (29); treatment group 2 (29); control group (26)
◦ Number, % women: treatment group 1 (12, 46%); treatment group 2 (17,
59%); control group (14, 48%)
◦ Mean age ± SD (years): treatment group 1 (73 ± 14); treatment group 2 (74
± 12); control group (76 ± 12)
◦ Serum sodium concentration (mmol/L): treatment group 1 (125 ± 3);
treatment group 2 (123 ± 5); control group (124 ± 4)
◦ Cause of hyponatraemia
⋄ Treatment group 1: SIADH (7, 27%); heart failure (8, 31%);
malignancy (2, 8%); post-surgery (1, 4%); idiopathic (6, 23%); unclear (2, 8%)
⋄ Treatment group 2: SIADH (7, 24%); heart failure (10, 35%);
malignancy (3, 10%); post-surgery (1, 3%); idiopathic (5, 17%); unclear (3, 10%)
⋄ Control group: SIADH (4, 14%); heart failure (7, 24%); malignancy
(2, 7%), post-surgery (1, 3%), COPD (2, 7%); idiopathic (4, 14%); unclear (9, 31%)
Interventions Treatment group 1
• IV conivaptan: 20 mg loading dose + 80 mg/d continuous infusion
Treatment group 2
• IV conivaptan: 20 mg loading dose + 40 mg/d continuous infusion
Control group
• IV Placebo: 100 mL 5% dextrose in water + 250 mL/d 5% dextrose in water
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continuous infusion
Co-interventions (all groups)
• Fluid restriction: <2 L/d
• Dietary sodium intake: no restriction, sodium intake kept at levels consistent with
baseline
Outcomes • Death
• Response in serum sodium concentration (categorical outcome): serum sodium
concentration increase ≥ 6 mmol/L or serum sodium concentration ≥ 135 mmol/L at
any time during treatment
• Serum sodium concentration (continuous outcome): change from baseline to the
end of treatment
• Outcomes related to over-correction of serum sodium concentration
◦ Rapid increase in serum sodium concentration: serum sodium concentration
increase > 12 mmol/L on day 1; or serum sodium concentration increase > 24 mmol/L
in total; or serum sodium concentration > 145 mmol/L; or treatment reduced or
withheld following increase in serum sodium concentration judged by the investigator
as too rapid
◦ Osmotic demyelination syndrome
• Treatment-specific side-effects
◦ AKI: kidney dysfunction or worsening kidney function
◦ Hypotension
◦ Thirst (insufficiently reported to allow contribution to meta-analysis)
◦ Serious adverse events: not otherwise defined
◦ Injection-site phlebitis
◦ Injection-site thrombosis
◦ Liver function abnormalities: significantly elevated liver enzymes
• Treatment discontinuation
Notes • Funding source: Astellas Pharma US, Inc.
• 88 were randomised - 4 excluded after randomisation for not having received the
study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ’patients were stratified by volume
status and randomly assigned to...’
Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ’...
double-blind, placebo-controlled study,...’
and ’The placebo group received a 100-ml
loading dose of D5W on day 1 followed by
124Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zeltser 2007 (Continued)
continuous infusion of 250 ml D5W...’
Comment: blinding probably attempted,
and although participants are unlikely to
be fully blinded due to important increases
in urine output, all measured outcomes
fairly objective. Co-interventions Fluid-re-
striction and salt intake were similar for all
groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinding outcome assessors for
non patient-reported outcomes probably
attempted and main measured outcomes
objective. Unlikely for participants to have
been fully blinded, and plausible ’high risk’
of bias for self-reported outcome of thirst
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: overall 25% attrition due to ex-
clusion after randomisation (4%) and treat-
ment discontinuation (21%); reasons well-
documented. ’Low risk’ for death, but ’high
risk’ for sodium concentration measure-
ments given reinclusion occurred using last
available measurement before discontinua-
tion. Although the opportunity for intro-
ducing bias is probably limited in such a
short-term study - we judged it ’high risk’
as matter of principle
Selective reporting (reporting bias) Low risk Comment: no protocol, but death, serum
sodium concentration and outcomes re-
lated to rapid increase in serum sodium
concentration reported. However, viola-
tion intention to treat analysis may be an
issue. Quote: ’The efficacy analyses were
conducted using a modified intent-to-treat
approach and included all randomised pa-
tients who had at least 1 baseline serum
[Na+]measurement, received at least 1 dose
of studymedication, and had at least 1 valid
efficacy measurement.’ Comment: 4 (4%)
excluded after randomisation for not hav-
ing received the study drug
Other bias High risk • Bias through possible financial
conflict of interest of the authors
◦ Quote: ’Neila Smith: Astellas
Pharma US, Inc., Deerfield, Ill., USA’;
’Disclosure - Grant/Research support:
Yamanouchi Pharma America, Inc - grant
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(Verbalis), employee (Bisaha and Smith),
consultant: Yamanoushi Pharma America,
Inc.; J.G.V. is a consultant for Astellas
Pharma US, Inc., Otsuka Pharmaceutical
Co., Ltd and Sanofi-Aventis; has received
funds for research from Yamanouchi
Pharma America, Inc. and Astellas Pharma
US, Inc; and has received fees for speaking
from Astellas Pharma US, Inc. D.Z. has
nothing to declare. N.S., A.B. and M.A.
are employed by Astellas Pharma US, Inc.
’; ’Joseph Verbalis, No Product/Research
Disclosure Information; Grant monies
(from industry related sources) Joseph G.
Verbalis, Astellas Pharma US, Inc;
Employee Bruce McNutt, Bo Yan, Astellas
Pharma US, Inc.; Consultant fee, speaker
bureau, advisory committee, etc. Joseph
G. Verbalis is a consultant for Astellas
Pharma US, Inc., Otsuka Pharmaceutical
Co., Ltd., and Sanofi-Aventis, and has
received fees for speaking from Astellas
Pharma US, Inc.’
◦ Comment: senior author’s
affiliation: Astellas Pharma; several
authors affiliated with the company
commercialising the compound
• Sponsorship bias
◦ Quote: ’This study was
supported by Astellas Pharma US, Inc.
(formerly Yamanouchi Pharma America,
Inc.)
◦ Comment: senior author’s
affiliation: Astellas Pharma; several
authors affiliated with the company
commercialising the compound
AKI - acute kidney injury; ALT - alanine aminotransferase; AST - aspartate aminotransferase; AVP - Arginine vasopressin; BP - blood
pressure; BPM - beats per minute; BUN - blood urea nitrogen; CHF - chronic heart failure; COPD - chronic obstructive pulmonary
disease; CrCl - creatinine clearance; FDA - food and Drug Administration; GFR - glomerular filtration rate; Hb - haemoglobin; INR
- international normalised ratio; MI - myocardial infarction; NYHA - New York Heart Association; PCW - pulmonary capillary
wedge; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; SF-12 - Short Form Health Survey;
SIADH - syndrome of inappropriate antidiuretic hormone; VAS - visual analogue scale; WCC - white cell count
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abraham 2006 Wrong population: RCT comparing lixivaptan versus placebo in participants with heart failure. Study
population included both participants with and without hyponatraemia. We attempted to contact the
authors on 24/10/2014 with a request for the outcome data for the subgroup of participants with hypona-
traemia, but received no response
Albert 2013 Wrongpopulation: RCTcomparingfluid restriction versus usual care after discharge in patients hospitalised
for acute decompensation of chronic heart failure. Inclusion criteria state hyponatraemia - but defined as a
serum sodium concentration≤ 137 mmol/L. At discharge, and hence start of the intervention, themedian
serum sodium concentration in both groups equalled 135.5 mmol/L with interquartile ranges 134 to 137
mmol/L. This means hardly no participants had hyponatraemia as defined in this review. Consequently,
any treatment given does not have the same harms (rapid increases in serum sodium concentration, osmotic
demyelination syndrome) to consider. We judged the studied participants in this trial did not meet the
projected characteristics of the patient group targeted by this review
Alexander 1991 Wrong population: people with hyponatraemia due to primary psychogenic polydipsia are excluded from
the review
Angeli 2010 Wrong population: RCT comparing combined versus sequential diuretic treatment in participants with
cirrhosis. Study population included both participants with and without hyponatraemia. We attempted to
contact the authors on 23/10/2014 with a request for the outcome data for the subgroup of participants
with hyponatraemia, but received no response
Bernardi 1993 Wrong intervention: RCT in which in patients with liver cirrhosis and ascites two different salt-restricted
diets are evaluated in combination with step-wise increase of diuretic treatment in both groups in order
to reduce weight and ascites
De Vita 2012 Wrong population: RCT comparing rituximab monotherapy versus the best available treatment in patients
with mixed cryoglobulinaemia syndrome
Galton 2011 Wrong population: RCT in which a single dose of conivaptan was given to normonatraemic critically ill
patients with severe traumatic brain injury
Ghali 2012 Wrong population: RCT comparing lixivaptan versus placebo in participants with heart failure. Study
population included both participants with and without hyponatraemia. We attempted to contact the
authors on 23/10/2014 with a request for the outcome data for the subgroup of participants with hypona-
traemia, but received no response
Gines 2007 Double counting of included participants. Study represents a second RCT built on top of a first included
RCT (Gines 2008b) using the same study drug. Including the trial would give rise to double counting of
participants
Guyader 2002 Wrong population: RCT comparing satavaptan with placebo in participants with liver cirrhosis. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors with a request for the outcome data for the subgroup of participants with hyponatraemia. We
received a response from the sponsor with inclusion of the full text. However, no additional data were
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provided
K-STAR 2017 Wrong population: Post-hoc analysis of RCT comparing tolvaptan versus placebo in participants with
heart failure. Study population included both participants with and without hyponatraemia.We attempted
to contact the authors on 04/12/2016 with a request for the outcome data for the subgroup of participants
with hyponatraemia. As the primary study data have not yet been published, primary author unable to
supply raw data
Licata 2003 Wrong population: RCT comparing high-dose furosemide + low volume hypertonic saline versus high-
dose furosemide in participants with heart failure. Study population possibly included both participants
with and without hyponatraemia. We attempted to contact the authors on 24/10/2014 with a request for
the outcome data for the subgroup of participants with hyponatraemia, but received no response
Matsuzaki 2011a Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors on 24/10/2014 with a request for the outcome data for the subgroup of participants with
hyponatraemia, but received no response
Matsuzaki 2011b Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors on 24/10/2014 with a request for the outcome data for the subgroup of participants with
hyponatraemia, but received no response
Mori 1999 Wrong population: study evaluating fludrocortisone for preventing hyponatraemia in people with sub-
arachnoidal bleeding. Patients were not hyponatraemic at randomisation
Okita 2014 Wrong population: RCTcomparing tolvaptan versus placebo in participants with liver cirrhosis and hepatic
oedema. Study population included both participants with and without hyponatraemia. We attempted to
contact the authors on 04/12/2016 with a request for the outcome data for the subgroup of participants
with hyponatraemia, but received no response
Owen 2014 Wrong population: RCT in people with acute hyponatraemia after an ultra-distance run
Paterna 2000 Wrong population: RCT comparing high-dose furosemide + low volume hypertonic saline versus high-
dose furosemide in participants with heart failure. Study population possibly included both participants
with and without hyponatraemia. We attempted to contact the authors on 24/10/2014 with a request for
the outcome data for the subgroup of participants with hyponatraemia, but received no response
Rajan 2015 Wrong population: RCT on conivaptan in people with acute hyponatraemia
Ramsay 1988 Wrong population: RCT in people with congestive heart failure, but none had hyponatraemia at the start
of the study
Rogers 2011 Wrong population: RCT in people with exercise-associated hyponatraemia, which is to be seen as a form of
acute hyponatraemia present < 48 hours, requiring immediate intervention. Only chronic hyponatraemia,
defined as present > 48 hours is included in the review
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Sakaida 2014 Wrong population: RCTcomparing tolvaptan versus placebo in participants with liver cirrhosis and hepatic
oedema. Study population included both participants with and without hyponatraemia. We attempted to
contact the authors on 04/12/2016 with a request for the outcome data for the subgroup of participants
with hyponatraemia, but received no response
SALSA 2017 Wrong population: RCT comparing intermittent infusion of small volumes of NaCl 3% versus slow
continuous infusion of NaCl 3% in people with moderately severe or severe symptoms attributed to
hyponatraemia. These people are considered requiring immediate intervention to increase the serum
sodium concentration. Only those that did not require immediate treatment were considered in the review
SECRET of CHF 2017 Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Study pop-
ulation included both participants with and without hyponatraemia. We attempted to contact the authors
on 04/12/2016 with a request for the outcome data for the subgroup of participants with hyponatraemia,
but received no response
Shanmugam 2016 Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Abstract
title implies all participants had hyponatraemia, but investigators actually included everyone with serum
sodium concentration below 140 mmol/L. Study population included both participants with and without
hyponatraemia according to our definition. We attempted to contact the authors on 04/12/2016 with
a request for the outcome data for the subgroup of participants with hyponatraemia, but received no
response
Suzuki 2013b Wrong population: RCT comparing tolvaptan versus carperitide in participants with heart failure. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors on 24/10/2014 with a request for the outcome data for the subgroup of participants with
hyponatraemia, but received no response
TACT-ADHF 2016 Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Study pop-
ulation included both participants with and without hyponatraemia. We attempted to contact the authors
on 04/12/2016 with a request for the outcome data for the subgroup of participants with hyponatraemia,
but received no response
TACTICS-HF 2017 Wrong population: RCT comparing tolvaptan versus placebo in participants with heart failure. Study pop-
ulation included both participants with and without hyponatraemia. We attempted to contact the authors
on 04/12/2016 with a request for the outcome data for the subgroup of participants with hyponatraemia,
but received no response
Thuluvath 2006 Wrong population: RCTcomparing tolvaptan versus placebo in participants with liver cirrhosis and ascites.
Study population included both participants with and without hyponatraemia. We attempted to contact
the authors on 04/12/2016 with a request for the outcome data for the subgroup of participants with
hyponatraemia, but received no response
Wong 2009 Wrong population: RCT comparing satavaptan versus placebo in participants with liver cirrhosis and hep-
atic oedema. Study population included both participants with and without hyponatraemia.We attempted
to contact the authors on 04/12/2016 with a request for the outcome data for the subgroup of participants
with hyponatraemia, but received no response
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Wong 2010a Wrong population: RCT comparing satavaptan with placebo in participants with liver cirrhosis. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors with a request for the outcome data for the subgroup of participants with hyponatraemia. Dr
Wong referred us to the sponsor, who was subsequently contacted on 24/10/2014. The sponsor agreed to
provide the data but to date we received no further communication
Wong 2012 Wrong population: RCT comparing satavaptan versus placebo in participants with liver cirrhosis. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors with a request for the outcome data for the subgroup of participants with hyponatraemia. Dr.
Ginès referred us to the sponsor, who was subsequently contacted on 24/10/2014, but we received no
response
Yang 2010b Wrong population: RCT comparing clonidine versus placebo in participants with liver cirrhosis. Study
population possibly included both participants with and without hyponatraemia. We attempted to contact
the authors on 24/10/2014 with a request for the outcome data for the subgroup of participants with
hyponatraemia, but received no response
Zamboli 2011 Wrong population: RCT in people with CKD stage 3 or 4. This is not a group that likely contains a
substantial number of people with hyponatraemia
Zellweger 2001 Wrong population: RCT comparingcyclooxygenase-2 inhibitors versus non-selective NSAID and the risk
of developing hyponatraemia
CKD - chronic kidney disease; NSAID - non-steroidal anti-inflammatory drugs; RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Vasopressin receptor antagonists (VRA) versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 6 months 15 2330 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.92, 1.33]
1.1 Conivaptan 4 222 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.13, 1.17]
1.2 Lixivaptan 3 950 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.85, 1.80]
1.3 Tolvaptan 8 1158 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.89, 1.39]
2 Health-related quality of life 2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Mental component SF-12 2 297 Mean Difference (IV, Random, 95% CI) 4.76 [0.11, 9.41]
2.2 Physical component SF-
12
2 300 Mean Difference (IV, Random, 95% CI) 1.04 [-1.81, 3.90]
3 Cognitive function: trail making
test Part B
2 858 Mean Difference (IV, Random, 95% CI) 6.89 [-6.34, 20.12]
4 Length of hospital stay 3 610 Mean Difference (IV, Random, 95% CI) -1.63 [-2.96, -0.30]
4.1 Satavaptan 1 139 Mean Difference (IV, Random, 95% CI) -1.80 [-3.80, 0.20]
4.2 Tolvaptan 2 471 Mean Difference (IV, Random, 95% CI) -1.50 [-3.28, 0.29]
5 Change from baseline serum
sodium concentration
21 2641 Mean Difference (IV, Random, 95% CI) 4.17 [3.18, 5.16]
5.1 Conivaptan 5 292 Mean Difference (IV, Random, 95% CI) 5.17 [2.65, 7.69]
5.2 Lixivaptan 4 1070 Mean Difference (IV, Random, 95% CI) 2.24 [0.78, 3.70]
5.3 Satavaptan 3 257 Mean Difference (IV, Random, 95% CI) 4.91 [2.88, 6.94]
5.4 Tolvaptan 9 1022 Mean Difference (IV, Random, 95% CI) 4.22 [3.55, 4.89]
6 Response in serum sodium
concentration
18 2104 Risk Ratio (M-H, Random, 95% CI) 2.49 [1.95, 3.18]
6.1 Conivaptan 4 282 Risk Ratio (M-H, Random, 95% CI) 2.48 [1.54, 4.01]
6.2 Lixivaptan 4 1024 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.19, 4.10]
6.3 Satavaptan 4 331 Risk Ratio (M-H, Random, 95% CI) 3.33 [1.88, 5.89]
6.4 Tolvaptan 6 467 Risk Ratio (M-H, Random, 95% CI) 2.36 [1.75, 3.18]
7 Rapid increase in serum sodium
concentration
14 2058 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.16, 2.40]
7.1 Conivaptan 4 290 Risk Ratio (M-H, Random, 95% CI) 3.77 [0.89, 15.98]
7.2 Lixivaptan 4 994 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.90, 2.17]
7.3 Satavaptan 4 331 Risk Ratio (M-H, Random, 95% CI) 2.61 [0.73, 9.30]
7.4 Tolvaptan 2 443 Risk Ratio (M-H, Random, 95% CI) 6.70 [0.82, 54.56]
8 Hypernatraemia during
treatment
10 1592 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.63, 3.01]
8.1 Conivaptan 1 83 Risk Ratio (M-H, Random, 95% CI) 2.87 [0.14, 57.89]
8.2 Lixivaptan 2 306 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.04, 5.78]
8.3 Satavaptan 3 262 Risk Ratio (M-H, Random, 95% CI) 1.98 [0.35, 11.11]
8.4 Tolvaptan 4 941 Risk Ratio (M-H, Random, 95% CI) 2.73 [0.81, 9.22]
9 Thirst 13 Odds Ratio (Random, 95% CI) 2.77 [1.80, 4.27]
10 Other adverse events 17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Polyuria 6 1272 Risk Ratio (M-H, Random, 95% CI) 4.69 [1.59, 13.85]
10.2 Hypotension 14 1748 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.75, 1.63]
10.3 Acute kidney injury 8 1920 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.67, 1.18]
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10.4 Liver function
abnormalities
3 811 Risk Ratio (M-H, Random, 95% CI) 2.43 [0.88, 6.70]
11 Injection-site complications at
2 to 7 days
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Reactions 1 49 Risk Ratio (M-H, Random, 95% CI) 7.56 [0.49, 115.93]
11.2 Phlebitis 2 133 Risk Ratio (M-H, Random, 95% CI) 3.52 [1.00, 12.41]
11.3 Thrombosis 2 133 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.21, 14.80]
12 Treatment discontinuation 14 2429 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.85, 1.00]
12.1 Conivaptan 4 288 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.39, 1.30]
12.2 Lixivaptan 4 1008 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
12.3 Satavaptan 2 145 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.17, 1.46]
12.4 Tolvaptan 4 988 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.13]
13 Death during follow-up:
sensitivity analysis
16 2404 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.91, 1.32]
13.1 Conivaptan 5 296 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.19, 1.15]
13.2 Lixivaptan 3 950 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.37, 3.15]
13.3 Tolvaptan 8 1158 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.89, 1.39]
14 Rapid increase in serum sodium
concentration: sensitivity
analysis
14 2058 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.16, 2.40]
14.1 > 8 mmol/L/d 4 257 Risk Ratio (M-H, Random, 95% CI) 3.22 [0.65, 15.94]
14.2 > 12 mmol/L/d 10 1801 Risk Ratio (M-H, Random, 95% CI) 1.63 [1.09, 2.43]
A D D I T I O N A L T A B L E S
Table 1. Change in serum sodium concentration: meta-regression and confounding
Covariate Number of studies in-
cluded in meta-regres-
sion
Scale Absolute change in
mean difference
P value
Baseline serum sodium
concentration
21 Per 1 mmol/L increase -0.33 (-0.65 to -0.02) 0.04
Compound 21 Relative to conivaptan - 0.17
Conivaptan 5 - - -
Lixivaptan 4 - -2.79 (-5.47 to -0.10) -
Satavaptan 3 - -0,23 (-3.34 to 2.87) -
Tolvaptan 9 - -0.82 (-3.13 to 1.50) -
Cause of hyponatraemia 21 Relative to SIADH - 0.18
SIADH 5 - - -
Combined SIADH -
Heart failure, cirrhosis
10 - 0.67 (-1.77 to 3.13) -
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Table 1. Change in serum sodium concentration: meta-regression and confounding (Continued)
Heart failure 6 - -1.19 (-3.84 to 1.47) -
Treatment duration 21 Per day increase -0.02 (-0,04 to 0.00) 0.1
Risk of selection bias 21 Relative to low risk - 0.86
Low risk 8 - - -
High risk 13 - 0.18 (-1.90 to 2.27) -
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Liver function abnormalities were not anticipated as an adverse effect attributable to vasopressin receptor antagonists. A communication
issued by Otsuka, indicating concerns around possibility for liver failure - be it in patients with autosomal polycystic kidney disease
and at doses higher than those given for hyponatraemia - highlighted the outcome for inclusion in our review.
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